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Abstract 
Oxidation of LDL is widely believed to be a key process in the pathogenesis of 
atherosclerosis. However, LDL oxidation has been shown to be inhibited by 
interstitial fluid and also large clinical trials have shown no protection by 
antioxidant. Recent work has shown that LDL can be oxidised by iron within the 
lysosomes of macrophages. Here, we have explored the possible mechanism by 
which iron is able to oxidise LDL under lysosomal conditions, and also how 
lysosomotropic antioxidant, cysteamine is able to prevent it.  
More recently, it has been shown that human macrophages are able to rapidly 
phagocytose LDL aggregated by enzymes, such as sphingomyelinase (SMase-
LDL) and oxidised it by iron inside lysosomes, which have a pH of about 4.5. Here, 
the chemical characteristics (lipid hydroperoxides and oxysterols) of SMase-LDL 
oxidised by inorganic iron at lysosomal pH (4.5) have been determined in vitro and 
compared to the native LDL. In the lysosomes of macrophages, SMase-LDL 
increased the intralysosomal lipid peroxidation and ceroid formation which was 
greatly inhibited by cysteamine. 
There is good evidence which suggests that lysosomal dysfunction plays an 
important role in the atherosclerotic plaque development. Here, it is shown that 
lysosomal oxidation of SMase-LDL in human macrophages can cause lysosomal 
dysfunction, induce ceroid associated cellular senescence, and increase the 
expression of inflammatory cytokine like TNF-α. The work here also demonstrates 
that preventing the lysosomal LDL oxidation, with antioxidants like cysteamine, 
offers protection against the SMase-LDL induced lysosomal dysfunction. 
 
 
 
v 
 
Table of Contents 
Declaration ...................................................................................   
Acknowledgements ..................................................................... ii 
Posters and Publications ............................................................ iii 
Abstract ........................................................................................ iv 
Table of Contents ......................................................................... v 
List of Figures .............................................................................. x 
List of Abbreviations ................................................................... xiii 
Chapter 1- Introduction ............................................................... 1 
1.1 Atherosclerosis ................................................................................ 2 
1.1.1 Definition and clinical significance .............................................. 2 
1.1.2 Theories of Atherosclerosis ........................................................ 3 
1.1.3 Development of atherosclerotic plaque ....................................... 6 
1.1.4 Risk factors ................................................................................. 15 
1.2 Lipid metabolism ............................................................................. 20 
1.2.1 Lipoproteins ................................................................................ 20 
1.2.2 Exogenous metabolism .............................................................. 21 
1.2.3 Endogenous metabolism ............................................................ 22 
1.2.4 Cellular cholesterol metabolism .................................................. 23 
1.2.5 Reverse cholesterol transport ..................................................... 24 
 
 
 
vi 
 
1.3 Low Density Lipoprotein (LDL) ....................................................... 26 
1.3.1 Structure and characteristics of LDL ........................................... 26 
1.3.2 LDL and atherosclerosis ............................................................. 28 
1.3.3 Origins of the LDL oxidative hypothesis ...................................... 30 
1.3.4 LDL oxidation .............................................................................. 31 
1.3.5 Atherogenic effects of oxidised LDL (OxLDL) ............................. 35 
1.3.6 Role of transitions metals in LDL oxidation ................................. 36 
1.3.7 Antioxidants in the treatment of atherosclerosis ......................... 37 
1.3.8 LDL aggregation ......................................................................... 38 
1.4 Lysosomes ....................................................................................... 41 
1.4.1 Lysosomes in atherosclerosis ..................................................... 41 
1.4.2 Lysosomal iron............................................................................ 43 
1.4.3 Lysosomal oxidation theory ........................................................ 44 
1.4.4 Lysosomotropic drugs with antioxidant property ......................... 46 
1.4.5 Cysteamine and lysosomal oxidation of LDL .............................. 47 
1.5 Thesis aims and hypothesis ........................................................... 50 
Chapter 2- Materials and methods ........................................... 52 
2.1 General laboratory reagents and solutions ................................... 53 
2.1.1 Laboratory reagents .................................................................... 53 
2.1.2 Laboratory equipment ................................................................. 55 
2.1.3 General Solutions ....................................................................... 56 
2.2 LDL .................................................................................................... 59 
2.2.1 LDL isolation ............................................................................... 59 
2.2.2 LDL protein assay ....................................................................... 60 
2.2.3 LDL aggregation by sphingomyelinase ....................................... 61 
2.2.4 Enrichment of LDL with lipid hydroperoxides .............................. 63 
2.2.5 LDL oxidation with iron ............................................................... 63 
2.2.6 Lipoprotein-deficient serum ........................................................ 63 
2.3 Assessment of LDL oxidation......................................................... 64 
2.3.1 Measurement of conjugated diene formation .............................. 64 
 
 
 
vii 
 
2.3.2 LDL-tryptophan fluorescence measurements ............................. 65 
2.3.3 Monitoring of ferrous iron levels .................................................. 65 
2.3.4 Measurement of lipid hydroperoxides ......................................... 66 
2.4 HPLC analysis of lipid species ....................................................... 67 
2.4.1 Preparing oxidised LDL samples for HPLC analysis ................... 67 
2.4.2 HPLC analysis ............................................................................ 67 
2.5 Cell culture ....................................................................................... 71 
2.5.1 Human THP-1 cells ..................................................................... 71 
2.5.2 Cryopreservation of THP-1 cells ................................................. 71 
2.5.3 Differentiation of THP-1 cells into macrophages ......................... 72 
2.5.4 Detection of intralysosomal ceroid .............................................. 73 
2.5.5 Lysosomal lipid peroxidation ....................................................... 74 
2.5.6 Assessment of lysosomal function .............................................. 75 
2.5.7 Measurement of lysosomal pH in macrophages ......................... 76 
2.5.8 Senescence associated β-galactosidase staining ...................... 78 
2.5.9 TNF-α detection and quantification by ELISA ............................. 79 
2.6 Statistical analysis ........................................................................... 81 
Chapter 3- Mechanism of LDL oxidation by iron at 
lysosomal pH .......................................................................... 82 
3.1 Introduction ...................................................................................... 83 
3.2 Methods ............................................................................................ 88 
3.3 Results .............................................................................................. 89 
3.3.1 Oxidation of LDL with ferrous and ferric iron ............................... 89 
3.3.2 Measurement of ferrous ion levels .............................................. 93 
3.3.3 Oxidation of hydroperoxide-rich LDL .......................................... 95 
3.3.4 Oxidation of LDL by iron in presence of probucol ....................... 99 
3.3.5 Oxidation of LDL by iron in presence of DPPD ........................... 103 
3.3.6 HPLC analysis of LDL oxidation by iron in presence of 
probucol and DPPD ................................................................................. 107 
 
 
 
viii 
 
3.3.7 Oxidation of LDL by iron in presence of cysteamine ................... 111 
3.3.8 HPLC analysis of LDL oxidation by iron in presence of 
cysteamine .............................................................................................. 115 
3.4 Discussion ........................................................................................ 121 
Chapter 4- Antioxidant potential of cysteamine in 
preventing LDL oxidation ...................................................... 127 
4.1 Introduction ...................................................................................... 128 
4.2 Methods ............................................................................................ 132 
4.3 Results .............................................................................................. 133 
4.3.1 Comparison between antioxidant activity of cysteamine and 
cysteine on LDL oxidation by iron at pH 4.5 ............................................ 133 
4.3.2 Comparison of antioxidant activity of cysteamine with other 
known lysosomotropic antioxidants ......................................................... 135 
4.3.3 Effect of cysteamine on LDL aggregation during oxidation 
with iron at pH 4.5 .................................................................................... 140 
4.3.4 Effect of cysteamine on LDL oxidation by copper at pH 4.5 ....... 142 
4.3.5 Effect of cysteamine on LDL oxidation by copper at pH 7.4 ....... 144 
4.4 Discussion ........................................................................................ 146 
Chapter 5- Oxidation of sphingomyelinase aggregated LDL 
by iron under lysosomal pH conditions ................................ 151 
5.1 Introduction ...................................................................................... 152 
5.2 Methods ............................................................................................ 154 
5.3 Results .............................................................................................. 154 
5.3.1 Total lipid hydroperoxides in SMase-LDL ................................... 154 
5.3.2 Measure of oxidation of SMase-LDL by iron at lysosomal pH .... 156 
 
 
 
ix 
 
5.3.3 Chemical characterisation of SMase-LDL oxidation by iron 
at lysosomal pH ....................................................................................... 159 
5.3.4 The effect of cysteamine on oxidation of SMase-LDL by iron 
at lysosomal pH ....................................................................................... 168 
5.3.5 Measurement of lysosomal lipid peroxidation in human 
macrophages ........................................................................................... 171 
5.3.6 Oxidation of SMase-LDL in the lysosomes of macrophages ...... 175 
5.4 Discussion ........................................................................................ 179 
Chapter 6- Implications of lysosomal oxidation of LDL ............ 186 
6.1 Introduction ...................................................................................... 187 
6.2 Methods ............................................................................................ 192 
6.3 Results .............................................................................................. 192 
6.3.1 Effect of SMase-LDL and cysteamine on lysosomal function ..... 192 
6.3.2 Effect of SMase-LDL oxidation and cysteamine on 
lysosomal pH of macrophages................................................................. 196 
6.3.3 Effect of lysosomal oxidation of SMase-LDL on cell 
senescence ............................................................................................. 200 
6.3.4 The effect of lysosomal oxidation of SMase-LDL on 
macrophage TNF-α expression ............................................................... 203 
6.4 Discussion ........................................................................................ 207 
Chapter 7- General discussion ................................................... 213 
7.1 General discussion .......................................................................... 214 
7.2 Limitations of the study .................................................................. 221 
7.3 Future work ...................................................................................... 222 
References ................................................................................... 223 
 
 
 
x 
 
List of Figures 
Figure 1.1 A normal and an atherosclerotic artey ................................................ 8 
Figure 1.2 NF-κB activation pathway ................................................................... 10 
Figure 1.3 Schematic of the exogenous and endogenous lipid metabolism 
pathways .......................................................................................... 22 
Figure 1.4 Schematic representation of cholesterol efflux ................................... 25 
Figure 1.5 A schematic diagram of an LDL particle ............................................. 27 
Figure 1.6 A schematic diagram showing the oxidation of PUFA’s by free 
radical reaction ................................................................................. 34 
Figure 1.7 Chemical structure of cysteamine ...................................................... 47 
Figure 2.1 Aggregation of LDL by sphingomyelinase .......................................... 62 
Figure 2.2 Example chromatogram showing cholesterol, cholesteryl oleate, 
cholesteryl arachidonate and cholesteryl arachidonate in SMase-
LDL ................................................................................................... 69 
Figure 2.3 Example chromatogram showing cholesteryl linoleate 
hydroperoxide in SMase-LDL ........................................................... 70 
Figure 2.4 Example chromatogram showing 7-ketocholesterol in SMase-LDL ... 70 
Figure 2.5 Lysosomal pH calibration curve .......................................................... 78 
Figure 3.1 Chemical structures of probucol and DPPD ....................................... 87 
Figure 3.2 Comparison of the oxidation of LDL by ferrous and ferric iron at pH 
4.5 .................................................................................................... 91 
Figure 3.3 Kinetics of decrease of LDL-tryptophan fluorescence during Fe2+ 
and Fe3+ mediated oxidation............................................................. 92 
Figure 3.4 Kinetics of ferrous ion levels during LDL oxidation by FeSO4 at pH 
4.5 .................................................................................................... 94 
Figure 3.5 Effect of 13-HPODE on LDL oxidation with FeSO4 at pH 4.5 ............. 97 
Figure 3.6 Effect of 13-HPODE on LDL-tryptophan fluorescence during Fe2+ 
mediated oxidation. .......................................................................... 98 
Figure 3.7 Effect of probucol on LDL oxidation by iron at pH 4.5 ........................ 101 
Figure 3.8 Effect of probucol on LDL-tryptophan fluorescence during LDL 
oxidation by iron ............................................................................... 102 
Figure 3.9 Effect of DPPD on the oxidation of LDL by iron at pH 4.5 .................. 105 
Figure 3.10 Effect of DPPD on LDL-tryptophan fluorescence during LDL 
oxidation by iron ............................................................................... 106 
 
 
 
xi 
 
Figure 3.11 HPLC profile of LDL oxidation by iron in presence of probucol or 
DPPD ............................................................................................... 109 
Figure 3.12 Effect of cysteamine on LDL oxidation by iron at pH 4.5 .................. 113 
Figure 3.13 Effect of cysteamine on LDL-tryptophan fluorescence during 
oxidation by iron at pH 4.5 ................................................................ 114 
Figure 3.14 Effect of cysteamine on LDL cholesteryl esters during oxidation 
by iron at pH 4.5 ............................................................................... 117 
Figure 3.15 Effect of cysteamine on LDL oxidation products during oxidation 
by iron at pH 4.5 ............................................................................... 119 
Figure 4.1 Chemical structures of cysteine, amiodarone, propranolol and 7,8-
dihydroneopterin. .............................................................................. 130 
Figure 4.2 Comparison of antioxidant effect of cysteine and cysteamine on 
LDL oxidation by iron at pH 4.5 ........................................................ 134 
Figure 4.3 Comparison of antioxidant effect of propranolol and cysteamine on 
LDL oxidation by iron at pH 4.5 ........................................................ 137 
Figure 4.4 Comparison of antioxidant effect of 7,8-dihydroneopterin and 
cysteamine on LDL oxidation by iron at pH 4.5 ................................ 138 
Figure 4.5 Comparison of antioxidant effect of amiodarone and cysteamine 
on LDL oxidation by iron at pH 4.5 ................................................... 139 
Figure 4.6 Effect of cysteamine on aggregation of LDL during oxidation with 
iron at pH 4.5 .................................................................................... 141 
Figure 4.7 Effect of cysteamine on LDL oxidation by copper at pH 4.5 ............... 143 
Figure 4.8 The effect of cysteamine on LDL oxidation by copper at pH 7.4 ........ 145 
Figure 5.1 Pre-existing lipid hydroperoxides in SMase-LDL and native LDL ....... 155 
Figure 5.2 Comparison of oxidation of SMase-LDL and native LDL by iron at 
pH 4.5 ............................................................................................... 157 
Figure 5.3 Loss of LDL-tryptophan fluorescence during oxidation of SMase-
LDL and native LDL by iron at pH 4.5 ............................................... 158 
Figure 5.4 Comparison between lipid profile of SMase-LDL and native LDL 
during oxidation of by FeSO4 at pH 4.5 ............................................ 162 
Figure 5.5 Comparison between lipid profile of SMase-LDL and native LDL 
during oxidation of by FeSO4 at pH 4.5 ............................................ 164 
Figure 5.6 Oxidation product levels durng oxidation of SMase-LDL and native 
LDL by FeSO4 at pH 4.5 ................................................................... 166 
Figure 5.7 The effect of cysteamine on the oxidation of SMase-LDL by iron ....... 169 
 
 
 
xii 
 
Figure 5.8 The loss of LDL-tryptophan fluorescence during SMase-LDL 
oxidation by iron ............................................................................... 170 
Figure 5.9 Flow cytometry analysis of Foam-LPO in THP1 macrophages .......... 173 
Figure 5.10 Measure of lipid peroxidation by Foam-LPO in lysosomes of 
macrophages .................................................................................... 174 
Figure 5.11 Lysosomal ceroid formation .............................................................. 177 
Figure 5.12 Percentage ceroid in THP1 macrophages ........................................ 178 
Figure 6.1 Effect of SMase-LDL and cysteamine on lysosomal function of 
macrophages .................................................................................... 194 
Figure 6.2 Effect of lysosomal oxidation of LDL on lysosomal function of 
macrophages .................................................................................... 195 
Figure 6.3 Effect of lysosomal oxidation of SMase-LDL on the pH of 
lysosomes in THP-1 macrophages. .................................................. 198 
Figure 6.4 Effect of cysteamine on lysosomal pH of macrophages ..................... 199 
Figure 6.5 Effect of lysosomal oxidation of LDL on senescence of THP-1 
macrophages .................................................................................... 201 
Figure 6.6 Effect of cysteamine on SMase-LDL induced senescence in THP-1 
macrophages .................................................................................... 202 
Figure 6.7 Effect of SMase-LDL on TNF-α expression in THP-1 macrophages .. 205 
 
 
 
xiii 
 
List of Abbreviations 
 
ACAT   AcylCoA:cholesterol acyltransferase 
ABCA1  ATP binding cassette transporter-1 
ANOVA   One-way analysis of variance 
AP-1    Activator protein-1 
ApoB-100   Apolipoprotein B-100 
ApoE    Apolipoprotein E 
BHT   Butylated hydroxytoluene 
BP   Bathophenanthrolinedisulfonic acid 
BSA   Bovine serum albumin 
CA   Cholesteryl arachidonate 
CE   Cholesteryl esters 
CHD   Coronary heart disease 
CL   Cholesteryl linoleate 
CLOOH  Cholesteryl linoleate hydroperoxide 
CVD   Cardiovascular disease 
DMSO  Dimethyl sulphoxide 
DTPA   Diethylenetriaminepentacetate 
EDTA   Ethylenediaminetetraacetic acid 
EC   Endothelial cells 
ER   Endoplasmic reticulum 
FCS   Fetal calf serum 
FH   Familial hypercholesterolemia 
FITC   Fluorescein isothiocyanate 
HEPES   N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] 
HDL   High density lipoprotein 
HPODE  13S-hydroperoxy-9Z,11E-octadecadienoic acid 
HPLC   High performance liquid chromatography 
IDL   Intermediate density lipoprotein 
IFNγ   Interferon-γ 
IL   Interleukin 
 
 
 
xiv 
 
LAL   Lysosomal acid lipase 
LCAT   Lecithin:cholesterol acyltransferase 
LDL   Low density lipoprotein 
LPL    Lipoprotein lipase 
LOOH   Lipid hydroperoxide 
LOX-1   Lectin-like oxidised LDL receptor-1 
LPS   Lipopolysaccharide 
MCP-1  Monocyte chemotactic protein-1 
MES   2-(N-morpholino)ethanesulfonic acid 
MI   Myocardial infarction 
MMP   Matrix metalloproteinase 
NF-κB   Nuclear factor-kappa of activated B cells 
oxLDL   Oxidized LDL 
PAI-1   Plasminogen activator inhibitor 1 
PBS   Phosphate buffered saline 
PLA2   Phospholipase A2 
PMA    Phorbol 12-myristate 13-acetate 
PUFA   Polyunsaturated fatty acid 
RPMI   Roswell Park Memorial Institute 
SDS    Sodium dodecyl sulphate 
SR-A   Scavenger receptor A 
SR-B1  Scavenger receptor B1 
SREBP  Sterol regulatory element binding protein 
TNF-α   Tumour necrosis factor -alpha 
VCAM-1  Vascular cell adhesion molecule-1 
VLDL   Very low density lipoprotein 
VSMC   Vascular smooth muscle cell 
WHHL  Watanabe Heritable Hyperlipidemic 
 
 
 
1 
 
 
Chapter 1- Introduction 
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1.1 Atherosclerosis 
1.1.1 Definition and clinical significance  
Atherosclerosis is a pathological process characterised by the build-up of lipids 
and fibrous material in the walls of large and medium-sized arteries. 
Atherosclerosis is a major risk factor for many cardiovascular diseases (CVDs) 
including coronary heart disease (CHD), cerebrovascular disease, peripheral 
arterial disease and diseases of the aorta.   
CVD is the major cause of death in the United Kingdom (Bhatnagar et al., 2015) 
and worldwide (WHO, 2014).  The World Health Organisation estimate that in 
2012, 17.5 million people died globally from CVD, accounting for approximately 
one third of all death worldwide. Of these deaths, an estimated 7.4 million were 
due to coronary heart disease (CHD) and 6.7 million were due to stroke. Over 80% 
of these CVD deaths take place in low-and middle-income countries and occur 
almost equally in men and women. WHO estimates that CVD death will increase 
to reach 22.2 million by 2030, based on current projections (WHO, 2014).  
According to the British Heart Foundation, in 2014 alone over 154639 people died 
from CVD in the UK. One in six male deaths and one in nine female deaths were 
from coronary heart disease (CHD) - a total of nearly 74,000 deaths. Stroke 
caused nearly 39,282 deaths in the UK.  CVD is the most common cause of 
premature death in the UK causing 26% of premature death in men and 18% of 
premature death in women.  In total CVD is estimated to cost the UK economy just 
under £19 billion per year as a result of direct health costs, productivity losses and 
informal care of people with the disease (Bhatnagar et al., 2015).   
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1.1.2 Theories of Atherosclerosis 
Over the last century, a number of theories have been advanced to explain how 
atherosclerosis evolves. These hypotheses are not mutually exclusive and 
numerous experimental and clinical observations have shown how processes 
highlighted in one theory may be linked to those in another (Fuster et al., 1992, 
Huff et al., 2016). Much of the controversy over these theories has to do with 
individual opinion concerning which of the aspects of atherosclerosis is most 
important. 
1.1.2.1 Lipid Insudation Hypothesis 
This theory was proposed by the German pathologist Rudolf Virchow in 1856 
(Virchow, 1856). He suggested that the critical events in atherosclerosis centre on 
the focal accumulation of fat in the vessel wall and that the lipid in the 
atherosclerotic lesion is derived from the lipids in the blood (Mayerl et al., 2006). 
There is good evidence now that the lipid in the plaque comes from the blood; 
there is also substantial evidence correlating the severity of hypercholesterolaemia 
(particularly elevated LDL cholesterol) with the severity of atherosclerosis both in 
human and in animal models (Gould, 1998; Steinberg, 2002). Although there is still 
controversy over how the lipid accumulates in the vessel wall, the hypothesis is 
widely accepted. Whereas this hypothesis explains the source of plaque lipid, it 
does not provide a complete explanation for the pathogenesis of the 
atherosclerotic lesion. Since many other clinically important features of the plaque, 
such as smooth muscle cell (SMC) proliferation and thrombosis, remain 
unexplained, lipid deposition appears to be necessary but not sufficient to explain 
plaque development and growth (Brown et al., 1980). 
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1.1.2.2 The Incrustation Hypothesis  
In 1852, Carl Rokitansky, a renowned Austrian pathologist, proposed the 
‘incrustation theory’ of atherosclerosis. This theory asserted that material from 
blood gets deposited on the inner surface of arteries and leads to thickening of the 
inner lining (Rokitansky, 1852).  A modern version of this idea holds that intimal 
thickenings present in artery walls result from fibrin deposition from thrombi, with 
subsequent organization by smooth muscle cells and secondary lipid accumulation 
(Duguid, 1946). There is however little evidence that thrombosis is a factor in the 
initiation of spontaneous, or naturally occurring, atherosclerosis, but substantial 
evidence suggests that thrombosis has an essential role in the progression of 
spontaneous atherosclerosis (Fuster et al., 1991). 
1.1.2.3 The Reaction-to-Injury Hypothesis 
This theory proposed that the cells at atherosclerotic sites played an active role in 
the initiation and progression of the lesions (Ross and Glomset, 1973).   According 
to the hypothesis, endothelial injury or dysfunction (loss of normal homeostatic 
function) enhances endothelial adhesiveness for leukocytes and platelets.  The 
recruited leucocytes and platelets release cytokines and growth factors which 
cause smooth muscle cells to migrate to the intima and proliferate.  Alternatively, 
monocytes might be attracted to the zone of injury; the monocyte/macrophage 
might then be activated and start to elaborate growth-promoting activity (Ross and 
Glomset, 1976a, 1976b; Ross, 1999). The reaction-to-injury hypothesis suggests a 
possible mechanism for the accumulation of connective tissue cells and matrix but 
it fails to provide an explanation for the lipid accumulation or the monoclonal 
nature of the advanced atherosclerotic plaque (Benditt and Benditt, 1973). 
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1.1.2.4 The Monoclonal Hypothesis 
The monoclonal concept is focused on smooth muscle proliferation and comes 
from the observation that the smooth muscle cells that form fibrous caps of 
atherosclerotic plaques appear to migrate from the underlying media and then 
proliferate. This hypothesis is based on the observation that individual plaques of 
human females who are heterozygotes for the X-linked marker glucose-6-
phosphate dehydrogenase frequently exhibit one, but not both, of the isotypes of 
this enzyme (Benditt and Benditt, 1973). Single cells might be stimulated to enter 
the growth cycle and undergo several rounds of division leading to the formation of 
a monoclonal lesion. The mechanism of cell activation leading to such lesions is 
not evident as yet; the only other known monoclonal cell masses in humans are 
neoplasias (e.g., leiomyomas). This would tend to suggest carcinogens or possibly 
viruses as possible etiologic agents and thereby might explain the link between 
cigarette smoking and atherosclerosis (Murry et al., 1997). 
1.1.2.5 The Lipoprotein Oxidation Theory 
The 'oxidation theory' for atherosclerosis proposes that lipid and/or protein 
oxidation products are responsible for lesion formation/development. It suggests 
that some pathogenetic stimuli take part in the production of reactive oxidative 
species in the endothelial microenvironment which target the intimal low-density 
lipoprotein (LDL). Oxidation of LDL particles represents a crucial process in the 
development of modified LDL forms. This theory originated from studies 
demonstrating that LDL oxidised by endothelial cells could be internalized and 
accumulated quickly by macrophages, leading to foam cell formation (Steinbrecher 
et al., 1984). 
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1.1.3 Development of atherosclerotic plaque 
1.1.3.1 Normal Arterial Wall 
A normal artery wall consists of three layers: the intima, closest to the arterial 
lumen and therefore most ‘intimate’ with the blood; the media which is the middle 
layer; and the outer layer, the adventitia (Figure 1.1). The intimal surface consists 
of a single layer of endothelial cells which acts as a metabolically active barrier 
between circulating blood and the vessel wall. The internal elastic lamella 
separates the intima from the media. The media consists predominantly of layers 
of smooth muscle cells surrounded by an extracellular matrix consisting mainly of 
elastic fibres and collagen.  The external elastic lamina separates this layer from 
the outermost layer, which is known as the adventitia. The adventitia consists of a 
loose matrix of elastin, fibroblasts and collagen and contains the nerves, 
lymphatics and blood vessels (vasa vasorum) that nourish the cells of the arterial 
wall. The living artery wall is a scene of dynamic interchange between its cellular 
components – most importantly, endothelial cells, vascular smooth muscle cells, 
and their surrounding extracellular matrix (Lilly, 2012; Yuan XM, Brunk UT, 2000). 
1.1.3.2 Atherosclerotic plaque development 
Animal models of atherosclerosis, by virtue of the fact that the disease process 
happens much more quickly in them than in humans, have provided an insight into 
how atherosclerosis develops and progresses. The genetically modified apo E-
deficient mouse and the Watanabe heritable hypercholesteraemic rabbit, which 
lacks a functional LDL receptor, have been widely studied. The first observable 
change in these hypercholesteraemic animals is the accumulation of lipid particles 
and their aggregates in the intima of the arteries (Williams and Tabas, 1995). This 
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is followed by the adherence of monocytes to the endothelial layer and their 
migration into the intima, where they differentiate into macrophages. Macrophages 
accumulate lipid and become foam cells. As the lesion progresses, an extracellular 
pool of lipid is formed, probably due to the release of lipids from dying foam cells 
or direct deposition from lipoproteins. In more advanced lesions, this core of lipid is 
separated from the lumen by a fibrous cap. The fibrous cap is formed when 
smooth muscle cells migrate into the intima from the media and begin to secret 
extracellular matrix. As the lesions advance they can encroach upon the lumen, 
restricting blood flow through the arteries which in the case of the coronary artery 
can cause angina. The advanced lesions are vulnerable to rupture and can trigger 
the formation of a thrombus. The thrombus may occlude the arteries supplying the 
heart causing a myocardial infarction (MI), or the brain causing a stroke. A 
diagram of advanced atherosclerotic lesion is shown in Figure 1.1.  
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
  
                   
 
                          
Figure 1.1 A normal and an atherosclerotic artey 
The diagram shows a normal artery and an atherosclerotic artery at the ‘atheroma’ stage 
of the disease. The lumen of the atherosclerotic artery has not been compromised by the 
plaque, due to the outward compensatory expansion of the artery. 
 
1.1.3.3 Lesion-prone areas 
Atherosclerotic lesions form preferentially on the inner curvatures of the arteries or 
at arterial branch points. The development of lesions at these sites is thought to be 
due to increased or disturbed shear stress (Davies, 1997). Shear stress is the drag 
force exerted on the endothelium as a result of blood flow. It modulates endothelial 
cell structure and function through a mechanotransduction mechanism and low 
shear stress leads to the activation of transcription factors such as nuclear factor-
kappa B (NF-κB) (Tzima et al., 2005).  
Lipid core 
Adventitia 
Media 
Intima 
Lumen 
    Normal artery     Atherosclerotic artery 
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NF-κB is the collective name for a group of ubiquitous transcription factors that 
regulate cellular responses to multiple stimuli, primarily by initiating transcription of 
proinflammatory genes (Li and Verma, 2002). The NF-κB dimer, consisting 
commonly of the subunits p50 and p65 (RelA), is present in the cytosol in an 
inactive state, bound to inhibitory proteins that are collectively termed as IκB. Upon 
cell stimulation, IκB is phosphorylated by IκB kinase complex (IKK) leading to 
degradation of the inhibitor, leaving NF-κB free to translocate into the nucleus and 
induce transcription (Ghosh and Karin, 2002, Pomerantz and Baltimore, 2002). 
The classical activation of the canonical NF-κB pathway (Figure 1.2) can be 
initiated by a wide range of stimuli. Firstly, cytokines such as tumor necrosis factor 
(TNF) and interleukin-1 (IL-1) acting as paracrine signals lead to NF-kB activation. 
Additionally, pathogen associated molecular patterns (PAMPs) originating from 
viruses, bacteria and fungi, function as ligands for different Toll-like receptors 
(TLRs), upstream of the NF-kB signalling pathway (de Winther et al., 2005).  
Atherosclerotic processes involve several mediators including adhesion molecules 
and chemokines, which play a role in different stages of the disease from the 
initiation of plaque formation to the plaque rupture (Pamukcu et al., 2011). 
Activation of NF-κB leads to expression of genes encoding proteins that are 
thought to be involved in atherogenesis, such as vascular cell adhesion molecule 
1 (VCAM-1) which binds and recruits inflammatory cells such as monocytes, 
aiding their infiltration into the intima (Monaco and Paleolog, 2004, Yu et al., 
2015). In areas of high laminar shear stress, the endothelial cells adapt to the flow 
and the response to the stress is downregulated, however, at areas of low or 
disturbed stress, the genes are activated in a sustained manner (Mohan et al., 
1999). The expression of proteins encoded by NF-κB activated genes is thought to 
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be the initial event that occurs at lesion-prone sites, before other markers of 
atherosclerosis  are apparent (Yu et al., 2015).  
 
Adapted from (de Winther et al., 2005) 
 Figure 1.2 NF-κB activation pathway 
The NF-κB activation can occur by two ways. The classical NF-κB activation pathway (left) 
involves the activation of the IKK complex with the subsequent degradation of IκBα and 
nuclear translocation of the NF-κB dimer. The alternative NF-κB activation cascade (right) 
is mediated through IKK1 and results in the processing of p100 to p52, resulting in the 
nuclear transfer of the relB-p52 dimer. 
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1.1.3.4 Classification of lesions 
Pathologists have subdivided the lesions of atherosclerosis into various stages 
based on their morphology. In 1994-95, the American Heart Association (AHA) 
through the appointment of a consortium of investigators in the field of 
atherosclerosis classified the atherosclerotic lesions into 8 categories (Table 1.1) 
(Stary et al., 1994a). Early lesions, marked by foam cell infiltration (type I lesions), 
mature into lesions with smooth muscle infiltration and lipid (type II, “fatty streak”) 
and connective tissue deposition (type III). The early lesions develop within the 
first three decades of life in areas of localized turbulent flow within the coronary 
arteries. As these early lesions grow into softer plaques with a high extracellular 
lipid and cholesteryl ester content and progressively thinner fibrous cap (types IV–
Va, “atheroma”), they become more vulnerable to disruption (Loree et al., 1994; 
Stary et al., 1995). Disruption of plaque exposes thrombogenic substances within 
the plaque to blood and may result in thrombotic occlusion of the affected vessel 
(type VI or complicated lesions). When they achieve a significant degree of 
stenosis without sufficient collateralization (circulation of blood established through 
enlargement of minor vessels and anastomosis of vessels with those of adjacent 
parts when a major vein or artery is functionally impaired), these lesions result in 
acute coronary syndromes. In the period after the acute syndrome, thrombus over 
the complicated disrupted lesion organizes and the lesion calcifies (type Vb) or 
fibroses (type Vc) into a chronic stenotic lesion. The complicated lesion may 
contain organizing thrombus from prior episodes of plaque rupture, cap ulceration 
or intra-plaque haemorrhage, followed by lysis of the thrombus and organization. 
The AHA classification is based on the premise that plaque rupture is the only 
mechanism responsible for coronary thrombosis however, some studies have 
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described existence of plaque erosion as well (van der Wal et al., 1994; Virmani et 
al., 2000).  
Table 1.1 Atherosclerotic lesion types according to the Committee on Vascular 
Lesions of the Council on Arteriosclerosis, American Heart Association (Stary et 
al., 1994a, 1994b) 
Plaque type Characteristics of plaque 
Associated 
clinical syndrome 
I, “Initial Lesion” 
Intimal thickening, macrophages, 
isolated foam cells 
Asymptomatic 
IIa, “Progression–
prone type II lesion” 
Accumulation of intracellular lipid in 
infiltrating macrophages and smooth 
muscle cells 
Asymptomatic 
IIb, “Progression-
resistant type II lesion” 
Accumulation of intracellular lipid in 
infiltrating macrophages and smooth 
muscle cells 
Asymptomatic 
III, “Intermediate 
lesion” 
(preatheroma) 
As above, plus incipient extracellular 
lipid and connective tissue 
deposition 
Asymptomatic 
IV, “Atheroma” 
 
Large extracellular intimal lipid core; 
inflammatory cell infiltration, 
including macrophages, foam cells 
and T-cells 
Usually 
asymptomatic; can 
also be associated 
with stable angina 
Va, “Fibroatheroma” Atheroma with fibrous layer or layers Same as type IV 
Vb “Calcific lesion” 
Atheroma with extensive calcification 
in the lipid core or elsewhere in the 
lesion 
Stable angina 
pectoris; can also 
be asymptomatic 
Vc “Fibratheroma” 
Fibrosed atheroma or organized 
mural thrombus with minimal or 
absent lipid component 
Same as type Vb 
VI, “Complicated 
lesion” 
Disrupted type IV or V lesion with 
intramural haemorrhage and/or 
overlying thrombosis 
MI or thrombotic 
stroke 
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1.1.3.5 Plaque vulnerability 
It is well established now that the majority of fatal MI arises due to rupture of the 
fibrous cap of advanced atherosclerotic plaques (Braganza and Bennett, 2001, 
Davies, 2000, Falk et al., 1995). The plaques that are more likely to rupture are 
known as ‘vulnerable’ plaques and are characterised as being rich in 
macrophages and having a thin, collagen fibrous cap, covering a large necrotic 
core (Shah, 2003). Plaque rupture is often localised to the regions of the 
atherosclerotic lesion where macrophages are found in abundance (Bjorkerud and 
Bjorkerud, 1996). Macrophages express various proteases including matrix 
metalloproteinases (MMPs) which degrade extracellular matrix material, thereby 
thinning the fibrous cap and making it more susceptible to rupture (Anderson and 
Mosser, 2002, Galis et al., 1995, Jones et al., 2003a, Newby, 2007). Macrophages 
also secrete pro-inflammatory cytokines such as interleukin-1β, TNF-α and nitric 
oxide which are able to induce expression of MMPs by smooth muscle cells (Galis 
et al., 1994, Lee et al., 1995, Liang et al., 2007).  
Plaque stability may be further disrupted by the death of macrophages and smooth 
muscle cells, particularly if death occurs near the surface of the atherosclerotic 
lesion. The morphological changes that occur in apoptosis are due to the action of 
a family of cysteine proteases known as caspases. Caspases are activated by 
proteolytic cleavage and activate each other in a cascade that leads to the 
cleavage of cellular proteins (Hirata et al., 1998). The caspase cascade can be 
activated by both extrinsic and intrinsic pathways. The major extrinsic pathways 
occur via membrane bound receptors of the tumour necrosis family (TNF), such as 
the TNF-receptor 1 and the Fas receptor (reviewed in Kavurma et al., 2008, 
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Schmitz et al., 2000). These receptors contain death domains within their 
cytoplasmic tails. When the receptors bind their ligands (such as Fas and TNF-
alpha) they aggregate, leading to the recruitment and binding of adaptor proteins, 
such as Fas-associated death domain (FADD), to the death domain of the 
receptor (Muzio et al., 1996). The main intrinsic pathway of apoptosis involves 
cytochrome c release from the mitochondria, a process that is regulated by the 
Bcl-2 family of proteins. Released cytochrome c binds to apoptotic protease 
activating factor 1 (Apaf-1) and procaspase 9 (reviewed in Kavurma et al., 2008). It 
is noteworthy that apoptotic macrophages and SMCs are found in the shoulder 
region and fibrous cap of plaques (Falk et al., 1995, Kolodgie et al., 2000, Lim and 
Park, 2014). Moreover, the pro-apoptotic Fas receptor appears to be expressed on 
up to 66% of all cells in the fibrous cap (Geng et al., 1997). Due to the fact that 
macrophages play a central role in plaque rupture, one would assume that 
macrophage apoptosis in advanced plaques would stabilise the plaque, however 
this is usually not the case (Schrijvers et al., 2007). In advanced plaques the ability 
of macrophages to remove apoptotic bodies is impaired causing secondary 
necrosis. Secondary necrosis triggers inflammation and may contribute to the 
growth of the necrotic core (Clarke et al., 2006, Gautier et al., 2009, Tabas, 2004). 
Plaque rupture is a structural defect in the fibrous cap which exposes the highly 
thrombogenic core, including collagen to coagulation factors and platelets present 
in the bloodstream (Farb et al., 1996). Macrophages within the plaque express 
tissue factor which triggers the coagulation cascade and plasminogen activator 
inhibitor-1, which inhibits fibrinolysis and thus stabilises thrombi (Hutter et al., 
2004, Lupu et al., 1993, Oikonomopoulou et al., 2012, Wilcox et al., 1989). 
Superficial erosion of endothelial cells from the surface of the plaque can also 
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expose the plaque contents to the bloodstream, triggering thrombus formation 
(Matsuzawa and Lerman, 2014). Activated endothelial cells express MMP-1 that 
activates MMP-2, which in turn can cleave the collagen in the basement 
membrane leading to endothelial cell erosion (Rajavashisth et al., 1999). The 
activated endothelial cells may also stabilise the thrombus through the expression 
of fibrinolysis inhibitors such as PAI-1 (Schneiderman et al., 1992). 
Neovascularisation (the formation of new blood vessels) is another factor that has 
emerged as a feature of vulnerable plaques (Huang et al., 2010, McCarthy et al., 
1999, Mofidi et al., 2001, Simone et al., 2014). Neovessels mainly originate from 
the adventitia and grow into the base of atherosclerotic lesions, thus providing an 
alternative entry pathway for monocytes and immune cells (Kumamoto et al., 
1995). The plaque neovessels lack supporting cells and are thin and fragile, giving 
rise to local extravasation of plasma proteins and erythrocytes (Sluimer et al., 
2009). Such intraplaque haemorrhages can cause plaque instability, and may 
expand the necrotic core and promote inflammation (Kolodgie  et al., 2003).  
1.1.4 Risk factors 
Classical risk factors for CVD have been identified from the large prospective 
cohort studies such as the Framingham Heart Study, the Seven Countries study 
and the INTERHEART study. It is estimated that 90% of the population attributable 
cardiovascular events are due to smoking, high blood pressure, obesity, abnormal 
lipids, sedentary lifestyle and diabetes mellitus. Prevention of cardiovascular 
disease morbidity and mortality in patients at high risk of developing the disease 
(primary prevention) and in patients with existing CVD (secondary prevention) is 
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largely through modification of these risk factors, through lifestyle changes and /or 
drug therapy. 
1.1.4.1 Lipids 
Abnormal blood lipids are a major risk factor for CVD. These include elevated total 
plasma cholesterol, triglyceride and LDL levels and lowered high density 
lipoprotein (HDL) (Sherpa et al., 2011). Hypertriglyceridemia is often associated 
with insulin resistance, diabetes mellitus, obesity and hyperinsulinemia. Fasting 
triglycerides are predictive of future CHD among men independent of age, lipid-
lowering medication, diabetes, total cholesterol, in a population in which metabolic 
syndrome prevails (Onat et al., 2006).  
1.1.4.2 High blood pressure 
Raised blood pressure is a risk factor for ischaemic and haemorrhagic stroke as 
well as coronary heart disease (Whitworth, 2003). The risk of death from CVD 
increases with increasing blood pressure (Kannel, 1996, McMahon et al., 2011, 
Pei et al., 2011). Randomised clinical trials have indicated that a reduction in blood 
pressure can reduce stroke by 40% and myocardial infarction by 15% (Chalmers 
et al., 2003). Following a stroke or transient ischaemic attack (TIA), blood pressure 
lowering has been shown to reduce subsequent major cardiovascular events 
(Lawes et al., 2004, Williams et al., 2004).  
1.1.4.3 Obesity 
Obesity has been shown to be an important long term predictor of CVD incidence 
among individuals. CVD risk increases as body weight (measured as body mass 
index, BMI) increases (Jousilahti et al., 1996, Khosravi et al., 2012, Poirier et al., 
2006). The distribution of body fat (adipose tissue) is thought to be important, with 
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an increase in abdominal fat causing an increased CVD risk (Després, 2012, 
Zhang et al., 2008). Adipose tissue secretes various cytokines and pro-
inflammatory factors such as tumour necrosis factor-alpha (TNF-α), IL-6 and IL-1, 
which are involved in atherosclerosis and insulin resistance (Ahima and Flier, 
2000, Fortuno et al., 2003, Hauner, 2005). Weight loss has been shown to affect 
CVD, for example, in a study conducted by Pascual et al. (2009) metabolic 
syndrome participants who lost weight during the trial had decreased systolic and 
diastolic blood pressures as well as LDL cholesterol. 
1.1.4.4 Diabetes 
Diabetic patients both types 1 and 2 are at a higher risk of CVD compared with 
non-diabetics, even when taking into account other risk factors (Bierman, 1992, 
Laakso, 2010). The Framingham Study demonstrated that diabetes mellitus is 
associated with a two to five fold increase in CVD and related death (Hubert et al., 
1983). Diabetics lack the ability to make sufficient insulin or there is insulin 
resistance and thus glucose becomes abundant in the blood. With glucose build 
up, arteries become damaged perpetuating CVD (Kalofoutis et al., 2007, Wilcox, 
2005). Some of the increased risk for CVD seen in diabetic individuals is 
attributable to the concurrent presence of other risk factors such as dyslipidaemia, 
hypertension, and obesity (Buse et al., 2007). Management of these risk factors 
has been shown to effectively reduce the incidence of major coronary events in 
persons with diabetes (Gibbons et al., 2002).  
1.1.4.5 Smoking 
Smoking has been recognized as an increased risk for CVD for over 40 years 
(Mahan and Krause, 2012). The risk of developing CVD from smoking is related to 
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the duration of smoking and the amount of tobacco smoked daily (Ambrose and 
Barua, 2004, Benowitz, 2003, Burns, 2003). A 50 year cohort study of British 
doctors found that mortality from CHD was around 60% higher in smokers than 
non-smokers (Doll et al., 2004). Studies have shown that even passive smoking 
increases the risk of CHD, and it has been seen that there is about a 25% 
increase in risk in those regularly exposed to passive smoking (He et al., 1999, 
Law et al., 1997, Metsios et al., 2010, Whincup et al., 2004). Cessation of smoking 
has been seen to decline the CVD risk (Mons et al., 2015). The risk in people who 
show no symptoms drops to the level of those that have never smoked within 10 
years of stopping (Dobson et al., 1991, Kawachi et al., 1994). Smoking has been 
shown to increase fibrinogen levels (Kaptoge et al., 2007), levels of tissue factor 
(Matetzky et al., 2000, Sambola et al., 2003), platelet P-selectin expression 
(Neubauer et al., 2009) and platelet thrombin generation (Hioki et al., 2001). 
Smokers have high PAI-1 levels, which impairs the fibrinolytic activity of the 
plasma (Simpson et al., 1997) and thus delays thrombus dissolution. 
1.1.4.6 Sedentary lifestyle  
Low level of fitness (i.e. physical inactivity) is an independent risk factor for CVD 
(Mahan and Krause, 2012). Sedentary lifestyle has been shown to increase the 
risk of heart disease and stroke by 50% (Warren et al., 2010). Without exercise, 
atherogenesis can occur rapidly forming plaque in the arterial walls and decrease 
the vascularity of the myocardium (Okabe et al., 2006, Puffer, 2001). Physical 
inactivity also has an impact on other risk factors including hypertension, 
triglycerides, HDL, diabetes and obesity which when combined with lack of 
exercise can increase the risk of CVD (Braith et al., 1994, Hills et al., 2011, Taylor 
et al., 2004). The UK government recommends that adults participate in moderate 
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physical activity for a minimum of thirty min or at least five days of the week, 
however more men meet these requirements then women and it seems to decline 
with age in both the genders (BHF, 2015).  
1.1.4.7 Non-modifiable risk factors 
Non-modifiable risk factors include age, gender and family history. In both men 
and women, with increase in age, there is an increase in CVD mortality rates, with 
96% of death from CHD or stroke occurring in people aged 55 or over (Yazdanyar 
and Newman, 2009). The incidence of premature CVD in men aged 35 to 44 is 
about three times that of women of the same age (Mahan & Escott-Stump, 2008). 
There is a speculation that oestrogen may play a protective role against CVD in 
young women, however large clinical trials of hormone replacement therapy in 
postmenopausal women have shown no cardioprotective effect (Yang and 
Reckelhoff, 2011). Ethnic differences have also been seen to affect the CVD risk, 
with some ethnic groups, like South Asians, African-Americans and Mexican 
Americans, exhibiting a higher prevalence of CVD than Caucasians (Forouhi and 
Sattar, 2006).  
1.1.4.8 Other risk factors 
Apart from the above mentioned risk factors, there are other factors which are 
under investigation. They include elevated levels of C-reactive protein (CRP), 
lipoprotein (a), fibrinogen and homocysteine. C-reactive protein and fibrinogen are 
increased during the inflammatory response (Lagrand et al., 1999). Fibrinogen is 
cleaved during the coagulation cascade to form fibrin, a major component of blood 
clots (Herrick et al., 1999). Lipoprotein (a) is an LDL-like particle, where an 
apolipoprotein (a) molecule is attached via a disulphide bond to apolipoprotein B-
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100 and its levels are seen to increase during inflammation (Milionis et al., 2000). 
Studies have also shown that there is an increased relative cardiovascular risk in 
patients with higher CRP concentrations compared to baseline concentrations in 
healthy individuals (Ridker, 2003). Homocysteine is a sulphur containing amino 
acid which is formed as a by-product of methionine metabolism. Large meta-
analyses have shown that increased homocysteine levels are associated with 
increased risk of CHD (Ganguly and Alam, 2015, Wierzbicki, 2007).  
 
1.2 Lipid metabolism 
1.2.1 Lipoproteins 
Lipids are fats that are either absorbed from food or synthesised by cells. Lipids 
are hydrophobic and insoluble in water, so the dietary and endogenously produced 
lipids are transported in the blood plasma bound to proteins, known as 
apolipoproteins. Lipoproteins are classified by size and density (defined as the 
ratio of lipid to protein) into five classes, namely chylomicrons, very low density 
lipoproteins (VLDL), intermediate density lipoproteins (IDL), LDL and HDL. Apart 
from different densities, the classes of lipoproteins differ in their lipid composition, 
size, apolipoprotein composition and electrophoretic mobility. As well as playing a 
structural role, apolipoproteins are ligands for lipoprotein receptors, facilitating the 
cellular uptake of lipoproteins (Feingold and Grunfeld, 2000, Zamora and Hidalgo, 
2016).  
 
 
 
21 
 
1.2.2 Exogenous metabolism 
The vast majority (>95%) of dietary lipids are triglycerides; and the rest are free 
fatty acids, phospholipids, cholesterol and fat-soluble vitamins (Burdge and 
Calder, 2015). The dietary triglycerides and cholesterol are emulsified by 
combination with bile acid and phospholipids to form micelles before being 
hydrolysed in the intestines by pancreatic enzymes. After absorption, triglycerides 
and cholesterol are re-esterified in the intestinal mucosal cells and then coupled 
with various apolipoproteins (e.g. apolipoprotein-B48), phospholipids, and 
unesterified cholesterol into lipoprotein particles called chylomicrons (Mansbach 
and Siddiqi, 2010) (Figure 1.3). Chylomicrons are secreted from the intestinal 
mucosa into the bloodstream via the lymph system and the thoracic duct. In the 
bloodstream, chylomicrons acquire apolipoprotein C and E from HDL and deliver 
triglycerides to muscles for use as an energy source or to adipose tissue for 
storage. The triglycerides are then removed from the chylomicrons by the action of 
an enzyme called lipoprotein lipase which is attached to the endothelium of 
capillaries perfusing muscle and adipose tissue (Merkel et al., 2002). HDL 
transfers cholesteryl esters to the chylomicrons in exchange for triglycerides 
through the action of cholesteryl ester transfer protein (CETP) (Barter et al., 2003, 
Chung et al., 2004). The resultant chylomicron remnants richer in cholesterol 
travels to the liver to be cleared from the blood, through a process mediated by 
apolipoprotein E (Havel, 1998).  
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Figure 1.3 Schematic diagram of the exogenous and endogenous lipid metabolism 
pathways (McLaughlin, 2014) 
 
1.2.3 Endogenous metabolism 
The liver constantly synthesises triglycerides from free fatty acids and 
carbohydrates, which are secreted into the circulation in the core of very-low-
density lipoprotein particles (VLDL) (Janero et al., 1984) (Figure 1.3). In the tissue 
capillaries, lipoprotein lipase causes hydrolysis of the triglyceride-rich core of the 
VLDL particles producing smaller remnant VLDL particles rich in cholesteryl esters 
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(intermediate-density lipoproteins, IDL) and liberation of free fatty acids (Merkel et 
al., 2002). The resultant cholesteryl ester-rich IDL particles can be removed by the 
liver via LDL receptors or can lose lipoprotein E and further depleted by lipoprotein 
or hepatic lipases to from LDL particles (Feingold and Grunfeld, 2000). The LDL 
particles circulate in the bloodstream and can be absorbed by cells in the liver or 
peripheral tissues. The particles can bind to the target tissue with the LDL receptor 
(Goldstein and Brown, 2009) through apolipoprotein B-100 and internalised by 
endocytosis, whereby they are then hydrolysed in lysosomes to release lipids such 
as cholesterol (Myant, 1990).  
1.2.4 Cellular cholesterol metabolism 
Cholesterol is delivered to cells via LDL through LDL receptors found on the 
plasma membrane of most cells (Goldstein and Brown, 1973, 1974). Cholesterol 
import is initiated by the interaction of the apolipoprotein B-100 (apoB-100) part of 
the LDL with the LDL receptor (Mahley et al., 1977). The high efficiency of 
internalization is assured by clustering of the LDL receptor in clathrin-coated pits 
found on the cell surface (Anderson et al., 1977, Pearse, 1987), which are pinched 
off to form clathrin-coated vesicles inside the cells (Hirst and Robinson, 1998, Roth 
and Porter, 1964).  These endocytic vesicles fuse with lysosomes, in which the 
protein moiety of LDL is broken down to free amino acids and the cholesteryl 
esters are hydrolysed by lysosomal acid lipase, releasing free cholesterol (Brown 
and Goldstein, 1975). The resulting free cholesterol crosses the lysosomal 
membrane, with the aid of proteins known as Niemann-Pick C1 (NPC1) and 
Niemann-Pick C2 (NPC2) (Frolov et al., 2003, Infante et al., 2008), and is thus 
distributed to other membranes, such as the endoplasmic reticulum, plasma 
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membrane or mitochondria (Maxfield and Wustner, 2002). Cellular cholesterol 
synthesis, uptake and processing reactions are regulated by two main nuclear 
receptor systems, sterol regulatory element binding proteins (SREBPs) (Wang et 
al., 1994) and liver X receptors (LXRs) (Janowski et al., 1996). SREBP activation 
increases the transcription of gene products (LDL receptors and 3-hydroxy-3-
methylglutaryl coenzyme A reductase) that function to increase cellular cholesterol 
levels, whereas LXR activation facilitates cholesterol removal from peripheral cells 
via reverse cholesterol transport and increased biliary sterol secretion (Goldstein 
et al., 2006, Tontonoz and Mangelsdorf, 2003). Intracellular cholesterol also 
stimulates cholesterol esterification by the enzyme acyl coenzyme A:cholesterol 
acyltransferase (ACAT), so excess cholesterol is stored as cholesteryl esters in 
cytoplasmic droplets (Cheng et al., 1995).   
1.2.5 Reverse cholesterol transport 
Reverse cholesterol transport is a multi-step process resulting in the net 
movement of cholesterol from peripheral tissues back to the liver via the plasma 
(Tall, 1998). Figure 1.4 shows the schematic representation of reverse cholesterol 
transport process. The first step in reverse cholesterol transport is efflux of free 
cholesterol from the cell plasma membrane to HDL, either by transporter-
independent or transporter-dependent mechanisms. The transporter-independent 
pathway involves simple diffusion (aqueous diffusion pathway) and facilitated 
diffusion (SR-BI mediated pathway). The active processes invlove ATP-binding 
cassette (ABC) family of transmembrane transporters (ABC1 and ABCG1) (Adorni 
et al., 2007).  The free cholesterol is esterified in the HDL particles by lecithin–
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cholesterol acyltransferase (LCAT) which is then sequestered into the core of a 
lipoprotein particle (Glomset et al., 1966). 
 
Figure 1.4 Schematic representation of cholesterol efflux 
Arrows are indicative of cholesterol movement and particle maturation, (Figure modified 
from Rader and Tall (2012) 
On the other hand, the tissue-derived cholesteryl esters in HDL can also be 
transferred to the apoB-containing lipoproteins, in exchange for triglycerides, 
through the action of cholesteryl ester transfer protein (CETP) (Agellon et al., 
1991, Lewis and Rader, 2005). As reverse cholesterol transport removes 
cholesterol from lipid-laden macrophages within atherosclerotic plaques, modifying 
HDL plasma concentrations and upregulating reverse cholesterol transport are the 
bases of several therapeutic strategies for the treatment of atherosclerosis that are 
currently being developed (Ono, 2012). 
Macrophage 
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1.3 Low Density Lipoprotein (LDL) 
1.3.1 Structure and characteristics of LDL 
Lipoproteins are sub-microscopic particles composed of lipid and protein held 
together by non-covalent forces. Lipoprotein particles within the density limits of 
1.019–1.063 g/ml are referred to as LDL (Atkinson et al., 1977). They have an 
average diameter of 22 nm and are important for the transport of cholesterol in the 
blood and around the body, for use by cells (Segrest et al., 2001). The overall 
structure of an LDL molecule is that of a putative spheroidal micro-emulsion 
(Figure 1.5) with the core consisting of about 170 triglyceride and 1600 cholesteryl 
ester molecules and the surface monolayer comprising about 700 phospholipid 
molecules and a single copy of a protein called apoB-100 (513,000 daltons).  In 
addition, they also contain about 600 molecules of unesterified cholesterol, of 
which about one-third is located in the core and two-thirds in the surface (Lund-
Katz and Phillips, 1986). 
The main phospholipid components are phosphatidylcholine (about 450 
molecules/LDL particle) and sphingomyelin (about 185 molecules/LDL particle). 
The LDL particles also contain lysophosphatidylcholine (about 80 molecules/LDL 
particle), phosphatidylethanolamine (about 10 molecules/LDL particle), 
diacylglycerol (about 7 molecules/LDL particle), ceramide (about 2 molecules/LDL 
particle) and some phosphatidylinositol (Hevonoja et al., 2000). In addition to 
lipids, LDL particles also carry lipophilic antioxidants, such as α-tocopherol (about 
6 molecules/LDL particle) and minute amounts of γ-tocopherol, carotenoids, 
oxycarotenoids and ubiquinol-10 (Esterbauer et al., 1992). The particles are in a 
dynamic state, their structure and physical properties being dependent on their 
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lipid composition as well as on the conformation of apoB-100 (Esterbauer et al., 
1992). 
 
 
 
 
 
Figure 1.5 A schematic diagram of an LDL particle  
The hydrophobic core of LDL constitutes of cholesteryl esters, triglycerides and some free 
cholesterol while the outer layer constitutes free cholesterol and phospholipids surrounded 
by apoprotein B-100 molecule. 
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1.3.2 LDL and atherosclerosis 
There is abundant evidence from experimental data, epidemiological studies, 
therapeutic studies of LDL lowering drugs and genetic studies that links LDL with 
atherosclerosis. In 1913 Nikolai N. Anitschkow, a Russian pathologist, 
demonstrated that feeding a high cholesterol diet to rabbits resulted in high plasma 
cholesterol levels and the formation of lesions resembling atherosclerotic lesions 
in humans (Steinberg, 2004). In 1950 Gofman and Lingren also observed that 
feeding rabbits with a high cholesterol diet for 15 weeks increased the plasma LDL 
levels in them which correlated with the degree of atherosclerosis that they 
developed.  The group also found a correlation between the higher LDL levels  in 
blood  and  incidences of myocardial infarction in humans (Gofman and Lindgren, 
1950).  
Further evidence to suggest that high LDL levels were an independent cause of 
atherosclerosis and CHD came from the observation that patients with familial 
hypercholesterolaemia (FH) had premature CHD (Khachadurian, 1964).  FH is a 
disease characterised by high plasma LDL cholesterol levels, especially in the 
homozygous form, which in the majority of cases is due to mutations in the LDL 
receptor gene (Goldstein and Brown, 1987). FH can lead to the development of 
atherosclerosis and CHD as early as five years of age occurs in people who are 
homozygous for the defective LDL receptor gene (Hopkins et al., 2011, Slack, 
1969, Stone et al., 1974).   
Many epidemiological studies have identified a positive correlation between serum 
LDL levels and CHD mortality (Epstein, 1996).  The Seven Countries study, which 
began in 1958, examined 12,763 men for CHD risk factors (Gofman, 1958). The 
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men were aged between 40 and 59 years and formed 16 groups in seven 
countries: the USA, Finland, the Netherlands, Italy, Greece, the former Yugoslavia 
and Japan.  The men were followed up for 25 years, during which time risk factor 
surveys were conducted and total mortality data were collected.  The study 
showed that the population average dietary saturated fat and serum cholesterol 
levels were significantly associated with 25 year mortality from CHD (Kromhout et 
al., 2002). The Framingham Heart Study began in 1948, originally recruited 5209 
men and women between the ages of 30 and 62 (Dawber et al., 1951), but since 
then have recruited many of their children and grandchildren. Through monitoring 
of the participants over the last 60 years many CVD risk factors have been 
identified, including elevated plasma LDL cholesterol levels (Tsao and Vasan, 
2015).  
Various autopsy studies have also shown a relationship between blood cholesterol 
and the extent of atherosclerosis (Solberg and Strong, 1983). Several large lipid 
lowering clinical trials have provided conclusive evidence that lowering the level of 
plasma LDL causes a decrease in CVD. The first trial to do so was the Lipid 
Research Clinics Coronary Primary Prevention Trial (Gordon et al., 1986), which 
followed 3,806 asymptomatic middle aged men with hypercholesterolaemia.  They 
were randomized to receive a bile acid sequestrant (a drug that reduces plasma 
LDL levels) or a placebo for an average of 7.4 years.  Treatment with the drug was 
associated with a significant 19% reduction in CHD or non-fatal MI. Statins are 
now the most widely used drugs to lower plasma LDL levels. They work by 
inhibiting the liver enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMG Co-A 
reductase) (Endo, 1992, Istvan and Deisenhofer, 2001). By inhibiting this enzyme, 
the conversion of HMG CoA to mevalonic acid is decreased. This step is crucial 
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for the production of cholesterol by the liver and its inhibition results in the 
upregulation of the LDL receptors in the liver and thus increased clearance of 
plasma LDL. Randomised statin trials like the 4S study reported a 30% reduction 
in mortality (Pedersen et al., 2004).  
1.3.3 Origins of the LDL oxidative hypothesis 
Lipid oxidation has been  implicated in the development of atherosclerosis since 
1950’s when Glavind and co-workers found that atherosclerotic lesions of the 
human aorta contained lipid peroxides and that the extent of peroxidation 
correlated with the extension of the lesions (Glavind et al., 1952). In 1977, 
Goldstein and Brown observed that FH patients, in spite of defective LDL 
receptors, contained foam cells, which meant that LDL was able to enter the cells 
by an alternative mechanism. They proposed that macrophages were taking up 
LDL after it had been chemically modified. They tested their theory on mouse 
macrophages, which were incubated with radiolabelled acetylated-LDL. They 
observed that macrophage uptake of acetylated LDL was 20 times greater than 
native LDL. It was shown that the acetyl-LDL was being taken up by a separate 
receptor to the native LDL receptor, as native LDL failed to compete with the 
acetyl-LDL for binding to the receptor.    
In 1979, Goldstein’s group observed that prior incubation of the macrophages with 
unlabelled acetyl-LDL caused a massive deposition of cholesterol and cholesteryl 
esters in the cells, but this did not inhibit the subsequent binding of radiolabelled 
acetyl-LDL, indicating that unlike the native receptor, the acetyl-LDL receptor was 
not regulated by intracellular cholesterol levels (Goldstein et al., 1979).  The 
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acetyl-LDL receptor was later cloned and was named scavenger receptor A (SRA) 
(Kodama et al., 1990)   
After it had been shown that modification of LDL could transform it to a form that 
was easily taken up by macrophages, the search began to find modifications of 
LDL that took place in vivo.  It was shown that incubating LDL overnight with 
arterial endothelial cells or arterial smooth muscle cells converted it to a form that 
was rapidly taken up by macrophages, in a saturable manner (Henriksen et al., 
1983).  It was later shown that when antioxidants or metal chelators were added to 
the culture medium, the transformation of the LDL was prevented. Further to this, 
incubating the LDL with copper, in the absence of cells, caused the same 
transformation of the LDL into the form that was rapidly taken up by macrophages 
(Steinbrecher et al., 1984). The modification that was taking place was LDL 
oxidation (Morel et al., 1984). In 1989 Steinberg and co-workers proposed the 
oxidative modification theory which suggested that LDL, modified by oxidation in 
the intima of the artery was a key event in the pathogenesis of atherosclerosis 
(Steinberg et al., 1989).  
1.3.4 LDL oxidation 
Several modifications of LDL have been described that convert it to a form 
recognised by macrophage scavenger receptors (Steinberg, 2009). Modifications 
that can lead to foam cell formation in vitro include oxidation, aggregation, 
enzymatic modification, and immunoglobulin complexing (Oorni et al., 2000, 
Steinbrecher et al., 1990, Torzewski et al., 2004). However, the best studied and 
the one for which there are the most in vivo data is oxidative modification (Stocker 
and Keaney, 2004). It was proposed that LDL is oxidised in the arterial wall, 
 
 
 
32 
 
sequestered by proteoglycans and other extracellular matrix constituents, where it 
is protected from plasma antioxidants. LDL that enters the arterial wall may be 
oxidized by vascular cells (endothelial cells, smooth muscle cells, macrophages 
and lymphocytes) with oxidizing enzymes like lipoxygenase and myeloperoxidase 
in the presence or absence of transition metal ions (iron or copper). Mildly oxidized 
LDL has a low affinity to macrophage scavenger receptors, and thereby, mildly 
oxidized LDL can re-enter the blood circulation and can be detected as a serum 
oxidized LDL (Levitan et al., 2010, Yoshida and Kisugi, 2010). Such mildly 
oxidized LDL stimulates adhesion molecules and chemokines (Berliner et al., 
1990). Extensively oxidized LDL can be taken up by macrophages through the 
scavenger receptors, leading to the formation of foam cells (Itabe, 2009). 
Once initiated, oxidation of LDL is a free radical driven lipid peroxidation chain 
reaction (Heinecke, 1998). Lipid peroxidation is initiated by free radical attack on a 
double bond in a polyunsaturated fatty acid (PUFA) (Ayala et al., 2014). Figure 1.6 
shows the basic reaction sequence involved in lipid peroxidation. The aldehydes 
generated, like malonaldehyde, react with amino groups of the lysine residues of 
apolipoprotein B-100, altering the domain recognised by the classical LDL receptor 
and causing the LDL to be recognised by scavenger receptors, consequently 
causing unregulated LDL uptake and the formation of foam cells (Esterbauer et al., 
1990).  The cholesterol within the LDL particle is also oxidised to form oxysterols.  
In mildly oxidising conditions it is converted to 7β or 7α-hydroperoxycholesterol 
(Brown et al., 1997). In more extensively oxidised LDL, the cholesterol is 
converted to 7-oxygenated sterols such as 7-ketocholesterol (Brown et al., 1996). 
The degradation of PUFAs by lipid peroxidation is preceded by the loss of the 
endogenous antioxidants in the LDL particle.  The major antioxidant in LDL is α-
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tocopherol which is a chain breaking antioxidant, which prevents the propagation 
of the lipid peroxidation by scavenging the lipid peroxyl radicals, as follows: 
LOO• + α- tocopherol  →  LOOH + α - tocopherol• 
In experiments where plasma was supplemented with α-tocopherol prior to LDL 
isolation, the α-tocopherol content of the LDL was increased and a delay in the 
onset of the propagation phase of lipid peroxidation, with macrophages (Jessup et 
al., 1990) or copper ions at pH 7.4, was proportionally increased (Esterbauer et al., 
1991). 
 
 
 
 
34 
 
 
 O 
 O 
O 
O 
O 
+ O + 
X 
O2 
LH
H 
Fe
2+
 or 
Cu
+
 
 O 
  OH 
+ Fe3+ or Cu2+ + OH- 
 
+ XH 
+ L 
    
 
Figure 1.6 A schematic diagram showing the oxidation of PUFA’s by free radical 
reaction 
 
1. Abstraction of a hydrogen atom 
from a PUFA give a lipid alkyl radical 
 
2. Intramolecular re-arrangement to 
form the more stable conjugated 
diene alkyl radical 
 
 
3. Reaction with molecular oxygen 
causes the production of the lipid 
peroxyl radical 
 
 
 
4. Reaction with another PUFA to give 
a lipid hydroperoxide and a lipid 
alkyl radical 
 
 
 
5. Reaction of lipid hydroperoxides 
with transition metals to give lipid 
alkoxyl radicals 
 
 
 
6. Peroxyl radicals decompose by β 
scission to produce lipid alkyl 
radicals and aldehydes 
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1.3.5 Atherogenic effects of oxidised LDL (OxLDL) 
There is evidence that oxidised LDL exists in vivo, within atherosclerotic lesions.  
Antibodies raised against OxLDL have identified it in atherosclerotic lesions but 
not in normal arteries (Boyd et al., 1989, Javed et al., 1999, Palinski et al., 1989).  
Auto-antibodies to oxidised LDL have been identified in human and animal sera 
(Palinski et al., 1989), indicating that oxidised LDL or something similar must have 
been present in order to generate an immune response. Oxidised apo B-100 
epitopes and increased levels of lipid peroxidation products can be detected in 
LDL extracted from rabbit and human atherosclerotic lesions (Ylä-Herttuala et al., 
1989). Studies in different animal models of atherosclerosis show that progression 
of the lesions can sometimes be delayed by intervention with antioxidants 
(reviewed in Feig, 2014). OxLDL exhibits a wide array of biological properties that 
are proatherogenic: OxLDL can stimulate the release of macrophage colony 
stimulating factor (MCSF) from the endothelial cells, causing monocytes to 
differentiate into macrophages (Rajavashisth et al., 1990).  Oxidised LDL induces 
the expression of vascular cell adhesion molecule 1 (VCAM-1) on the surface of 
the endothelial cells, causing adhesion of monocytes. It may cause endothelial 
injury or dysfunction as it is cytotoxic for endothelial cells in culture (Hessler et al., 
1983) and inhibits nitric oxide-induced vasodilatation by reducing l-arginine 
availability to endothelial nitric oxide synthase for NO production (Kugiyama et al., 
1990). It causes inhibition of lipopolysaccharide-induced expression of NF-κB and 
increases collagen synthesis by smooth muscle cells (Steinberg, 2009, Young and 
McEneny, 2001). 
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1.3.6 Role of transitions metals in LDL oxidation 
Various substances have been shown to induce LDL oxidative modification to 
such a similar form to that observed in atherosclerosis. Transition metals such as 
iron and copper are the two principle biological redox-active metals that have 
received the most attention as potential contributors to the oxidation of LDL that is 
associated with atherosclerosis. Both iron and copper support LDL oxidation in 
vitro in a number of cell types including endothelial cells (Steinbrecher et al., 
1984), smooth muscle cells (Heinecke et al., 1986) macrophages (Leake and 
Rankin, 1990), and lymphocytes (Lamb et al., 1992). There is also evidence for 
the presence of transition metals in atherosclerotic plaque (Lamb et al., 1995, 
Stadler et al., 2004, 2008), and it is known that physiologically relevant forms of 
both iron (e.g. hemin and ferritin) and copper (e.g. ceruloplasmin) can promote 
LDL oxidation in vitro, particularly under conditions related to inflammation (Balla 
et al., 1991, DiSilvestro and Jones, 1996, Lamb and Leake, 1994, Zhang et al., 
2010). Though copper is able to oxidise LDL in vitro, the free copper ions are 
scarce in the blood systems appearing in the form of ceruloplasmin, which is not 
considered a pro-oxidant (reviewed in detail by Burkitt, 2001). Iron, in contrast, 
exists in the blood as haemoglobin at extremely high (millimolar) concentrations, 
as myoglobin and as heme- and iron-sulphur proteins in mammalian cells (Doyle 
and Hoekstra, 1981, Ponka et al., 1998). In these forms of biological iron, access 
of redox-active reactants is regulated tightly, which thus limits and directs the 
catalysis of redox reactions by iron chelates. The intercellular and intracellular 
transport of iron is regulated by ferritin-transferrin and similar systems (Mackenzie 
et al., 2008, Ponka et al., 1998). Ferritin, under normal physiological conditions, 
serves to store much of the excess iron in cells (Theil, 2013), thereby limiting 
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production of free radical species or related oxidants (Wood et al., 2004). 
Nevertheless, there is ample data which shows the presence of catalytically active 
iron in human atherosclerotic plaques (Ahluwalia et al., 2010, Raman et al., 2008, 
Tasic et al., 2015b). 
1.3.7 Antioxidants in the treatment of atherosclerosis  
In 1991, the National Heart, Blood and Lung Institute (USA) convened a workshop 
to review the evidence about the oxidative modification hypothesis. The experts at 
the workshop concluded that the evidence was sufficiently strong to justify 
initiating clinical intervention trials. The conferees recommendations of the 
committee were to start trials with naturally occurring antioxidants like vitamin E, 
vitamin C or β-carotene (Steinberg, 1992). 
Two large primary prevention studies: the α-Tocopherol, β-Carotene Cancer 
Prevention (ATBC, 1994) and the Primary Prevention Project studies (de Gaetano, 
2001) investigated the effect of supplemental vitamin E on myocardial infarction 
(MI), CVD or stroke at 3–6 years. Neither of them showed any protective effect of 
supplementation against cardiovascular risk. Two other smaller studies; the 
Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study (Salonen 
et al., 2000) and Vitamin E Atherosclerosis Prevention Study (VEAPS) (Hodis et 
al., 2002) used intima-medial thickness progression as a marker of ongoing CVD. 
Apart from one subgroup, neither showed any effect of vitamin E on progression of 
disease in healthy subjects at low risk of CVD. Several other prospective double-
blind, placebo-controlled studies of the effects of vitamin E supplementation in 
patients with pre-existing CVD (secondary prevention) showed no benefits of 
antioxidant supplementation. In 2002, another major study (Heart Protection 
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Study) concluded that antioxidant vitamins (vitamin E and C and β-Carotene)  did 
not produce any significant reductions in the 5-year mortality from, or incidence of, 
any type of vascular disease, cancer, or other major outcome (HPS, 2002).  
However, the Cambridge Heart AntiOxidant Study (Stephens et al., 1996) reported 
a major reduction in the risk of non-fatal MI (although fatal MI was non-significantly 
increased in patients with angiographically proven coronary atherosclerosis), 
whereas a significant decrease in acute MI was reported in a small group of 
haemodialysis patients with supplemental vitamin E (SPACE) (Boaz et al., 2000).   
Looking at the results from various clinical trials, it might seem that the negative 
results would be conclusive and that additional clinical trials of any antioxidants 
would be pointless. However, it is important to appreciate that the trials of chronic 
antioxidant therapies have focused on easily available agents rather than those 
that are most efficacious. The lack of benefit seen in clinical trials to date does not 
disprove the central role of oxidative stress in atherosclerosis. Although much 
effort has been directed at proving the benefits of antioxidants, the findings to date 
are far from clear mostly because there is no clear understanding on how LDL is 
oxidised in vivo.  
1.3.8 LDL aggregation 
The molecular mechanisms of foam cell formation in the arterial sub-endothelium 
is not fully understood, however, it is becoming increasingly clear that aggregation 
and fusion of LDL particles may prevent their exit from the arterial wall and 
contribute to atherogenesis (Bancells et al., 2010a, Camejo et al., 1998, Guyton, 
1994, Hurt-Camejo et al., 2000, Oorni et al., 2000, Paananen et al., 1995, 
Parasassi et al., 2008, Pentikainen et al., 1996). Several lines of evidence support 
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the presence of LDL aggregates in the arterial wall and their involvement in LDL 
retention by arterial proteoglycans during atherogenesis (Aviram et al., 1995, Hoff 
and Morton, 1985). For example, the aortic intima in cholesterol-fed and Watanabe 
Heritable Hyperlipidaemia rabbits has been shown to contain aggregated 
lipoproteins bound to subendothelial matrix (Frank and Fogelman, 1989). LDL 
aggregates isolated from atherosclerotic lesions are capable of macrophage foam 
cell formation in a process which has been seen to be independent of LDL uptake 
by scavenger receptors (Steinbrecher and Lougheed, 1992). In addition, it has 
been reported that aggregated LDL can cause cholesterol accumulation in 
coronary vascular smooth muscle cells and turn them into foam cells (Llorente-
Cortes and Badimon, 2005).  
Enzymes secreted by the arterial intimal cells, like phospholipase A2 (PLA2), 
phospholipase C and sphingomyelinase are capable of causing aggregation of 
LDL (Oorni et al., 2000).  PLA2 hydrolyses fatty acids of phospholipids at the sn-2 
position to give lysophosphatidylcholine and fatty acids, which in the presence of 
lipid binding proteins, such as albumin, are released from the LDL particle. This 
causes rearrangement of the LDL particle structure and causes conformational 
changes in apo-B100, subsequently causing LDL aggregation (Hakala et al., 1999, 
Webb, 2005).  
Phospholipase C hydrolyses LDL phospholipids to phosphocholine and 
diacylglycerol. Phosphocholine is released from the LDL particle leaving the 
hydrophobic domains on the surface of the LDL and thus inducing LDL 
aggregation via hydrophobic interactions between LDL particles (Liu et al., 1993).  
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Sphingomyelinase (SMase) is a zinc-dependent acidic metalloenzyme secreted by 
smooth muscle cells and macrophages of arterial intima (Marathe et al., 1999). 
The enzyme can act on LDL at pH 7.4 if the lipoprotein is modified by oxidation or 
phospholipase A2 or enriched with apo-CIII (Schissel et al., 1998). It hydrolyses 
sphingomyelin molecules within the LDL particle causing the formation of water-
soluble phosphocholine, which is released from the surface, and water-insoluble 
ceramide which is retained in the core of the LDL (Walters and Wrenn, 2008). This 
causes an increase in the apolar core lipids at the expense of the polar surface 
lipids, resulting in a hydrophobic mismatch between the core and surface, which is 
expected to cause lipoprotein fusion. LDL fusion upon SMase reaction is 
supported in vivo by the observation that aggregated LDL found in atherosclerotic 
lesions are rich in ceramide (Schissel et al., 1996). Moreover, treatment of isolated 
LDL with SMase induces lipoprotein aggregation and fusion in vitro (Oorni et al., 
1998).  
LDL retention in the arterial wall by proteoglycans is considered an important 
event in the development of atherosclerosis. Proteoglycans are a component of 
the extracellular matrix which can bind to apoB-100, therefore causing LDL to be 
retained within the arterial intima (Boren et al., 1998, Williams and Tabas, 1995). 
Aggregated LDL has been seen to bind proteoglycans more readily than native 
LDL, possibly due to greater number of apoB-100 molecules in LDL aggregates 
(Paananen et al., 1995). Therefore, as well as causing macrophage lipid uptake, 
LDL aggregation may enhance the retention of LDL in arterial intima. 
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1.4 Lysosomes  
Lysosomes are spherical cellular organelles, bound by a single membrane. They 
were discovered in 1955 by Christain De Duve (De Duve et al., 1955). They are 
involved in the digestion of macromolecules using a range of hydrolytic enzymes 
which they contain. Lysosomes digest cellular material such as damaged or 
unwanted organelles, in a process known as autophagy (Eskelinen and Saftig, 
2009). They also digest material brought into the cells by endocytosis or 
phagocytosis such as bacteria and neutrophils. The pH of the lysosomal 
compartment is around 4.5 which is essential for the hydrolytic activity of its 
enzymes. The acidic pH is maintained by ATP-dependent proton pumps present 
within the lysosomal membrane (Ohkuma et al., 1982). 
1.4.1 Lysosomes in atherosclerosis 
Several studies have demonstrated that incubation of macrophage cell lines with 
various forms of modified lipids can disrupt lysosomal function resulting in over-
accumulation of intralysosomal cholesteryl esters (Jerome, 2010). In 1974 
Christian de Duve hypothesised that lysosomal deficiency or lysosomal defects 
lead to the accumulation of lipids within lysosomes and, eventually, to the 
formation of foam cells (de Duve, 1974). The hypothesis was based partly on the 
observation of lipid-engorged lysosomes in post-mortem liver tissue samples from 
Wolman disease patients, which completely lack lysosomal acid lipase (LAL) 
(Lake and Patrick, 1970, Patrick and Lake, 1969) and premature atherosclerosis 
seen in the cholesteryl ester storage disease patients, which have LAL deficiency 
(Sloan and Fredrickson, 1972). Du et al. (2001) showed that external 
administration of LAL decreased the amount of atherosclerosis in LDL receptor 
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knockout mice which were fed an atherogenic diet, indicating that lysosomal 
accumulation of lipid is important in disease progression. These results were 
further confirmed by Sun et al. (2014), who demonstrated that LAL treatment is 
effective in the advanced stages of the disease. Cox et al. (2007) have reported a 
general loss of lysosomal function including reduction in LAL-dependent 
cholesteryl ester hydrolysis over time following incubation of human macrophages 
with mildly oxidised LDL or aggregated LDL. It was suggested that as most 
lysosomal enzymes require an acidic pH to function properly, neutralisation of the 
lysosomes could explain the inhibition of cholesteryl ester hydrolysis. Sheedy et al. 
(2013) demonstrated that inefficient lysosomal hydrolysis and transport of oxLDL-
derived cholesteryl esters leads to in-situ cholesterol crystal formation. As well as 
providing a link between oxLDL and cholesterol crystal formation, the study also 
demonstrated that lysosomal dysfunction can initiate inflammation. Interestingly, 
Ullery-Ricewick et al. (2009) demonstrated that in THP-1 human macrophages 
lysosomal cholesterol ester accumulations from aggregated LDL could be reduced 
by 50% by chase incubation with triglyceride (TG)-rich lipid dispersions or VLDL. 
They noted that TG treatment re-established the acidic pH by restoring v-ATPases 
in the lysosomal membrane. Recently (Emanuel et al., 2014), built on these 
concepts by demonstrating the development of lysosomal dysfunction in primary 
macrophages exposed to oxLDL and cholesterol crystals. They noticed the effects 
on morphological changes like lysosomal engorgement and functional changes 
like increased lysosomal pH and decreased degradation capacity. Moreover, they 
also noticed that macrophages isolated from atherosclerotic aortas of ApoE-null 
mice showed signs of lysosomal dysfunction, not found in macrophages from other 
tissues of the same mice.  Moreover, recent large-scale, genome-wide association 
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studies have identified single nucleotide polymorphisms (SNPs) in lysosomal acid 
lipase A (LIPA), the gene encoding LAL, as a susceptibility locus for coronary 
artery disease (C4D, 2011, Consortium, 2011, Wild et al., 2011). 
Overall, accumulating evidence suggests that endosomal uptake of modified lipids 
initiates a condition very similar to lysosomal lipid storage diseases. In fact, in 
advanced atherosclerosis lesions, foam cells have been seen to accumulate lipids 
within enlarged lysosomes. Lipids accumulate inside lysosomes causing 
dysfunction and in cases wherein lipid content overwhelms the transport 
machinery, cholesterol crystals are formed leading to disruptions in membrane 
integrity.  
1.4.2 Lysosomal iron 
Several studies have shown that lysosomes contain redox active iron (Terman and 
Kurz, 2013, Yu et al., 2003, Yuan et al., 1996, Zdolsek et al., 1993). Lysosomes 
derive most of their iron from the degradation of ferritin (Kidane et al., 2006, 
Radisky and Kaplan, 1998, Sibille et al., 1989, Yu et al., 2003), the normal 
autophagic turn-over of iron-rich mitochondrial proteins (Persson et al., 2001, Yu 
et al., 2003) and in the case of macrophages the phagocytosis of erythrocytes 
(Myagkaya et al., 1979, Yuan et al., 1996). However, there is a variation in the 
concentration of iron in individual lysosomes, probably due to variability in the 
phagocytic/degradative state of the lysosomes (Kurz et al., 2008). Experiments 
even suggest that the cytosolic non-ferritin bound iron pool (known as labile iron 
pool) may actually originate from the lysosomes (Tenopoulou et al., 2005). As the 
lysosomal compartment is acidic and rich in reducing equivalents, such as 
cysteine and glutathione, any low mass iron would likely be in the ferrous form 
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(Fe2+) (Schafer et al., 2000). Fe2+ can promote the generation of oxidising species 
(Graf et al., 1984), which may cause peroxidation of material under degradation, 
resulting in lipofuscin or, if substantial, damage to and permeabilisation of the 
lysosomal membrane (Terman et al., 2010). 
1.4.3 Lysosomal oxidation theory 
The oxidation hypothesis of atherosclerosis fails to address the high antioxidant 
capacity of extracellular fluids, as even a few percent of serum or interstitial fluid 
can inhibit the oxidation of LDL (Dabbagh and Frei, 1995, Leake and Rankin, 
1990). The conventional theory also fails to explain why the larger antioxidant 
clinical trials showed no protection against cardiovascular disease (Steinberg, 
2002). In 2007, Wen and Leake, in this laboratory showed that aggregated or 
acetylated LDL is rapidly endocytosed by macrophages and then oxidised within 
lysosomes. J774 cells (mouse macrophage-like cells) and human monocyte-
derived macrophages (HMDM) rapidly took up non-oxidatively aggregated LDL 
(produced by vortexing) and generated ceroid in their lysosomes after 7 days 
(Wen and Leake, 2007). Ceroid is the final product of lipid oxidation and it consists 
of insoluble polymerised lipids and proteins. It has been found within foam cells in 
atherosclerotic lesions (Mitchinson, 1982).  
There was an increased production of oxysterols (e.g. 7-ketocholesterol) in the 
J774 macrophages when incubated with non-oxidized acetylated LDL (Wen and 
Leake, 2007). The increase in oxysterols was inhibited by the lipid-soluble 
antioxidants probucol, α-tocopherol, and butylated hydroxytoluene, which were 
shown to be taken up by the cells, but not by the water-soluble antioxidant trolox. 
The water-soluble antioxidant, trolox, may not have been able to enter the 
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lysosomes efficiently and therefore failed to provide protection against the 
intralysosomal oxidation of LDL. Chloroquine, a weak base that concentrates in 
lysosomes and increases their pH, inhibited the oxidation of LDL, showing that the 
oxidation takes place at acidic pH. Adding ferrous sulphate or ferritin during the 
chase incubation approximately doubled the oxysterol production and adding 
desferrioxamine, which is delivered to lysosomes by pinocytosis, significantly 
inhibited the oxysterol production. It was further established that iron is highly 
effective in oxidizing LDL in a simple buffer at pH 4.5, the approximate pH of 
lysosomes, but very poor at doing so at pH 7.4, as iron is more soluble at acidic 
pH and may precipitate at pH 7.4 (Satchell and Leake, 2012, Wen and Leake, 
2007).  
Based on these results, this laboratory has proposed that LDL undergoes non-
oxidative aggregation in the extracellular space and is then phagocytosed by 
macrophages and oxidised within lysosomes by catalytically active iron. It has 
been suggested that the oxidised lipids could then be released from the lysosomes 
into the rest of the cell or could engorge the lysosomes and disrupt their function. 
As well as this, the oxidised LDL could be released into the intima upon the death 
of the cells in which it is formed and affect the function of the neighbouring cells. 
More recently this laboratory has shown that LDL aggregated by the enzyme 
sphingomyelinase (SMase-LDL) is rapidly phagocytosed by human macrophages 
and through confocal microscopy it was revealed that the lipids and lysosomes co-
localised with each other  (Wen et al., 2015). Incubating macrophages with 
SMase-LDL for 7 days produced intralysosomal ceroid in them, while native LDL 
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treatment produced no ceroid. These results provide further support for the 
lysosomal LDL oxidation theory.  
1.4.4 Lysosomotropic drugs with antioxidant property  
A potential therapy to target lysosomal lipid accumulation in atherosclerosis is to 
stimulate the transport of cholesterol from lysosomes into the cytoplasm. However, 
it is a challenging issue as the lysosomal cholesterol derived from oxLDL has been 
found to be resistant to efflux. Furthermore, studies in both arteries and cells in 
culture suggest that the cholesterol in lysosomes is trapped partly (in the form of 
ceroid), and cannot be decreased simply by inhibiting further uptake of lipoproteins 
or by increasing efflux of extra-lysosomal cholesterol stores (Dhaliwal and 
Steinbrecher, 2000, Yancey and Jerome, 2001). However, a possible way to 
prevent the effect of lysosomal cholesterol accumulation is to prevent the 
intralysosomal oxidation of LDL by using agents which are able to concentrate in 
the lysosomes and able to sequester intralysosomal oxidising species. 
For example, desferrioxamine, which is delivered to lysosomes by pinocytosis, is 
able to inhibit LDL oxidation process by redox-active iron within lysosomes (Minqin 
et al., 2005, Wen and Leake, 2007) and have been shown to slow down the early 
stages of atherosclerosis in mice (Zhang et al., 2010). A study conducted by Yu et 
al. (2003) found that WR-1065 (thiol metabolite of amifostine) accumulates in 
lysosomes and interacts with the lysosomal iron thereby minimizing iron-catalysed 
lysosomal damage and ensuing cell death. Propranolol, a β-receptor blocker has 
been reported to concentrate up to 1000-fold in lysosomal compartments within 
cells (Cramb, 1986). Propranolol, 9-amino-acridine-propranolol, 4-hydroxy 
propranolol and D-propranolol have been reported to exhibit antioxidant activity 
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attributed to their ability to compartmentalise within lysosomes, providing direct 
protection against oxidative lysosomal membrane injury and indirect protection by 
preventing release of iron into the cytosol to perpetuate the oxidative process 
further (Dickens et al., 2002, Kramer et al., 2012, Mak and Weglicki, 2004). Lipid-
soluble antioxidants like probucol, α-tocopherol, and butylated hydroxytoluene 
have been shown to prevent oxysterol formation in macrophages (Wen and Leake, 
2007).  
1.4.5 Cysteamine and lysosomal oxidation of LDL 
Cysteamine (Figure 1.7) is an aminothiol currently used for the treatment of the 
lysosomal storage disorder cystinosis, an inherited disease caused by the 
absence of functional cystinosin, the ubiquitous lysosomal cystine transporter 
(Kalatzis et al., 2001). The accumulation of cystine in the lysosomes of all the cells 
in the body leads to progressive dysfunction of multiple organs. Cysteamine reacts 
with intralysosomal cystine to form the mixed disulfide of cysteamine and cysteine, 
which can then leave the lysosome via the lysine transport system (Jezegou et al., 
2012). The therapy, considered the only effective treatment for cystinosis, 
prolongs the patients’ lives from about 10 years to as much as 40 years (Dohil et 
al., 2010).  
 
Cysteamine 
Figure 1.7 Chemical structure of cysteamine  
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Cysteamine exhibits strong antioxidant activity and has been proposed for the 
treatment of neurodegenerative disorders. Recent studies have found that 
cysteamine exhibits neuroprotective effects in a mouse model of Huntington's 
disease (HD) through inhibiting the transglutaminase activity and enhancing the 
brain-derived neurotrophic factor (BDNF) level (Karpuj et al., 2002). Another study 
has shown that cysteamine, at low dose confers potent neuroprotection against 
MPTP-induced toxicity of dopaminergic neurones (Sun et al., 2010). Moreover, a 
phase I study using cysteamine in HD patients showed the drug to be safe and 
tolerable (Dubinsky and Gray, 2006), suggesting it might be a promising drug for 
treating neurodegenerative disorders. Cysteamine has also been proposed for the 
treatment of non-alcoholic fatty liver disease (NAFLD), where it has been seen to 
improve serum alanine aminotransferase (ALT) and serum aspartate 
aminotransferase (AST) concentrations by increasing ROS scavenging and 
glutathione production, as well as by inhibiting transglutaminase activity (2012, 
Dohil et al., 2011). In addition, the use of cysteamine has been proposed for 
treating malaria and as an adjunct in cancer chemotherapy (Min-Oo and Gros, 
2011, Wan et al., 2011).  
This laboratory recently studied the possible protection of cysteamine against LDL 
oxidation, both in vitro and in vivo (submitted work). It was found that addition of 
cysteamine inhibited the oxidation of LDL by iron at pH 4.5 in a concentration-
dependent manner. The lag phase, during which endogenous and exogenous 
antioxidants are consumed, increased from about 1 h to over 30 h on adding 250 
µM cysteamine. In human macrophages which were treated with modified LDL 
(SMase-LDL) cysteamine, at final concentrations of 1, 5, and 10 µM, inhibited the 
production of intralysosomal ceroid by more than 80%. The effect of cysteamine 
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was also investigated on atherosclerosis in LDL receptor-deficient mice which 
were fed on an atherogenic diet. The results showed a significant reduction in the 
en face lesion area in the aortic arch of the mice with the dose of cysteamine 
equivalent to that received by patients with cystinosis. 
Although the laboratory has obtained data demonstrating the anti-atherosclerotic 
activity of cysteamine, however, there are a substantial number of unanswered 
questions concerning this activity. The mechanisms by which thiols, such as 
cysteamine, inhibit oxidation reactions mediated by free radicals are far from clear. 
Thiols may scavenge free radicals, but whether they scavenge lipid radicals or 
protein radicals in apolipoprotein B-100 of LDL, which would then go on to oxidise 
lipids, is unknown.    
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1.5 Thesis aims and hypothesis 
The first aim of this thesis was to explore the mechanism of the oxidation of LDL 
by iron at lysosomal pH, as this is a novel and yet incompletely characterised 
method of oxidising LDL that might be relevant in vivo. Initial oxidation of LDL by 
transition metals has been proposed to be due the pre-existing lipid 
hydroperoxides in LDL. Therefore, it is hypothesised that LDL oxidation by iron at 
pH 4.5 should take place only in presence of pre-existing lipid hydroperoxides and 
increasing the initial hydroperoxide load of LDL should increase the rate of LDL 
oxidation by iron. The scavengers of lipid hydroperoxide radicals, e.g. probucol, 
should completely prevent the oxidation of LDL by iron at pH 4.5. However, if 
superoxide ions are involved in the initial oxidation of LDL, compounds, like thiols, 
which are known superoxide scavengers, should completely protect LDL oxidation 
by iron. 
The second aim of the thesis was to investigate the protective effects of existing 
lysosomotropic antioxidants in inhibiting the oxidation of LDL at lysosomal pH. 
Lysosomotropic drugs like propranolol, amiodarone and 7,8-dihydroneopterin have 
antioxidant properties and are currently in clinical use for treating various 
diseases. Therefore, it was hypothesised that these lysosomotropic antioxidants 
should inhibit the oxidation of LDL by iron at pH 4.5. Experiments were conducted 
to evaluate if they offer better protection than cysteamine in preventing LDL 
oxidation by iron at pH 4.5. 
The third aim of thesis was to investigate in detail the oxidation pattern of 
sphingomyelinase aggregated LDL (SMase-LDL) under lysosomal conditions. It 
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was hypothesised that oxidation of SMase-LDL by iron under lysosomal conditions 
should produce the lipid oxidation products same as native LDL. Characterisation 
of the oxidation products of SMase-LDL were carried out by high performance 
liquid chromatography (HPLC). Intralysosomal lipid peroxidation of LDL was 
studied in human macrophages by using the lysosomotropic dye Foam-LPO and 
by measuring intralysosomal ceroid formation. The protective effect of cysteamine 
was also investigated. 
The final aim of thesis was to begin to understand how relevant lysosomal 
oxidation of SMase-LDL might be to induce atherogenic events such as lysosomal 
dysfunction, cellular senescence and secretion of inflammatory cytokine secretion 
by macrophages. It was hypothesised that extensive oxidation of LDL in the 
lysosomes of macrophages would lead to accumulation of LDL oxidation products 
(e.g. ceroid) in the lysosomes of macrophages which can affect their function and 
will also induce the secretion of inflammatory cytokines such as TNF-α. 
Furthermore, inhibition of lysosomal oxidation of LDL by cysteamine should 
prevent these effects.   
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Chapter 2- Materials and methods 
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2.1 General laboratory reagents and solutions 
 
2.1.1 Laboratory reagents 
General laboratory reagents and companies from which they were purchased are 
listed below: 
Name               Company of purchase 
Acetic acid (glacial)     Sigma-Aldrich Ltd 
Acetic anhydride     Fisher Scientific Ltd 
Acetonitrile (HPLC grade)    Sigma-Aldrich Ltd 
Amphotericin B     Sigma-Aldrich Ltd 
Bathophenanthrolinedisulfonic acid  Sigma-Aldrich Ltd 
Bovine serum albumin    Invitrogen Ltd 
Chelex-100      Sigma-Aldrich Ltd 
Cholesterol      Sigma-Aldrich Ltd 
Cholesterol arachidonate    Sigma-Aldrich Ltd 
Cholesterol linoleate    Sigma-Aldrich Ltd 
Cholesterol linoleate hydroperoxide  Cayman chemicals 
Cysteine      Sigma-Aldrich Ltd  
Cysteamine hydrochloride    Sigma-Aldrich Ltd 
Diethylenetriaminepentaacetic acid (DTPA) Sigma-Aldrich Ltd 
Dimethyl sulphoxide    Sigma-Aldrich Ltd 
Dipotassium hydrogen orthophosphate  Fisher Scientific Ltd 
Disodium hydrogen orthophosphate  Fisher Scientific Ltd 
Ethanol (HPLC grade)    Sigma-Aldrich Ltd 
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Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich Ltd 
Ferric chloride     Sigma-Aldrich Ltd 
Fetal calf serum (FCS)    Sigma-Aldrich Ltd 
Ferrous sulphate     Sigma-Aldrich Ltd 
Folin and Ciocalteau phenol reagent  Fisher Scientific Ltd 
Hanks’ Balanced Salt Solution (HBSS)  Gibco 
Hexane (HPLC grade)    Sigma-Aldrich Ltd 
Human serum     Sigma-Aldrich Ltd 
Hydrochloric acid     Fisher Scientific Ltd 
Hydrogen peroxide     Fisher Scientific Ltd 
Isopropanol (HPLC grade)    Fisher Scientific Ltd 
7-Ketocholesterol     Sigma-Aldrich Ltd 
2-Keto-4-thiomethylbutanoic acid   Sigma-Aldrich Ltd 
Methanol (HPLC grade)    Fisher Scientific Ltd 
N,N,N′,N′-tetraacetylethylenediamine  Sigma-Aldrich Ltd 
Potassium acetate     Sigma-Aldrich Ltd 
Potassium bromide     Fisher Scientific Ltd 
Potassium chloride     Fisher Scientific Ltd 
Potassium dihydrogen orthophosphate  Fisher Scientific Ltd 
Potassium hydroxide    Fisher Scientific Ltd 
Potassium sodium tartrate     Fisher Scientific Ltd 
Sodium acetate     Sigma-Aldrich Ltd 
Sodium carbonate     Fisher Scientific Ltd 
Sodium chloride     Fisher Scientific Ltd 
Sodium dihydrogen orthophosphate  Fisher Scientific Ltd 
Sodium hydrogen carbonate   Fisher Scientific Ltd 
Sodium hydroxide     Fisher Scientific Ltd 
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Trichloroacetic acid               Sigma-Aldrich Ltd 
Triton X-100      Fisher Scientific Ltd 
Xylene       Fisher Scientific Ltd 
 
2.1.2 Laboratory equipment 
Name             Company of purchase 
Optima™ XPN ultracentrifuge    Beckman Coulter 
Lambda-2 6-cell spectrophotometer   Perkin Elmer 
Lambda Bio 40 8-cell spectrophotometer  Perkin Elmer 
Cary Eclipse fluorescence spectrophotometer  Agilent 
Libra S22 UV/Vis Spectrophotometer   Biochrom 
Agilent 1100 HPLC System    Agilent 
BD Accuri™ C6  flow cytometer   BD Biosciences 
Axioskop epifluorescent microscope   Carl Zeiss 
A1 Inverted epifluorescent Microscope   Carl Zeiss 
FLUOstar OPTIMA microplate reader   BMG LABTECH 
Countess II FL automated cell counter   Invitrogen 
Zetasizer Nano Series particle sizer   Malvern  
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2.1.3 General Solutions 
High density KBr solution (HDS) 1.316 g/ml 
KBr (2.97 M), NaCl (2.62 M) and Na2EDTA (297 µM) made up in ultrapure water, 
adjusted to pH 7.4 with 0.5M NaOH solution. 
Low density KBr solution (LDS) 1.006 g/ml 
NaCl (150 mM) and Na2EDTA (297 µM), made up in ultrapure water, adjusted to 
pH 7.4 with 0.5M NaOH. 
Dialysis buffer  
NaCl (140 mM), Na2HPO4 (8.1 mM), NaH2PO4 (1.9 mM) and Na2EDTA (100 µM) 
made up in ultrapure water and adjusted to pH 7.4 with 0.5 M NaOH.  
Lowry A reagent 
Na2CO3 (25 g), NaOH (5 g), potassium sodium tartrate tetrahydrate (0.5 g), 
dissolved in 230 ml ultrapure water. CuSO4.5H2O (0.125 g) dissolved in few 
millilitres of distilled water and added. Final volume made up to 250 ml with 
ultrapure water.  
Lowry B reagent 
Folin and Ciocalteau phenol reagent (6.67%, v/v) in ultrapure water, freshly 
prepared for each assay.  
Lipid hydroperoxide assay colour reagent 
KH2PO4 (163 mM), KI (120 mM), K2HPO4 (37 mM), Triton X-100 (2 g/l), NaN3 (150 
µM), benzalkonium chloride (0.1 g/l), and ammonium molybdate (10 µM) pH 
adjusted to 6.0. 
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Sodium chloride/sodium acetate buffer (Chelex-100 treated) 
NaCl (150 mM), acetic acid (10 mM), pH 4.5. Chelex-100 (washed in distilled 
water) added at 0.1 % (w/v), mixed overnight and removed by filtration prior to pH 
adjustment.  
MOPS buffer (Chelex-100 treated) 
3-[N-morpholino]propanesulfonic acid (MOPS, 10 mM), NaCl (150 mM), pH 7.4. 
Chelex-100 (washed in ultrapure water) added at 0.1 % (w/v), mixed overnight and 
removed by filtration prior to pH adjustment.  
Phosphate buffered saline (PBS) -1X 
NaCl (137 mM), KCl (2.68 mM), KH2PO4 (1.47 mM) and Na2HPO4 (8.1 mM) made 
up in 800 ml of ultrapure water, pH adjusted to 7.4 with 1 M HCl and final volume 
made up to 1 litre with ultrapure water.  
LDL stabilising buffer 
HEPES (5 mMl/L), NaCl (150 mM/l) dissolved in ultrapure water and pH adjusted 
to 7.4 using NaOH. 
HPLC oxidation mobile phase 
Acetonitrile, isopropanol and water (all HPLC grade): 40/54/2 % by volume. 
HPLC ester mobile phase 
Acetonitrile and isopropanol (all HPLC grade): 30/70 % by volume. 
Cryopreservation medium 
RPMI-1640 medium, foetal calf serum (FCS), dimethyl sulphoxide (DMSO), 
(50/40/10, v/v/v). 
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Oil Red O Stain 
Stock solution: Oil Red O (0.35 g) dissolved in isopropanol (100 ml), filtered and 
stored at room temperature. Working stain was freshly prepared by mixing Oil Red 
O stock with ultrapure water 60/40, following by filtering. 
FACS buffer 
HBSS with 0.6% BSA, 5mM EDTA 
Cell fixing solution (4% paraformaldehyde solution) 
4 g paraformaldehyde was placed in a 200 ml flask to which 60 ml PBS was 
added. The mixture was warmed to 60˚C in a fume hood and mixed with a 
magnetic stirrer. NaOH (0.5 M) was added drop-wise, until a clear solution was 
produced. The solution was allowed to cool and the pH was checked. Further 
NaOH was added to titrate to pH 7.4. The volume was made up to 100 ml with 
PBS. 
X-Gal Staining solution  
Potassium ferrocyanide (5 mM), potassium ferricyanide (5 mM), sodium chloride 
(150 mM, magnesium chloride 2 mM, citric acid 40 mM / sodium phosphate 50 
mM, (all Sigma) titrated to pH 6.0.  
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2.2 LDL 
2.2.1 LDL isolation 
LDL (d=1.019 to 1.063 g/ml) was isolated by sequential ultracentrifugation of 
plasma (Havel et al., 1955, Wilkins and Leake, 1994). Venous blood was obtained 
from healthy volunteers (250 ml from each volunteer) who had fasted for 
approximately 12 h before donation. The blood was drawn into sterile 50 ml 
syringes, which contained Na2EDTA (3 mM) as an anticoagulant, before being 
transferred to 50 ml centrifuge tubes. The blood was centrifuged at 1500 x g for 30 
min at 4 °C and the plasma was collected and pooled. High density KBr solution 
(2.97 M KBr, 2.62 M NaCl and 297 µM EDTA; density =1.316 g/ml) was added to 
the plasma to adjust its density to approximately 1.019 g/ml, using equation 1 (see 
below) to calculate the volume of HDS to add. 
VHDS = VPlasma (DReq - DCurr / DAdd - DReq)  (1) 
Where VHDS is the volume of HDS to be added, DAdd is the density of the high 
density KBr solution, VPlasma is the volume of pooled plasma, DCurr is the current 
density of the plasma (1.006 g/ml) and DReq is the final required density. 
The plasma was then dialysed against 2 litres of 1.019 g/ml density solution for 2 h 
at 4 °C to adjust the density to exactly 1.019 g/ml. The plasma was transferred to 
35 ml Ultracrimp ultracentrifuge tubes (Thermo Fisher Scientific Inc, USA) and was 
centrifuged at 40,000 rpm for 18 h at 4 °C. The tubes were then sliced through the 
clear band of solution in their centre, using a tube slicer. The top fraction, 
containing VLDL and IDL was discarded and the bottom fraction containing LDL, 
HDL and other plasma proteins was collected and pooled. 
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The density of the pooled LDL-containing fraction was then adjusted to 
approximately 1.063 g/ml by the addition of HDS, using equation 1 to determine 
the volume of HDS required. The density was adjusted to exactly 1.063 g/ml by 
dialysing the pooled fraction against 2 litres of 1.063 g/ml solution at 4 °C for 2 h. 
After dialysis, the plasma was transferred to 35 ml Ultracrimp ultracentrifuge tubes 
and was centrifuged at 40,000 rpm for 18 h at 4 °C. The tubes were then sliced 
below the upper LDL layer, using a tube slicer. The lower layer was discarded and 
the upper LDL layer portion collected in a plastic beaker. The LDL portion was 
then further purified by dialysing with 1 litre of 1.063 g/ml solution at 4 °C for 2 h 
and centrifuging at 40,000 rpm for further 18 h at 4 °C. The pure LDL portion was 
then dialysed against NaCl/phosphate/EDTA buffer at 4 °C with several changes 
overnight with stirring to remove the KBr. Finally the LDL was filter sterilised  with 
0.45 µm Minisart filter and stored at 4 °C in dark (Wilkins and Leake, 1994). 
2.2.2 LDL protein assay 
LDL protein concentration was determined using a modified Lowry assay 
(Markwell et al., 1978).  Standard concentrations of bovine serum albumin (BSA) 
protein were made up from 400 µg/ml stock with ultrapure water. LDL samples 
were prepared in triplicates as well. Standards and samples (125 µl) were added 
to assay tubes in triplicates. Lowry A reagent (1.5 ml) was added to each assay 
tubes and left at room temperature for ten min.  Freshly prepared Lowry B reagent 
(150 µl) was added to each assay tube which were then incubated for 5 min at 55 
°C.  After allowing the assay tubes to cool to room temperature the absorbance at 
650 nm was measured. 
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The basis for the assay is that peptide bonds in the LDL apolipoprotein B-100 or in 
the BSA standards form a complex with copper ions in the Lowry A reagent.  The 
complex then reduces the phosphomolybdic-phosphotungstic Folin reagent (Lowry 
B), giving a blue chromophore which absorbs light at 650 nm.  The protein content 
of the samples is then determined by comparison with the BSA standards. 
2.2.3 LDL aggregation by sphingomyelinase 
Freshly isolated native LDL was diluted to 2 mg protein/ml with a buffer containing 
NaCl (150 mM), MgCl2 (10 mM) and HEPES (5 mM), pH 7.4 in 15 ml plastic tubes. 
Sphingomyelinase from Bacillus cereus (Sigma-S9396-25N) was then added, at a 
final concentration of 10 mU/ml and the sample was then incubated in a water 
bath maintained at 37 °C to induce aggregation of LDL (Walters and Wrenn, 
2008). Aggregation was confirmed by dynamic light scattering in UV grade 
cuvettes with Zetasizer Nano Series particle sizer (Malvern Instruments, 
Worcestershire, UK) as well as by light scattering at 680 nm in a 
spectrophotometer (Khoo et al., 1988) (Figure 2.1). The aggregation was 
continued till the LDL particle size increased from about 25 nm to 200 nm. The 
sphingomyelinase aggregated-LDL (SMase-LDL) was then dialysed against 
phosphate buffer, pH 7.4 (which had been pre-treated with washed Chelex-100 to 
remove contaminating transition metals) (Van Reyk et al., 1995), and sterilised 
with 0.45 µm Minisart filter before use.  
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Figure 2.1 Aggregation of LDL by sphingomyelinase 
LDL (2 mg protein/mL) was incubated at 37° C with sphingomyelinase (10 mU/mL). (A) 
LDL particle size was measured by dynamic light scattering. (B) The increase in LDL 
particle size caused an increase in light scattering at 680 nm (measured after dilution to 
100 µg LDL protein/mL) monitored in a spectrophotometer, which is representative of four 
experiments. 
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2.2.4 Enrichment of LDL with lipid hydroperoxides 
The hydroperoxide content of freshly isolated LDL was increased by adding lipid 
hydroperoxide in the form of 13(S)-hydroperoxyoctadeca-9Z,11E-dienoic acid (13-
HPODE). The 13-HPODE treated samples were incubated for 30 min at 37 °C to 
allow the hydroperoxide enrichment of LDL particles before oxidation with iron. 
LDL was enriched to contain 30 nmol/mg or 60 nmol/mg LDL protein of 13-
HPODE (final levels), corresponding to about 4-8% of the maximum content of 
lipid hydroperoxides in oxidised LDL (Patterson et al., 2003a).  
2.2.5 LDL oxidation with iron 
Native LDL or SMase-LDL (1.6 ml at a concentration of 50 µg protein/ml) was 
oxidised with freshly dissolved FeSO4 (5 µM) at 37 °C in Chelex-100 treated 
NaCl/sodium acetate buffer (pH 4.5) in 15 ml polypropylene tubes (Triple Red Ltd, 
Bucks, UK) in the presence or absence of antioxidants. At various time points over 
24 h, the oxidations in one of the tubes was stopped by addition of BHT (final 
concentration 80 µM, from a stock of 2 mM in ethanol) and EDTA (final 
concentration 4 mM). Samples were then stored in the dark at 4 °C, until use.  
2.2.6 Lipoprotein-deficient serum  
Lipoprotein-deficient serum (LPDS) was made according to a protocol adapted 
from Renaud et al. (1982). FBS (of original density 1.006g/mL) was adjusted to a 
final density of 1.21 g/mL by adding solid KBr. The serum was centrifuged for over 
48 h at 22,000 x g, at 10 °C in Quick-Seal tubes (Beckman) using a 60Ti rotor 
(Beckman ultracentrifuge), with no brake. After centrifugation, the top layer of 
lipoproteins was carefully removed and the lower parts were recovered on a 
plastic cylinder on ice. The lipoprotein-free serum was dialysed in 4 changes of 1x 
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PBS pH 7.4 at 4 °C over the course of 24 h. The dialyzed LPDS was recovered, 
adjusted to the original volume of serum using dialysis buffer, and sterile-filtered 
using a 0.22 μm filter, divided into a number of tubes, and stored at −20 °C until 
use.  
2.3 Assessment of LDL oxidation 
2.3.1 Measurement of conjugated diene formation 
Free radical attack on polyunsaturated lipids within the LDL particle leads to the 
formation of lipid species, known as conjugated dienes, which contain two or more 
conjugated double bonds. Conjugated dienes can be measured directly using a 
spectrophotometer as they absorb UV strongly at 234 nm (Esterbauer et al., 
1989). 
LDL (native or SMase-LDL, 50 µg LDL protein/ml) was oxidised with freshly 
dissolved FeSO4, FeCl3 or CuSO4 (all at 5 µM final concentration) at 37 °C in a 
Chelex-100 treated NaCl/sodium acetate buffer (pH 4.5) or with CuSO4  in Chelex-
100 treated MOPS buffer (pH 7.4), in capped quartz cuvettes. The effect of 
antioxidants was studied by adding the antioxidants directly to the cuvettes 
containing LDL prior to the incubation at 37 °C. The change in absorbance at 234 
nm was measured at 37 °C against reference cuvettes containing all components 
except LDL.  Measurements were taken at one minute intervals in a double beam 
Lambda-2 6-cell or a Lambda Bio 40 8-cell spectrophotometer with UV winlab 
software (Perkin Elmer). The data were exported in excel and normalised for 
interpretation.  
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2.3.2 LDL-tryptophan fluorescence measurements 
ApoB-100 contains 37 tryptophan residues that give LDL a strong fluorescence at 
331 nm (Ex 282 nm). On oxidation, the LDL-tryptophan fluorescence decreases 
continuously indicating the LDL is being oxidised (Giessauf et al., 1995). 
The decrease in lipoprotein-bound tryptophan fluorescence was measured by a 
Cary Eclipse fluorescence spectrophotometer using the time-drive method at an 
emission wavelength of 331 nm, with excitation set at 282 nm (Giessauf et al., 
1995). The emission and excitation slits were set at 10 nm to obtain optimal 
fluorescence output. All kinetics experiments were performed as follows: LDL 
(native or SMase-LDL, 50 µg LDL protein/ml) was oxidised with freshly dissolved 
FeSO4 (5 µM) at 37 °C in a NaCl/sodium acetate buffer (150 mM NaCl, 10 mM 
acetic acid; pH 4.5) in capped quartz cuvettes and kinetics of decrease in 
tryptophan fluorescence was measured every 10 min for 1200 min. The 
experiments were performed in the presence or absence of different 
concentrations of antioxidants.  
2.3.3 Monitoring of ferrous iron levels 
The ferrous iron chelator bathophenanthrolinedisulfonic acid (BP) was used to 
measure ferrous iron (Fe2+) levels. BP is used to detect iron levels in blood and 
other biological fluids as it forms a red colour complex with Fe2+ at pH 2-9, with a 
molar absorption coefficient of 22,140 M-1cm-1, which absorbs light at 535 nm 
(Pieroni et al., 2001). Native LDL (50 µg protein/ml) was oxidised with freshly 
prepared FeSO4 (5 µM) in a NaCl/sodium acetate buffer (150 mM NaCl, 10 mM 
acetic acid; pH 4.5) in 15 ml polypropylene tubes in the presence or absence of 
cysteamine in a water bath maintained at 37 °C. Aliquots of 1 ml were taken at 
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different time points in the new tubes, BP (3 µl of 100 mM) was added to them and 
absorbance was measured at 535 nm with a spectrophotometer.   
2.3.4 Measurement of lipid hydroperoxides 
Lipid hydroperoxides (LOOH) were measured using a method adapted from that 
described by el-Saadani et al. (1989). Standard concentrations of H2O2 were made 
up using ultrapure water. Samples and standards (250 µl) were added to assay 
tubes in triplicate and 1 ml of colour reagent (0.2 M potassium phosphate, 0.12 M 
potassium iodide, 0.15 mM sodium azide, 2 g/l polyethyleneglycol mono[p-
(1,1',3,3'-tetramethyl-butyl)-phenyl]ether, 0.1 g/l alkylbenzyldimethylammonium 
chloride, 10 µM of ammonium molybdate; pH 6.0-6.2)  was added to each tube.  
After leaving the tubes in the dark for 1 h, the absorbance at 365 nm was 
measured.  
The basis for the assay is that peroxides in the samples or standards oxidise the 
iodide ions in the colour reagent to give molecular iodine.  This then reacts with 
excess iodide ions in the colour reagent to from the tri-iodide chromophore (I3
-) 
which absorbs ultraviolet radiation at 365 nm. The hydroperoxide content of the 
samples is then determined by comparison with the H2O2 standards. 
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2.4 HPLC analysis of lipid species 
Reverse phase high performance liquid chromatography (RP-HPLC) analysis was 
performed on the oxidised LDL samples (prepared as described in section 2.2.5) 
using a method based on that described by Kritharides et al. (1993). The HPLC 
was performed on Agilent 1200 system and the data was analysed using 
ChemStation software.  
2.4.1 Preparing oxidised LDL samples for HPLC analysis 
Methanol (1 ml) was added to each oxidised LDL sample (1.6 ml) and the samples 
were vortexed for 10 seconds. Hexane (3 ml) was then added to each sample and 
the samples were vortexed for 30 seconds to transfer the hydrophobic lipid fraction 
(cholesterol, cholesteryl esters and triglycerides) of LDL into the hexane. After 
centrifuging the samples for 15 min at room temperature and 1500 x g, 2 ml of the 
upper hexane layer was transferred to a 5 ml polypropylene tube and dried in a 
SpeedVac. The dried samples were dissolved in 200 µl of a relevant mobile phase 
and stored at -20 °C until analysis.  
2.4.2 HPLC analysis 
Each sample (20 µl) was injected into a reverse-phase Spherisorb ODS2 column 
(250 x 4.6 mm, 5 µm guard column, Waters, Hertfordshire, UK). The reverse-
phase columns contain hydrophobic stationary phase through which the more 
hydrophobic molecules are eluted first (Aguilar, 2003). Cholesterol, cholesteryl 
esters and their oxidation products were detected at 210 nm or 234 nm using the 
appropriate mobile phase and conditions as described in Table 2.1. Example 
chromatograms are shown in Figure 2.2 and Figure 2.3. Cholesterol, cholesteryl 
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esters and their oxidation products were quantified by comparison of peak area 
measurements with those of known concentrations of commercially available 
standards.  
 
 
Table 2.1 Target lipid species and analysis conditions for HPLC 
Mobile phase Wavelength Flow rate Time Lipid detected 
(A) -                          
44% Acetonitrile, 
54% Isopropanol,  
2% water                  
by volume 
 
234 nm 1.2 ml/min 15 min 7-ketocholesterol, 
cholesteryl 
linoleate 
hydroperoxide 
(CLOOH) 
 
(B) -                          
30% Acetonitrile, 
70% Isopropanol 
210 nm 1 ml/ml 15 min Cholesterol, 
Cholesteryl 
arachidonate, 
Cholesteryl 
linoleate, 
Cholesteryl 
oleate 
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Figure 2.2 Example chromatogram showing cholesterol, cholesteryl oleate, 
cholesteryl arachidonate and cholesteryl arachidonate in SMase-LDL 
Mobile phase ‘B’, a flow rate of 1 ml/min and a detection wavelength of 210 nm were 
used. 
 
 
 
 
 
Cholesterol 
Cholesteryl  
oleate 
Cholesteryl  
arachidonate 
Cholesteryl  
linoleate 
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Figure 2.3 Example chromatogram showing cholesteryl linoleate hydroperoxide in 
SMase-LDL 
Mobile phase ‘B’, a flow rate of 1.2 ml/min and a detection wavelength of 234 nm were 
used. 
 
 
 
Figure 2.4 Example chromatogram showing 7-ketocholesterol in SMase-LDL 
Mobile phase ‘B’, a flow rate of 1.2 ml/min and a detection wavelength of 234 nm were 
used. 
Cholesteryl  
Linoleate hydroperoxide 
7-ketocholesterol 
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2.5 Cell culture 
2.5.1 Human THP-1 cells  
Human THP-1 cells, a monocytic cell line derived from a monocytic leukaemia 
patient, were purchased from the European Collection of Cell Cultures (Salisbury, 
UK). Cells were counted with a Countess II FL automated cell counter (Invitrogen) 
and seeded at 3 x 105 cells/ml in RPMI-1640 medium [containing 2 mM L-
glutamine, 10 mM HEPES, 1 mM sodium pyruvate, glucose (4.5 g/l), and sodium 
bicarbonate (1.5 g/l)], supplemented with 10% v/v fetal calf serum (FCS), penicillin 
(20 IU/ml), streptomycin (20 µg/ml) and amphotericin B (0.95 µg/ml), in Corning® 
T75 or T150 flat bottomed flasks with filter caps. Cells were cultured at 37 °C in a 
humidified 95% air and 5% CO2 atmosphere until confluent. Culture medium was 
changed every 3-4 days to maintain the cells at desired confluency of 3 x 105 
cells/ml.  
Cells were subcultured by transferring the cell suspension under sterile conditions 
into 50 ml centrifuge tubes and centrifuging at 500 X g for 5 min at room 
temperature. The culture medium was then removed and the pellet was 
resuspended in fresh pre-warmed culture medium and seeded into new flasks as 
above.  
2.5.2 Cryopreservation of THP-1 cells 
THP-1 cells were frozen in cryopreservation media. Cells were centrifuged at 500 
x g for 5 min at room temperature. The culture medium was removed and the 
pellet was resuspended in cryopreservation media (2 ml per confluent T150). The 
cells were transferred to sterile cryopreservation vials and were frozen in 
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polystyrene containers (in order to allow them to freeze slowly) at -80 °C overnight. 
Vials were transferred to liquid nitrogen for long-term storage. When required, vials 
were thawed rapidly in a 37 °C water bath and their contents were transferred into 
50 ml centrifuge tubes containing RPMI-1640 medium, in order to dilute the DMSO 
in the cryopreservation media. They were centrifuged at 500 x g for 5 min at room 
temperature, resuspended in fresh culture medium and seeded as described 
above. 
2.5.3 Differentiation of THP-1 cells into macrophages 
The THP-1 cells were subcultured in a T75 flask and allowed to reach the density 
of 8 x 105 cells per ml. To obtain large cell numbers, the cells were subcultured in 
T150 flasks containing a maximum of 80 ml of culture medium. To maintain the 
viability of the cells, the cell density was not allowed to exceed 1 x 106 cells per ml. 
Differentiation of THP-1 monocytes into macrophages was triggered by incubating 
the cells with phorbol 12-myristate 13-acetate (PMA) (McSwine-Kennick et al., 
1991, Park et al., 2007). PMA differentiates THP-1 cells into macrophage-like cells 
by activating protein kinase C, ultimately resulting in cells with increased 
adherence and loss of proliferative activity (Richter et al., 2016). PMA inhibits 
THP-1 cells at G1-phase of the cell cycle, via a complex mechanism associated 
with the modulation of the expression of several cell cycle regulators (Traore et al., 
2005). The differentiation was done in 6-, 12- or 96-well plates depending on the 
type of experiment by incubating THP-1 monocytes for 72 h in the culture medium 
containing PMA (25 ng/ml).  After 72 h, the non-adherent cells were removed by 
washing with sterile PBS and the adherent macrophages were allowed to rest in 
PMA-free culture media for another 24 h before conducting experiments on them.  
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2.5.4 Detection of intralysosomal ceroid 
To detect intralysosomal ceroid formation, the monocytes were grown on sterile 
glass coverslips. Prior to starting the experiments sterile coverslips (18 x 18 mm) 
were carefully placed in 6-well tissue culture plates. THP-1 cells were adjusted to 
a density of 30,000 cells per ml in fresh culture media and treated with PMA at a 
final concentration of 25 ng/ml. With the help of a sterile micropipette, 200 µl of the 
cell suspension was carefully placed on the coverslip and incubated for 72 h at 37 
°C in a humidified 95% air and 5% CO2 to allow differentiation into macrophages. 
On differentiation the THP-1 cells attach to the glass coverslip and the 
undifferentiated cells were removed by washing the cells twice with sterile warm 
PBS.  To each well of the culture plates was added 2 ml of fresh culture medium 
(enough to cover the cells) and rested for 24 h before LDL treatment. Pre-warmed 
culture media (2 ml per well) either alone or containing native LDL (200 µg LDL 
protein/ml) or SMase-LDL (200 µg LDL protein/ml) was then added to the cells. 
After 24 h incubation, cells were washed three times with warm PBS to remove the 
LDL and the incubation was continued for 7 days with culture media containing 
lipoprotein deficient-serum with media changed every two days. To study the 
effects of antioxidants, freshly prepared cysteamine or probucol were added to the 
cells every day after the LDL was washed off. 
To demonstrate ceroid, cells on the coverslips were fixed with 4% (w/v) 
paraformaldehyde in PBS (2 ml per well) for 10 min. After washing the wells with 
PBS, coverslips were transferred to a wire staining rack and were submerged in 
60% (v/v) ethanol, 90% (v/v) ethanol, pure ethanol for 3 min each, in succession 
and then in xylene for five min to dissolve the soluble non-ceroid lipids within the 
cells. Xylene was replaced with ethanol, 90% ethanol (v/v) and 60% ethanol (v/v) 
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for 3 min each, in succession. The coverslips were then rinsed briefly in 60% (v/v) 
isopropanol before being stained for 10 min with Oil Red O (0.5%, w/v) in 60% 
(v/v) isopropanol. Coverslips were then rinsed with 60% (v/v) isopropanol and 
washed four times with distilled water. They were mounted onto slides using 
Vectashield® mounting medium (Vector Laboratories, UK), sealed with nail 
varnish and stored at 4 °C. Ceroid was visualised using light microscopy (Axioskop 
2, Carl Zeiss Ltd) and images were captured with Axiovision software. The 
quantification of ceroid was done using ImageJ (National Institute of Mental 
Health, Bethesda, Maryland, USA) by calculating the integrated density in five 
randomly positioned digital images containing a total of at least 100 cells in each 
slide. 
2.5.5 Lysosomal lipid peroxidation  
The process of lipid peroxidation in the lysosomes of macrophages was studied by 
employing a fluorescent probe called Foam-LPO, recently synthesised by Zhang 
et al. (2015). Foam-LPO is a BODIPY derivative containing a conjugated diene 
group within its fluorophoric structure which behaves as a lipid peroxidation 
signalling unit and a weakly alkaline tertiary amino group which enables the probe 
to be protonated and hence trapped and accumulated in the lysosomes. The 
conjugated diene group degrades in response to lipid peroxidation causing a 
fluorescent spectral shift from 586 nm to 512 nm, which can be measured by flow 
cytometry. 
THP-1 cells were incubated in RPMI-1640 (2 ml per well) (containing 10% v/v 
FCS)  with PMA (25 ng/ml) in 12-well tissue culture plates at 1 x 106 cells per well 
for 72 h, under 5% CO2 and 95% humidified air conditions, to differentiate into 
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macrophages. The macrophages were then washed and rested for another 24 h 
before treatment with LDL. After 24 h, they were incubated with pre-warmed 
culture media (2 ml per well) either alone or containing native LDL (200 µg 
protein/ml) or SMase-LDL (200 µg protein/ml) in the presence or absence of 
cysteamine for 24 h at 37 °C. The adherent macrophages were washed three 
times with pre-warmed PBS and then scraped into culture media using a plastic 
cell scraper. The culture medium was collected into 15 ml sterile polypropylene 
tubes and centrifuged at 500 x g for 5 min at room temperature. The cells were 
resuspended into 200 µl RPMI-1640 media each and transferred into a clear 96-
well round bottom microplate (Greiner CellStar®) and treated with Foam-LPO (2 
µM, a kind gift from Dr Xinfu Zhang, Dalian University of Technology, PRC) in 
RPMI-1640 for 15 min. Cells were pelleted at 500 x g for 5 min, and washed twice 
with HBSS and resuspended in FACS buffer. The cells were then analysed using 
a BD Biosciences C6 flow cytometer and the data was analysed using FlowJo 
software by determining mean fluorescence intensity for each histogram using 
untreated cells as a control. The fluorescence intensity ratio of the green channel 
(FL1) to red channel (FL2) (ratiometry) was taken as a measure of lysosomal lipid 
peroxidation.  
2.5.6 Assessment of lysosomal function   
The lysosomal function of cells was measured using a lysosomotropic tracking dye 
called LysoTracker® Red DND-99 (Life Technologies) (Pierzynska-Mach et al., 
2014). THP-1 cells were incubated in RPMI-1640 (2 ml per well) tissue culture 
media (containing 10% v/v FCS)  with PMA (25 ng/ml) in 12-well tissue culture 
plates at 1 x 106 cells per well for 72 h, under 5% CO2 and 95% humidified air 
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conditions, to differentiate into macrophages. The macrophages were then 
washed and rested for further 24 h before treatment with LDL. The macrophages 
were then incubated with pre-warmed culture media (2 ml per well) either alone or 
containing native LDL (100 µg protein/ml) or SMase-LDL (100 µg protein/ml) in the 
presence or absence of cysteamine for 72 h at 37 °C, with a change of media 
every 24 h. After 72 h, the macrophages were washed three times with pre-
warmed PBS to remove any residual LDL or cysteamine. The adherent 
macrophages were scraped into culture media using a plastic cell scraper, 
collected into 15 ml sterile polypropylene tubes and centrifuged at 500 x g for 5 
min at room temperature to remove cell debris. The cells were resuspended into 
200 µl RPMI-1640 media each and transferred into a clear 96-well round bottom 
microplate (Greiner CellStar®) and treated with LysoTracker Red (500 nM) in 
RPMI-1640 for 30 min at 37 °C. Cells were washed twice with HBSS, resuspended 
in FACS buffer and analysed using a BD Biosciences C6 flow cytometer. The data 
analysis was done using FlowJo software by determining mean fluorescence 
intensity for each histogram using untreated cells as a control.  
2.5.7 Measurement of lysosomal pH in macrophages 
Measurement of lysosomal pH in THP-1 cells was performed using a ratiometric 
lysosomal pH indicator dye called LysoSensor® Yellow/Blue DND-160 (Invitrogen) 
according to the protocol established by Lee et al. (2010). THP-1 cells in RPMI 
medium (containing 10% v/v FCS) were treated with PMA (25 ng/ml) and plated in 
black 96-well microplate (Corning) at 1 x105 cells per well for 72 h to differentiate 
into macrophages. The macrophages stuck to the plate were then washed with 
warm PBS and allowed to rest for a further 24 h in fresh culture media without 
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PMA. The macrophages were then treated with either no LDL or native LDL (100 
µg protein/ml) or SMase-LDL (100 µg protein/ml) every 24 h for 72 h in the 
presence or absence of cysteamine. After 72 h, the media containing LDL and 
cysteamine was washed off with PBS and the macrophages were then incubated 
with 5 µM Lysosensor Yellow/Blue for 30 min at 37 °C with 5% CO2.  
A separate set of THP-1 macrophages were used to generate the pH calibration 
curve according to the protocol established by Diwu et al. (1999). THP-1 cells 
were differentiated in a black 96-well microplate with PMA (25 ng/ml) at a density 
of 1 x105 cells per well. The cells were washed three times with pre-warmed PBS 
and after resting for 24 h, the macrophages were incubated in MES buffer (5 mM 
NaCl, 115 mM KCl, 1.3 mM MgSO4, 25 mM MES), with the pH adjusted to a range 
from 4 - 6.0. Ten min prior to the LysoSensor addition, the H+/Na+ ionophore, 
monensin and H+/K+ ionophore, nigericin were added to a final concentration of 10 
μM each. This allowed lysosomal pH to equilibrate with the MES/HEPES buffer 
and facilitated the creation of a standard curve correlating lysosomal pH with the 
magnitude of fluorescence emission.  
Both the plates were read in a Fluo Star Optima fluorometer (BMG Labtech), with 
excitation at 355 nm. The ratio of emission 440 nm/535 nm was then calculated for 
each sample and the pH values were determined from the standard plot generated 
(Figure 2.5).  
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Figure 2.5 Lysosomal pH calibration curve 
The ratio of emission at 440 nm and 535 nm plotted against the pH of the lysosomes.  
 
2.5.8 Senescence associated β-galactosidase staining 
Detection of senescent cells was done by using the senescence associated β-
galactosidase staining procedure described by Dimri et al. (1995). THP-1 cells (4 x 
103 per well) were differentiated into macrophages in a 12-well tissue culture plate 
(Corning®), with PMA as described above. The adherent macrophages were 
washed three times with pre-warmed PBS and rested for 24 h. The cells were then 
incubated in fresh culture media containing either no LDL, native LDL (100 µg 
protein/ml) or SMase-LDL (100 µg protein/ml) every 24 h for 72 h in the presence 
or absence of cysteamine. After 72 h, the medium was removed from the wells 
and cells were washed twice in PBS (2 ml) at room temperature. PBS was 
removed and cells were fixed for 3 min with 500 µl paraformaldehyde (4%) per 
well at room temperature. The fixative was removed and the cells were washed 
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with PBS. Cells were then exposed to the prepared X-gal staining solution (600 µl 
per well) and samples were incubated at 37 °C without CO2 for 18 h.  The staining 
solution was then removed and the plates were washed once with deionised water 
at room temperature. The cells were then washed through grading ethanol 
solutions of 75% (v/v), 95% (v/v), and 99.7% (v/v) using 600 µl per well for 1 min 
each. The plates were allowed to air dry after the last ethanol passage and the 
blue stained, senescent, cells were visualised using a Nikon inverted phase 
contrast light microscope, with images taken at ×10 magnification. Quantification 
of the blue stained cells was done manually (i.e. a cell was either blue or not) from 
5 distinct fields of view from each well. After the wells were analysed, the staining 
solution was removed and 1 ml of 70% (v/v) glycerol was added to each well, 
allowing long-term storage of the plates at 4 °C.  
2.5.9 TNF-α detection and quantification by ELISA 
TNF-α expression of THP-1 cells was analysed using the Human TNF alpha 
ELISA Ready-SET-Go!® reagent kit (eBioscience Cheshire, UK). 
THP-1 cells were incubated in RPMI-1640 (500 µl per well) tissue culture medium 
(containing 10% v/v FCS)  with PMA 25 (ng/ml) in 24-well tissue culture plates at 
3.5 x 105 cells per well for 72 h, under 5% CO2 and 95% humidified air conditions, 
to differentiate into macrophages. The macrophages were then washed three 
times with warm PBS and rested for a further 24 h in fresh culture media. The 
rested adherent cells were then incubated in fresh culture media either alone or 
with native LDL or SMase-LDL (both at 50 µg protein/ml) for either 12 h or 24 h. To 
study the effect of cysteamine, macrophages were pre-treated with different 
concentrations of cysteamine for 24 h prior to LDL addition. After incubation with 
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LDL, the media was removed and the wells were washed three times with warm 
PBS. The washed cells were then treated with fresh culture medium containing 
ultrapure LPS (10 ng/ml) for 4 h to trigger the production of TNF-α. The medium 
from each well were collected and assayed immediately using the manufacturer’s 
instructions. 
Prior to carrying out the assay all components were brought to room temperature. 
Firstly, the capture/coating antibody (anti-human TNF-α) was diluted 1:1000 in 
coating buffer and 100µl was added to each well in a 96-well polystyrene plate 
(Nunc Maxisorp®). The plate was sealed and incubated overnight at 4 °C. The 
supernatant was aspirated, wells were washed three times with ELISA wash buffer 
and the residual buffer was removed by blotting the plate on absorbent paper. The 
wells were then blocked with 200 µl/well ELISA diluent and incubated at room 
temperature for 1h. Assay diluent was aspirated and the wells were washed once 
with ELISA wash buffer. Test samples of cell medium and standards of 
recombinant human TNF-α, were added in 100 µl to designated wells and were 
then incubated overnight at 4 °C for maximal sensitivity. Then samples and 
standard were aspirated and wells were washed three times with ELISA wash 
buffer. Detection antibody (100 µl; 1:1250 in ELISA assay buffer) was added to 
each well and the plate was incubated at room temperature for 1 h. Wells were 
then washed three times, and 100 µl of streptavidin-horseradish peroxidase (HRP) 
solution was added to each well and incubated at room temperature for 30 min. 
Wells were washed three times and 50 µl TMB substrate was added and the plate 
was incubated in the dark for 15 min or until the colour developed. Finally 50 µl of 
1M H3PO4 stop solution was added and the colour intensity was measured at 450 
nm using an LT-4000 micro plate reader and Manta software. 
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2.6  Statistical analysis 
Unless stated otherwise, all results are expressed as means ± the standard error 
of the mean (S.E.M) of pooled data from 3 to 5 experiments as specified in figure 
legends. Comparison of two means was done using a 2-tailed unpaired Student’s t 
test. For comparing more than two means one-way ANOVA was used followed by 
Turkey’s post hoc analysis to measure the level of statistical significance between 
groups. Two-way ANOVA followed by Bonferroni post-tests were used to compare 
results of different HPLC time points of an LDL sample. The level of significance of 
difference is indicated in the graph as follows: * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 
0.001. ANOVA and post hoc analyses were carried out with GraphPad Prism 4 
software (La Jolla, CA). A p value of <0.05 was taken to be a statistically 
significant difference.  
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Chapter 3-  
Mechanism of LDL oxidation by iron at lysosomal pH 
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3.1 Introduction 
Many lines of evidence suggest that oxidation of LDL plays an important role in the 
pathogenesis of atherosclerosis, particularly in animal models (Maiolino et al., 
2013). The process of LDL oxidation is thought to occur in two main stages that 
are associated with a number of potentially proatherogenic events. For example, 
during the initial stages of LDL oxidation in vitro, oxidative modification of LDL 
cholesterol can occur in absence of any changes to apoB-100. Such LDL, now 
called minimally oxidised LDL, retains the affinity to the LDL receptor and induces 
inflammatory changes that increase local amounts of chemokines and cytokines 
(Cushing et al., 1990, Lee et al., 2000). The recruitment of inflammatory cells 
results in a variety of increased cytokines and thus continued oxidation of LDL 
during which the LDL protein is also modified (Parthasarathy et al., 2010). This 
highly oxidised LDL, now termed as oxidised LDL (OxLDL), loses recognition by 
the LDL receptor and shifts to recognition by scavenger receptors (oxidized LDL 
receptors). Hence results in the development of macrophage foam cells, the 
hallmark of the artery lesion (Levitan et al., 2010).  
It is believed that LDL oxidation does not take place in the circulation, as serum 
lipoprotein lipids are well protected from oxidation by the robust antioxidant 
defences (Leake and Rankin, 1990) and also because LDL itself contains a 
number of endogenous antioxidants (Stocker and Keaney, 2004). All the four 
major cells types present in early atherosclerosis lesions (endothelial cells, smooth 
muscle cells, monocyte-macrophages and lymphocytes) have been shown to 
oxidise LDL in vitro but its relevance in vivo has been questionable (Reviewed in 
detail by Steinberg and Witztum, 2010).  
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Despite these extensive data suggesting an important role for oxidation 
modification of LDL in atherosclerosis, both the location and the mechanisms of 
LDL oxidation have remained the subject of debate (Steinberg and Witztum, 2010, 
Yoshida and Kisugi, 2010).  
As mentioned previously, iron has been implicated as an obvious candidate for 
catalysing the oxidation of LDL in vivo. Animal studies have shown a positive 
correlation between iron-deposition within plaques and the severity of 
atherosclerosis (Lee et al., 1999). In addition, the rate of LDL oxidation by iron has 
been seen to increase at acidic pH. For example, under lower pH conditions, iron 
sequestering proteins release catalytically active free iron (Ji et al., 2012, Lee and 
Goodfellow, 1998) with the potential to catalyse the oxidation of LDL (Lamb and 
Leake, 1994, Morgan and Leake, 1995). One of the reasons for the increased rate 
of LDL oxidation by iron at low pH is the ability of the iron to redox cycle between 
the ferrous and ferric state and also the increased solubility at such lower pH 
(Leake, 1997, Morgan and Leake, 1993). It is also possible that if superoxide ions 
are involved, they would be converted to more powerful hydroperoxyl radicals at 
lower pH (Bedwell et al., 1989).  
Redox-active iron is also present within lysosomes (Yu et al., 2003). The source of 
elevated lysosomal iron is likely of a combination of processes including 
degradation of ferritin, the turnover of iron-containing organelles and the 
phagocytosis of erythrocyte (Zhang et al., 2010). To this end, Kidane et al. (2006) 
demonstrated that the release of free iron from ferritin occurs through lysosomal 
proteolysis. Furthermore, iron-catalysed free radical producing reactions within 
lysosomes lead to peroxidative damage to the lysosomal membrane and can 
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cause lysosomal rupture (Persson et al., 2001, Persson et al., 2003, Yu et al., 
2003). Whether iron in lysosomes exists in the ferric or ferrous state has been a 
matter of discussion (Collins et al., 1991), but because of the acidic and reducing 
environment within lysosomes the ferrous oxidation state of iron is likely to be 
favoured (Terman and Kurz, 2013).  However, this is not to say that the lower 
oxidation state predominates completely. In fact, the phagolysosomes of 
macrophages are known to contain ferric as well as ferrous iron (Meguro et al., 
2005). 
Strong evidence also exist that human macrophages, when incubated with 
modified LDL (e.g. aggregated LDL), internalise the lipoproteins via scavenger 
receptors, LDL receptors or lipoprotein receptor-related proteins (LRP) and deliver 
it to the lysosomes for degradation (Griffin et al., 2005, Jerome, 2006). In further 
support of this, Wen and Leake (2007) showed that nonoxidatively aggregated or 
acetylated LDL is endocytosed by macrophages and then is oxidised by the iron 
present in lysosomes (Wen and Leake, 2007). They further established that iron is 
highly effective in oxidizing LDL at pH 4.5, the approximate pH of lysosomes, but 
very poor at doing so at pH 7.4 (Wen and Leake, 2007). 
The mechanisms underlying LDL oxidation by iron in vitro and in vivo are wide 
ranging and complex. Various theories have been proposed for the mechanism of 
LDL oxidation by iron. It is also believed that iron may be able to initiate the 
oxidation of LDL by reacting with pre-existing lipid hydroperoxides (LOOH) in the 
LDL particles (Esterbauer et al., 1990). Some suggest that iron may be able to 
oxidise LDL via the production of hydroxyl radicals from hydrogen peroxide 
(Halliwell and Gutteridge, 1986, Lieu et al., 2001), while others believe that 
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superoxide ion is required for the initiation of LDL oxidation (Hiramatsu et al., 
1987, Lynch and Frei, 1993). The generation of highly reactive hydroxyl radicals 
through the Fenton reaction of ferrous iron with hydrogen peroxide has also been 
suggested to be the mechanism by which iron may be involved in LDL oxidation 
(Agil, Fuller et al. 1995) however, addition of hydrogen peroxide has been shown 
to inhibit the oxidation of LDL by iron at lysosomal pH (Satchell, 2007). 
A product of superoxide and nitric oxide, peroxynitrate, has also been suggested 
to oxidise lipoproteins in the artery wall and thus cause atherosclerosis (Darley-
Usmar et al., 1992). However, these mechanisms are based on reactions 
occurring at physiological pH (Lynch and Frei, 1993, Tang et al., 2000). Under 
such conditions, iron is prone to olation and ultimately precipitation (Dorey et al., 
1993). Hence, under more basic conditions the availability of free iron would be 
limited leaving the majority oxidised and unable to partake in the redox cycle. For 
the purpose of studying any antioxidant treatment for atherosclerosis, it is 
therefore essential to establish the exact mechanism by which iron oxidises LDL 
under conditions that are both amenable to the reactions of interest and 
representative of the conditions found within macrophage cells.  
Probucol is a lipid-soluble, bis-tertiary butyl phenol (Figure 3.1) capable of easily 
donating one of the hydrogens from its phenolic-OH groups and thus acting as an 
antioxidant. During lipid oxidation the lipid radical (L●), lipid alkoxyl radical (LO●) or 
lipid peroxyl radical (LOO●) easily abstract a hydrogen atom from probucol, hence 
inhibiting the lipid peroxidation chain reaction (Jackson et al., 1991). Therefore if 
the oxidation of LDL is mediated by any of these radicals (as is believed) probucol 
should be able to completely inhibit the oxidation of LDL by iron (Coffey et al., 
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1995). N,N'-Diphenyl-1,4-phenylenediamine (DPPD) is another strong antioxidant 
which is capable of donating a hydrogen atom from each of its secondary amine 
groups and hence prevents lipid peroxidation (Pryor et al., 1988, Takahashi et al., 
1989). Both probucol and DPPD are able to inhibit copper-catalysed oxidation of 
LDL at physiological pH and prevent atherosclerosis in animals (Braesen et al., 
1995, Niimi et al., 2013, Sparrow et al., 1992, Tangirala et al., 1995).  
 
              
 
Figure 3.1 Chemical structures of probucol and DPPD 
Superoxide anion (O2
●‐) has been proposed as a primary cell-derived oxidant with 
a role in LDL oxidation (Steinbrecher, 1988). A relationship between LDL oxidation 
by cells and superoxide production was first proposed in 1984 (Morel et al., 1984) 
and since then various groups have shown its role in LDL oxidation in smooth 
muscle cells (Heinecke et al., 1986), monocytes (Cathcart et al., 1989, Hiramatsu 
et al., 1987), and macrophages (Wilkins and Leake, 1990). Thiols are present in 
human cells at millimolar concentrations and are an important component of the 
cell’s antioxidant defence and are known to scavenge superoxide ions in protic as 
well as aprotic media (Cardey et al., 2007, Feroci and Fini, 2007). Therefore, if 
           Probucol           DPPD 
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LDL oxidation by iron at lysosomal pH is mediated by superoxide ions, addition of 
thiols like cysteamine should completely inhibit this process. 
Thus, the aim of this chapter is to establish the mechanisms which may be 
involved in oxidation of LDL by iron under lysosomal conditions. 
3.2 Methods 
Presence of lipid hydroperoxides in fresh LDL were measured by a tri-iodide assay 
as described in detail in section 2.3.4. The course of oxidation was followed by 
measuring the formation of conjugate dienes, kinetics of LDL-tryptophan 
fluorescence, specified oxidised lipids by HPLC or monitoring Fe2+ levels, as 
described in sections 2.3.1, 2.3.2 and 2.4 respectively.  
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3.3 Results 
3.3.1 Oxidation of LDL with ferrous and ferric iron 
As mentioned before, the oxidation of LDL by iron is supposed to take place only 
in the presence of pre-existing lipid hydroperoxides and hence LDL which has no 
detectable pre-existing hydroperoxides should resist oxidation by iron. Also, 
lysosomes of macrophages have been shown to contain catalytically active iron 
which redox cycles between ferrous (Fe2+) and ferric (Fe3+) states. Therefore, the 
oxidation of LDL can occur by both ferrous and ferric forms of iron and hence it is 
important to examine the nature of LDL oxidation with both ferrous and ferric iron.  
Freshly isolated LDL was first checked for the presence of pre-existing lipid 
hydroperoxides before conducting any oxidation experiments. There were no lipid 
hydroperoxides detected in the freshly isolated LDL samples at all times. The 
same LDL (50 µg LDL protein/ml) was oxidised in NaCl/sodium acetate buffer (pH 
4.5) at 37 °C in the presence of ferrous iron (FeSO4, 5 µM) or ferric iron (FeCl3, 5 
µM). The course of oxidation was followed by measuring the formation of 
conjugated dienes and loss of LDL-tryptophan fluorescence.  
Both ferrous sulphate and ferric chloride were able to oxidise fresh LDL at pH 4.5, 
even though no pre-existing lipid hydroperoxides were detected. The oxidation 
reaction proceeded at a significantly slower rate with ferric iron compared with 
ferrous iron and this was confirmed by both the conjugated diene measurement 
and loss of LDL-tryptophan fluorescence. 
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There was continuous formation of conjugated dienes during LDL oxidation with 
both ferrous and ferric iron (Figure 3.2). The time taken to reach an attenuance of 
0.1 was taken as the measure of oxidation as it represents the rapid oxidation 
phase during LDL oxidation with iron at pH 4.5 (Satchell and Leake, 2012).  
In the case of conjugated diene experiments, the time taken to reach an 
attenuance of 0.1 was 58 ± 1.4 min in the presence of ferrous iron compared with 
85 ± 9 min with ferric iron (p<0.05), mean±SEM of three independent experiments 
(Figure 3.2) indicating that the lipid peroxidation occurs faster with ferrous iron.  
There was a continuous loss of LDL-tryptophan fluorescence during oxidation of 
LDL with both ferric and ferrous iron (Figure 3.3). There was a sharp initial 
decrease in LDL-tryptophan fluorescence by ferrous iron oxidation. The 
percentage loss of tryptophan fluorescence after 150 min was 51 ± 1.3% in case 
of the ferrous-catalysed reaction while the loss was 25  ± 2% in case of the ferric-
catalysed oxidation reaction (Figure 3.3), indicating that apoB-100 of LDL was 
oxidised faster with ferrous iron. These results suggest that iron is able to oxidise 
LDL at pH 4.5 in absence of hydroperoxides and ferrous iron is a stronger 
oxidising agent than ferric iron. 
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Figure 3.2 Comparison of the oxidation of LDL by ferrous and ferric iron at pH 4.5 
LDL (50 µg LDL protein/ml) in sodium chloride/sodium acetate buffer (pH 4.5) was 
incubated with 5 µM FeSO4 or FeCl3 at 37 °C, in capped quartz cuvettes. (A) Oxidation of 
LDL cholesterol was monitored by measuring the change in attenuance at 234 nm against 
appropriate reference cuvettes. This is a representative example of 3 independent 
experiments. (B) Time taken to reach an attenuance of 0.1 during the oxidation process (* 
indicates p<0.05, 2-tailed unpaired Student’s t test, n = 3 independent experiments).  
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Figure 3.3 Kinetics of decrease of LDL-tryptophan fluorescence during Fe2+ and 
Fe3+ mediated oxidation.  
LDL (50 µg protein/ml) in sodium chloride/sodium acetate buffer (pH 4.5) was incubated 
with either 5 µM FeSO4 or FeCl3 at 37 °C in quartz cuvettes. (A) The kinetics of decrease 
in LDL-tryptophan fluorescence was measured every 10 min at excitation wavelength of 
282 nm and emission wavelength 331 nm in a spectrofluorometer. This is a representative 
example of at least three independent experiments. (B) Shows decrease in LDL-
tryptophan fluorescence after 150 min of oxidation (* indicates p<0.05, 2-tailed unpaired 
Student’s t test, n = 3 independent experiments).  
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3.3.2 Measurement of ferrous ion levels 
Under lysosomal conditions ferrous iron would be expected to be the main species 
and since LDL oxidation was seen to be faster with ferrous iron, it is therefore of 
interest to monitor the kinetics of ferrous iron during the LDL oxidation process. 
The levels of ferrous iron were monitored during LDL oxidation using the ferrous 
iron chelator bathophenanthrolinedisulfonic acid (BP). LDL (50 µg LDL protein/ml) 
was oxidised in NaCl/sodium buffer (pH 4.5) at 37 °C in the presence of ferrous 
iron (FeSO4, 5 µM) in plastic tubes and during the oxidation process samples were 
taken and checked for the ferrous iron levels using BP (10 mM).  
During the course of LDL oxidation, ferrous iron (Fe2+) was consumed in the first 
120 min (Figure 3.4). There was a sharp decrease in the Fe2+ level during the first 
60 min of oxidation where the concentration of Fe2+ decreased from 4.57 ± 0.6 µM 
to 0.40 ± 0.2 µM. This sharp decrease corresponds to the rapid oxidation phase as 
seen in the conjugated diene measurement and LDL-tryptophan fluorescence 
during LDL oxidation with iron (section 3.1.1 above). These results confirm that 
ferrous iron is consumed during the rapid phase of LDL oxidation and would be 
converted by oxidation presumably to ferric state. This probably explains why the 
rate of LDL oxidation slowed down afterwards.  
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Figure 3.4 Kinetics of ferrous ion levels during LDL oxidation by FeSO4 at pH 4.5 
LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated with 5 µM 
FeSO4 at plastic tubes maintained 37 °C. At various time points, aliquots were taken and 
ferrous ion concentration determined by measuring absorbance at 535 nm after treating 
with the iron chelator bathophenanthrolinedisulfonic acid (10 mM). This is a representative 
of 3 independent experiments.  
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3.3.3 Oxidation of hydroperoxide-rich LDL    
The results above show that iron is able to oxidise freshly isolated LDL even when 
it contains no detectable pre-existing lipid hydroperoxides. It could be that the 
levels of lipid hydroperoxides required to initiate the LDL oxidation are 
undetectable by the current methods. Therefore, to investigate if lipid 
hydroperoxides play any role in LDL oxidation by iron under lysosomal pH, fresh 
native LDL was externally supplemented with the lipid hydroperoxide 13(S)-
hydroperoxyoctadeca-9Z,11E-dienoic acid (13-HPODE). 13-HPODE is a 
significant component of oxidized LDL and has been shown to be present in 
atherosclerotic lesions (Folcik and Cathcart, 1994). It is the lipoxygenase product 
of linoleic acid. 13-HPODE has been shown to increase the rate of LDL oxidation 
with copper at pH 7.4 (Patterson et al., 2003a).  
LDL (50 µg LDL protein/ml) was enriched to contain 30 nmol/mg or 60 nmol/mg 
LDL protein of 13-HPODE and then oxidised in NaCl/sodium buffer (pH 4.5) at 37 
°C, in the presence of ferrous iron (5 µM FeSO4). The oxidation process was 
followed by measuring the formation of conjugated dienes and loss of LDL-
tryptophan fluorescence.  
Addition of lipid hydroperoxide to native LDL did not increase oxidation with 
ferrous iron at pH 4.5 (Figure 3.5). Native LDL (no HPODE added) reached an 
attenuance of 0.1 in 71 ± 6.1 min which was almost similar to the LDL that was 
spiked with 30 nmol HPODE/mg protein 77 ± 4 min, (P>0.05). There was also no 
significant difference in the rate of oxidation between the native LDL (no HPODE) 
and the LDL that was spiked with 60 nmol/mg protein HPODE (84.33 ± 2.03 min). 
Unexpectedly, it was seen that after about 400 min, oxidation slowed down in 
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HPODE spiked samples indicating that oxidation of LDL with iron at pH 4.5 was 
decreased by lipid hydroperoxides. 
The conjugated diene results were reflected in the LDL-tryptophan fluorescence 
experiments (Figure 3.6). LDL-tryptophan fluorescence decreased by 20.0 ± 
0.36% after 150 min when the native LDL (no HPODE added) was oxidised with 5 
µM FeSO4 and the fluorescence decreased by 19.0 ± 0.8% (P>0.05) in the case of 
LDL to which was added HPODE at 30 nmol/mg LDL protein (Figure 3.6B). In the 
case of LDL which was spiked with 60 nmol/mg HPODE the LDL-tryptophan 
fluorescence decreased by 19.0 ± 1% (P>0.05) after 150 min when compared with 
control LDL. These results suggest that pre-existing lipid hydroperoxides and 
hence lipid radicals do not initiate the iron mediated LDL oxidation at lysosomal 
pH. 
 
 
 
97 
 
 
 
Figure 3.5 Effect of 13-HPODE on LDL oxidation with FeSO4 at pH 4.5 
Native LDL and HPODE-rich native LDL (30 nmol/mg or 60 nmol/mg LDL protein) were 
oxidised by 5 µM FeSO4 at pH 4.5 in NaCl/sodium acetate buffer (pH 4.5) at 37 °C in 
quartz cuvettes. (A) Oxidation was monitored by measuring the change in attenuance at 
234 nm against appropriate reference cuvettes. This is a representative example of at 
least three independent experiments. (B) Shows the time taken to reach an attenuance of 
0.1 during LDL oxidation (p>0.05, ANOVA followed by Tukeys post-test, n = 3 
independent experiments).  
 
 
 
98 
 
 
 
Figure 3.6 Effect of 13-HPODE on LDL-tryptophan fluorescence during Fe2+ 
mediated oxidation.  
Native LDL (50 µg protein/ml) or HPODE enriched LDL (30 or 60 nmol/mg LDL protein) in 
NaCl/sodium acetate buffer (pH 4.5) was incubated with either 5 µM FeSO4 at 37 °C in 
quartz cuvettes. (A) Loss of LDL-tryptophan fluorescence was measured every 10 min at 
excitation wavelength of 282 nm and emission wavelength 331nm in a spectrofluorometer. 
This is a representative example of at least three independent experiments. (B) Shows 
decrease in LDL-tryptophan fluorescence after 150 min of oxidation (*** indicates p<0.001 
compared to untreated control LDL, student t-test, n = 3 independent experiments).  
 
 
 
99 
 
3.3.4 Oxidation of LDL by iron in presence of probucol  
As mentioned above, oxidation of LDL at physiological pH is believed to take place 
by the breakdown of pre-existing lipid hydroperoxides present in LDL and probucol 
is able to prevent this oxidation. It was therefore of interest to examine if probucol 
will prevent the oxidation of LDL by iron at lysosomal pH. 
LDL (50 µg LDL protein/ml) was oxidised in NaCl/sodium buffer (pH 4.5) at 37 °C 
in the presence of probucol (2 µM) with ferrous iron (5 µM). The course of the 
oxidation was followed by measuring the formation of conjugated dienes at 234 
nm and loss of LDL-tryptophan fluorescence (Ex/Em = 282/331 nm). 
Interestingly, probucol (2 µM) was unable to prevent initial oxidation of LDL by iron 
at pH 4.5. Probucol showed no antioxidant effect for about first 80 min, however 
the rate of oxidation slowed down later (Figure 3.7). The time required for the 
attenuance to reach 0.1 was 102 ± 6 min when LDL was incubated alone with iron 
and 116 ± 11 min when incubated in presence of probucol (p>0.05, n = 6 
independent experiments).  
There was a continuous loss of LDL-tryptophan fluorescence when LDL was 
incubated with iron and probucol (2 µM) appeared to moderately decrease the loss 
of LDL-tryptophan fluorescence, but the effect was not statistically significant, 
while the fluorescence intensity remained intact when the LDL was incubated 
alone at pH 4.5 (Figure 3.8A). After 80 min of LDL oxidation with iron the 
fluorescence intensity decreased by 24 ± 3% which was not significantly different 
(p>0.05) from that in presence of probucol where it decreased by 19 ± 2 % mean± 
SEM, unpaired t-test (Figure 3.8B).  
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Based on the above results it can be interpreted that the lipid radical species 
which are usually thought to initiate lipid peroxidation are not involved in initiating 
LDL oxidation at lysosomal pH. These results also suggest that perhaps the lipid 
peroxidation first occurs in the cholesterol ester rich hydrophobic core of LDL to 
which probucol has limited access. Probucol inhibits oxidation later on because 
the oxidation would spread from the core to the phospholipid monolayer where 
probucol resides.  
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Figure 3.7 Effect of probucol on LDL oxidation by iron at pH 4.5 
Native LDL (50µg protein/ml) was oxidised in presence or absence of 2 µM probucol by 
FeSO4 at pH 4.5 in NaCl/sodium acetate buffer at 37 °C in quartz cuvettes. (A) Oxidation 
was monitored by measuring the change in attenuance at 234 nm against appropriate 
reference cuvettes. This is a representative example of three independent experiments. 
(B) Shows the time taken to reach an attenuance of 0.1 during the oxidation process 
(p>0.05, unpaired student t-test, n = 6).  
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Figure 3.8 Effect of probucol on LDL-tryptophan fluorescence during LDL oxidation 
by iron 
LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated alone or with 
5 µM FeSO4 at 37 °C in presence of absence of 2 µM probucol in quartz cuvettes. (A) 
Kinetics of decrease in tryptophan fluorescence was measured every 10 min at excitation 
wavelength of 282 nm and emission wavelength 331nm in a spectrofluorometer. This is a 
representative example of at least three independent experiments. (B) Shows the 
percentage loss of LDL-tryptophan fluorescence after 80 min of oxidation (p>0.05, t-test, 
n=6). 
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3.3.5 Oxidation of LDL by iron in presence of DPPD 
DPPD is a potent antioxidant used to study the mechanisms of lipid peroxidation 
processes; however, it has limited application in living systems because of its 
mutagenic effects (Sparrow et al., 1992).  
Furthermore, DPPD has a polar surface area of 24.06 (PubChem) and thus has a 
greater access to the hydrophobic core of LDL than probucol which has a polar 
surface area of 91.1 (PubChem2). Therefore, if the initial lipid peroxidation of LDL 
which still occurs in the presence of probucol takes place in the hydrophobic core, 
DPPD should completely inhibit this oxidation. 
LDL (50 µg LDL protein/ml) was oxidised in NaCl/sodium buffer (pH 4.5) at 37 °C, 
in presence of DPPD (2 µM) with ferrous iron (5 µM). The course of the oxidation 
was followed by measuring the formation of conjugated dienes at 234 nm and loss 
of LDL-tryptophan fluorescence (Ex/Em = 282/331 nm). DPPD (2 µM) completely 
prevented the initial lipid peroxidation of LDL as measured by the formation of 
conjugated dienes (Figure 3.9). In presence of DPPD there was almost complete 
inhibition of conjugated diene formation initially and even after 250 min of oxidation 
attenuance did not reach the value of 0.1.  
As expected LDL oxidation by iron caused continuous loss of LDL-tryptophan 
fluorescence, interestingly, in the presence of DPPD (2 µM) LDL-tryptophan lost 
the fluorescence from the start of the experiment (Figure 3.10). After 100 min of 
the oxidation process, ferrous iron decreased the LDL-tryptophan fluorescence by 
49 ± 5 %, whereas in the presence of DPPD the fluorescence decreased by 61 ± 3 
% compared to the control to which no iron was added. 
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Therefore, DPPD is able to prevent the oxidation of the lipid portion of the LDL but 
is unable to protect the apoB-100 part of the LDL further indicating that the lipid 
radicals are not involved in initiating LDL oxidation by iron. These results also 
suggest that the initial lipid peroxidation (as seen in the presence of probucol) 
probably occurs in the hydrophobic core of the LDL molecule which can be 
inhibited by DPPD as it has access to the hydrophobic core. 
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Figure 3.9 Effect of DPPD on the oxidation of LDL by iron at pH 4.5 
LDL (50µg protein/ml) was oxidised in presence or absence of 2 µM DPPD by FeSO4 at 
pH 4.5 in sodium chloride/sodium acetate buffer at 37 °C in quartz cuvettes. Oxidation 
was monitored by measuring the change in attenuance at 234 nm against appropriate 
reference cuvettes. This is a representative example of three independent experiments. 
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Figure 3.10 Effect of DPPD on LDL-tryptophan fluorescence during LDL oxidation 
by iron 
LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated alone or with 
5 µM FeSO4 at 37 °C in the presence of absence of 2 µM DPPD in quartz cuvettes. (A) 
Kinetics of decrease in tryptophan fluorescence was measured every 10 min at excitation 
wavelength of 282 nm and emission wavelength 331nm in a spectrofluorometer. This is a 
representative example of at least three independent experiments. (B) Shows the 
percentage loss of LDL-tryptophan fluorescence after 100 min of oxidation (p>0.05, t-test, 
n=3). 
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3.3.6 HPLC analysis of LDL oxidation by iron in presence of probucol and 
DPPD 
Reverse phase high performance liquid chromatography (HPLC) is an important 
technique which enables the quantification of the lipid peroxidation process during 
LDL oxidation. HPLC measures the oxidation of the hydrophobic core of LDL by 
measuring the decrease in cholesterol ester content of LDL particles which absorb 
UV light at 210nm and the formation of lipid hydroperoxides, most importantly 
cholesterol linoleate hydroperoxide (CLOOH), which absorbs UV light at 234nm.  
Probucol has been found to concentrate more in the phospholipid monolayer 
surrounding the hydrophobic lipid core (Bard et al., 1994) while DPPD has been 
shown to penetrate the hydrophobic zones (Butterfield and McGraw, 1978, 
Demopoulos, 1973). Therefore, if the initial oxidation of LDL (seen in the presence 
of probucol) occurs in the hydrophobic core, the lipophilic antioxidant DPPD 
should be able to protect the oxidation of cholesterol esters in the hydrophobic 
core completely while probucol should have no effect on this oxidation. 
LDL (50 µg LDL protein/ml) was oxidised in sodium chloride/sodium buffer (pH 
4.5) at 37 °C with ferrous iron (5 µM), in the presence or absence of either 
probucol (2 µM) or DPPD (2 µM). Aliquots were taken at different times and were 
processed for HPLC analysis as mentioned in detail in the methods section in 
chapter 2.  
During LDL oxidation by iron there was continuous formation of CLOOH which 
was completely prevented by DPPD while probucol was unable to prevent it 
(Figure 3.11). CLOOH levels increased to 386 ± 32 nmol/mg LDL protein in control 
samples compared to 392 ± 21 nmol/mg LDL protein in the presence of probucol 
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(2 µM) (p>0.05), whereas there was no CLOOH detected in the samples treated 
with DPPD (2 µM).  These results agreed with the decreasing levels of cholesterol 
linoleate (CL). CL levels decreased from 1520 ± 20 to 635 ± 20 nmol/mg LDL 
protein in the first 120 min of oxidation in the control samples and in presence of 
probucol the levels decreased to 690 ± 0.4 nmol/mg LDL protein (p<0.05) after 
120 min, whereas DPPD greatly prevented the oxidation and levels only 
decreased to 1480 ± 22 nmol/mg LDL protein (Figure 3.11) 
The levels of the other major cholesteryl ester present in the core of LDL, 
cholesteryl arachidonate (CA), also decreased greatly both in control samples and 
in those treated with probucol while DPPD prevented it (Figure 3.11). As expected 
(Esterbauer et al., 1987), the levels of CA decreased faster than those of CL, as it 
contains four double bonds in its fatty acid moiety compared to two in CL. After 
120 min CA levels decreased from 150 ± 0.3 to 36.0 ± 1.2 nmol/mg LDL protein in 
control samples and it dropped to 38.7 ± 0.04 nmol/mg LDL protein in presence of 
probucol (p>0.05) while in presence of DPPD the levels only decreased to 148 ± 3 
nmol/mg LDL protein. 
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Figure 3.11 HPLC profile of LDL oxidation by iron in presence of probucol or DPPD 
Native LDL (50 µg LDL protein/ml) was oxidised with freshly dissolved FeSO4 (5 µM) in 
the presence or absence of either probucol (2 µM) or DPPD (2 µM) at 37 °C in a sodium 
chloride/sodium acetate buffer, pH 4.5. At various time points up to 2 h, oxidation was 
stopped by addition of EDTA (final concentration 2mM) and BHT (2mM). The samples 
were then assayed for cholesteryl linoleate hydroperoxide (A), cholesteryl linoleate (B) 
and cholesteryl arachidonate (C) by reverse phase HPLC. Graph represent mean (± SEM) 
of at least 3 independent experiments (*** indicates p<0.001 compared with the control 
sample to which no antioxidant was added, Two-way ANOVA followed by Bonferroni post-
test). 
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3.3.7 Oxidation of LDL by iron in presence of cysteamine 
Cysteamine belongs to a group of antioxidants called thiols. Thiol-type 
antioxidants constituting a class of organic sulfur derivatives (mercaptans) having 
the sulfhydryl functional groups (–SH) play a crucial role in protecting cells from 
oxidative damage (Deneke, 2000). Thiols are known to react with superoxide 
radical in both anionic form (O2
•-) and protonated form (the hydroperoxyl radical, 
HO2
•) (Cardey et al., 2007) and therefore prevent the oxidation process. To 
explore the hypothesis that LDL oxidation by iron at lysosomal pH is mediated by 
superoxide radicals, LDL oxidation was carried out in the presence of cysteamine. 
Cysteamine (pKa 8.60 for the thiol group, 10.75 for the amine group) is the 
simplest stable amino-thiol and during the antioxidant process is converted to its 
disulfide dimer, cystamine (Jocelyn, 1967, Mezyk, 1995). 
LDL (50 µg LDL protein/ml) was oxidised in NaCl/sodium buffer (pH 4.5) with 
ferrous iron (5 µM) at 37 °C, in the presence of different doses of cysteamine. The 
course of the oxidation was followed by measuring the formation of conjugated 
dienes at 234 nm and loss of LDL-tryptophan fluorescence (Ex/Em = 282/331 nm). 
As expected LDL was effectively oxidised when incubated with iron alone and 
followed the usual pattern of conjugated diene formation, aggregation and 
sedimentation (Figure 3.12). However, cysteamine showed a concentration-
dependent inhibition of LDL cholesterol oxidation by iron with 250 µM offering 
complete protection over at least 2000 min and the lower concentration of 25 µM 
preventing oxidation for about 500 min. The lower dose of 25 µM was chosen for 
statistical analysis and to conduct further experiments. In control samples to which 
no cysteamine was added it took 64 ± 4 min to reach an attenuance of 0.1 while in 
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the presence of cysteamine (25 µM) the conjugated dienes reached an attenuance 
of 0.1 after 526 ± 74 min (p<0.001), mean±SEM of 4 independent experiments 
(Figure 3.12). 
As discussed above, control samples which were incubated without iron showed 
no decrease in the loss of LDL-tryptophan fluorescence and incubation with iron 
led to continuous loss of this fluorescence indicating oxidation of apoB-100 of LDL 
(Figure 3.13). Cysteamine (25 µM) was able to completely prevent the oxidation of 
the apoB-100 part of LDL by iron for about first 500 min. After 150 min of LDL 
oxidation by iron the fluorescence of LDL decreased by 61 ± 3 %, whereas in the 
presence of cysteamine there was only 8 ± 1 % decrease in the fluorescence 
(p<0.001), mean±SEM of 4 independent experiments. 
These results show that superoxide scavengers like cysteamine are able to greatly 
prevent the initial oxidation of LDL cholesterol as well as apoB-100 by iron at 
lysosomal pH. The results so far indicate that during initial LDL oxidation by iron at 
pH 4.5 the oxidising agent not only attacks the protein part of LDL but is also able 
to penetrate into the cholesteryl ester-rich LDL core.  
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Figure 3.12 Effect of cysteamine on LDL oxidation by iron at pH 4.5 
LDL (50 µg protein/ml) was oxidised in the absence or presence of cysteamine (25 µM, 50 
µM or 250 µM) by FeSO4 at pH 4.5 in sodium chloride/sodium acetate buffer at 37 °C in 
quartz cuvettes. (A) Oxidation was monitored by measuring the change in attenuance at 
234 nm against appropriate reference cuvettes. This is a representative example of three 
independent experiments. (B) Shows the time taken to reach an attenuance of 0.1 during 
LDL oxidation in presence and absence of 25 µM cysteamine (*** indicates p<0.001, t-
test, n=4 independent experiments). 
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Figure 3.13 Effect of cysteamine on LDL-tryptophan fluorescence during oxidation 
by iron at pH 4.5 
 LDL (50 µg protein/ml) was oxidised in the absence or presence of cysteamine (25 µM) 
by FeSO4 at pH 4.5 in sodium chloride/sodium acetate buffer at 37 °C in quartz cuvettes. 
(A) Loss of LDL- tryptophan fluorescence was measured every 10 min at excitation 
wavelength of 282 nm and emission wavelength 331nm in a spectrofluorometer. This is a 
representative example of four independent experiments. (B) Shows the percentage loss 
of LDL-tryptophan fluorescence after 150 min of oxidation (*** indicates p<0.001, t-test, 
n=4). 
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3.3.8 HPLC analysis of LDL oxidation by iron in presence of cysteamine 
Cysteamine completely prevented the initial oxidation of LDL cholesterol by iron at 
pH 4.5. To further investigate the protective mechanism of cysteamine in 
preventing oxidation of LDL by iron, HPLC analysis was performed on the LDL 
samples.  
LDL (50 µg LDL protein/ml) was oxidised in NaCl/sodium buffer (pH 4.5) at 37 °C 
with ferrous iron (5 µM), in the presence or absence of cysteamine (25 µM). 
Samples were taken at different times and were processed for HPLC analysis as 
mentioned in detail in the methods section in chapter 2.  
During the oxidation of LDL with iron there was a continuous decrease in the 
levels of cholesterol arachidonate (CA) with time. However, cysteamine (25 µM) 
prevented the loss of CA levels for 6 h during LDL oxidation by iron (Figure 3.14). 
After 6 h of LDL oxidation CA levels in control samples decreased from 318 ± 31 
to 70 ± 27, whereas in the presence of cysteamine the levels only dropped to 301 
± 30 nmol/mg LDL protein (p<0.001), mean±SEM of 3 independent experiments. 
Similar trend was seen in the cholesterol linoleate (CL) levels. CL levels 
decreased continuously when LDL was oxidised by iron, however cysteamine (25 
µM) completely prevented the decrease in CL levels during initial 6 h of oxidation. 
After 6 h CL levels only decreased from 2034 ± 139 to 2027 ± 138 nmol/mg LDL 
protein when LDL was oxidised in the presence of cysteamine, whereas the levels 
dropped to 1200 ± 100 nmol/mg LDL protein in the absence of cysteamine 
(p<0.05), mean±SEM of 3 independent experiments.  
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The hydroperoxide product of CL was also measured by HPLC at 234 nm. There 
was continuous formation of cholesterol linoleate hydroperoxide (CLOOH) during 
oxidation of LDL with iron and cysteamine (25 µM) significantly prevented its 
formation during the course of LDL oxidation. In presence of cysteamine (25 µM) 
no CLOOH was detected for first 6 h during LDL oxidation, and after 12 h the 
CLOOH levels reached 21 ± 4 nmol/mg LDL protein (Figure 3.15). However, in 
control samples to which no cysteamine was added the CLOOH levels detected 
were 134 ± 16 nmol/mg LDL protein after 3 h (p<0.001), 170 ± 11 after 6 h (p< 
0.001) and 206 ± 41 after 12 h (p<0.001), mean±SEM of 3 independent 
experiments. 
The levels of the cholesterol oxidation product, 7-ketocholesterol, increased slowly 
and then rapidly from 1.15 ± 0.5 to 14 ± 1 nmol/mg LDL protein after 12 h of LDL 
oxidation by iron, in agreement with previous findings (Satchell and Leake, 2012), 
as the cholesterol is more difficult to oxidise than the fatty acyl groups of 
cholesteryl ester,  whereas in the presence of cysteamine the levels detected after 
12 h were 3.2 ± 0.2 nmol/mg LDL protein (p<0.001 compared to control), 
mean±SEM of 3 independent experiments.  
These results show that cysteamine is able to prevent the oxidation of the 
cholesteryl ester-rich hydrophobic core of LDL as well as the oxidation of free 
cholesterol, which is mainly in the surface monolayer of LDL. Together with the 
earlier results, where cysteamine prevented iron-mediated oxidation of LDL-
tryptophan, it can be concluded that cysteamine completely prevents the initial 
oxidation of LDL by iron at lysosomal pH.  
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Figure 3.14 Effect of cysteamine on LDL cholesteryl esters during oxidation by iron 
at pH 4.5 
Native LDL (50 µg LDL protein/ml) was oxidised with freshly dissolved FeSO4 (5 µM) in 
the presence or absence of cysteamine (25 µM) at 37 °C in a sodium chloride/sodium 
acetate buffer of pH 4.5. At various time points up to 12 h, oxidation was stopped by 
addition of EDTA (final concentration 2mM) and BHT (2mM). The samples were then 
assayed for cholesteryl arachidonate (A) and cholesteryl linoleate (B) by reverse phase 
HPLC. Graph represent mean (± SEM) of at least 3 independent experiments (* indicates 
p<0.05, *** indicates p<0.001 compared with the control sample to which no antioxidant 
was added, Two-way ANOVA followed by Bonferroni post-test). 
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Figure 3.15 Effect of cysteamine on LDL oxidation products during oxidation by 
iron at pH 4.5 
Native LDL (50 µg LDL protein/ml) was oxidised with freshly dissolved FeSO4 (5 µM) in 
presence or absence of cysteamine (25 µM) at 37 °C in a sodium chloride/sodium acetate 
buffer of pH 4.5. At various time points up to 12 h, oxidation was stopped by addition of 
EDTA (final concentration 2mM) and BHT (2mM). The samples were then assayed for 
cholesteryl linoleate hydroperoxides (A) and 7-ketocholesterol (B) by reverse phase 
HPLC. Graph represent mean (± SEM) of at least 3 independent experiments (*** 
indicates p<0.001 compared with the control sample to which no antioxidant was added, 
Two-way ANOVA followed by Bonferroni post-test). 
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3.4 Discussion 
Iron is a transition metal capable of redox cycling between oxidation states of Fe2+ 
and Fe3+. It is believed that iron is able to initiate the oxidation of LDL by reacting 
with pre-existing lipid hydroperoxides in the LDL particle (Esterbauer et al., 1990). 
Ferrous iron oxidizes LDL faster than ferric iron (Kuzuya et al., 1991, Satchell and 
Leake, 2012) and it is believed to be due to the faster reaction of Fe2+ with lipid 
hydroperoxides (reaction 2) than Fe3+ (reaction 3) (Satchell and Leake, 2012). 
Fe2+ + LOOH            Fe3+ + LO● + OH-- (fast)  (2) 
Fe3+ + LOOH         Fe2+ + LOO● + H+ (slow)  (3) 
The problem with the above reactions is that they have been proposed on the 
basis of rate constants for the analogous reactions of Fe2+ and Fe3+ with H2O2 and 
not the actual lipid hydroperoxides (Dunford, 1987, Minotti and Aust, 1992). In 
addition, these reactions were calculated at physiological pH (Lynch and Frei, 
1993, Tang et al., 2000), at which ferrous and ferric iron are insoluble and 
precipitate out (Dorey et al., 1993). The generation of highly reactive hydroxyl 
radicals through the Fenton reaction of ferrous iron with hydrogen peroxide has 
also been suggested to be the mechanism by which iron may be involved in LDL 
oxidation (Agil et al., 1995) however, addition of hydrogen peroxide has been 
shown to inhibit the oxidation of LDL by iron at lysosomal pH, maybe because it 
converts ferrous ions to the less reactive ferric ions (Satchell, 2007). 
Interestingly, the results of the current study show that oxidation of freshly isolated 
LDL by iron at lysosomal pH takes place even when there are no pre-existing lipid 
hydroperoxides detected in the LDL samples. Surprisingly, enrichment of fresh 
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LDL with lipid hydroperoxides like 13-HPODE does not increase the rate of LDL 
oxidation by iron, in fact addition of higher amounts of hydroperoxide 13-HPODE 
slightly decreases the oxidation of LDL. Probucol efficiently prevents copper 
catalysed oxidation of LDL at physiological pH (Tikhaze et al., 1999) by 
scavenging various lipid radicals (L●, LO●, LOO●) and hence inhibiting the lipid 
peroxidation chain reaction. However, in the present experimental conditions this 
strong antioxidant was unable to protect the initial oxidation of LDL by Fe2+ while 
the more hydrophobic antioxidant DPPD completely inhibited it. 
The HPLC data from this study have for the first time shown that initial oxidation of 
LDL by iron occurs mostly in the core of the LDL particles and probucol is unable 
to inhibit this oxidation but N,N′-diphenyl-p-phenylenediamine (DPPD) completely 
prevents it.  During the course of LDL oxidation with FeSO4, Fe
2+ levels decrease 
sharply during the first 60 min of the reaction corresponding to the rapid phase of 
LDL oxidation. This would suggest that during this rapid phase of LDL oxidation, 
ferrous iron is almost completely consumed. Previous work carried out in this 
laboratory have also shown that addition of higher concentrations of Fe2+ 
shortened the lag phase and increased the rates of the rapid, slow, and 
aggregation phases, whereas addition of higher concentrations of Fe3+ had little 
effect (Satchell and Leake 2012). Here it was noted that the rate at which 
conjugated dienes form during LDL oxidation occurs faster with Fe2+ than with 
Fe3+, therefore providing some further explanation of the role of Fe2+ in the 
observed results. 
Tryptophan loss is one of the most significant oxidative changes in oxidised 
proteins due to the high susceptibility of this amino acid to reactive oxygen species 
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(Ronsein et al., 2011). ApoB-100 of LDL contains 37 tryptophan residues and 
these have been proposed to be responsible for the initiation of LDL oxidation by 
copper ions at pH 7.4 (Giessauf et al., 1995). The results here show that there is a 
loss of LDL-tryptophan fluorescence during LDL oxidation with iron at pH 4.5. 
Furthermore, this loss of fluorescence is unaffected by the addition of 
hydroperoxides and is not prevented by antioxidants like probucol and DPPD. It 
was also noted that the loss of LDL-tryptophan fluorescence occurs faster when 
LDL is oxidised with Fe2+ than Fe3+, which implies that the presence of existing 
lipid hydroperoxides are not essential for the oxidation of LDL apoB-100 by iron at 
lysosomal pH.  
Lynch and Frei (1993) suggested that reduction of Fe3+ to Fe2+ in the presence of 
an exogenous reductant like superoxide (O2
●‐) is essential for iron-mediated LDL 
oxidation at pH 7.4. As mentioned before, at pH 4.5 Fe2+ levels dominate which 
during LDL oxidation is consumed and converted preferably to ferric iron with the 
generation of superoxide radicals (O2‐) (4) (Grady and Chasteen, 1991, Morgan 
and Lahav, 2007). 
Fe2+ + O2    Fe
3+ + O2
●‐  (4) 
Superoxide anions have been found to be weak oxidants and therefore fail to 
initiate LDL oxidation (Jessup et al., 1993), possibly as O2
●‐ is unable to penetrate 
into the LDL core due to its negative charge and also because it is non-reactive in 
aprotic environments and for amino acids (Abreu and Cabelli, 2010, Bielski, 1985, 
Frimer et al., 1996, Mao and Poznansky, 1992). Around 0.3% of superoxide anion 
(O2
●‐) present in the cell cytosol is found in its protonated form (HO2
●) (5) which is a 
stronger oxidant than the superoxide anion (De Grey, 2002). However, at pH 4.5 
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about 90% of the superoxide anion will be present as hydroperoxyl radical (HO2
●) 
which has a pKa value of 4.8, closer to lysosomal pH (Bedwell et al., 1989, Bielski 
et al., 1985, De Grey, 2002, Kehrer et al., 2010, Liochev and Fridovich, 2001).  
O2
●‐ + H+          HO2
●   (pKa 4.8) (5) 
The hydroperoxyl radical (HO2
●) is highly reactive at acidic pH and is capable of 
abstracting a hydrogen atom from a polyunsaturated fatty acid (LH) (6) (Bedwell et 
al., 1989, Bielski et al., 1983, Liochev and Fridovich, 2001) as well as tryptophan 
molecules (TrpH) (7) (Armstrong and Swallow, 1969, Dubinina et al., 2002). The 
uncharged condition of HO2
●, unlike O2
●‐
, allows it to permeate into the 
hydrophobic core where it could initiate lipid peroxidation (Cordeiro, 2014, Gebicki 
and Bielski, 1981). Therefore, at lysosomal pH, HO2
●
 is proposed to be the main 
species responsible for the oxidation of LDL and the uncharged nature of HO2
●, 
unlike O2‐, will allow it to permeate into the hydrophobic core and thus initiate lipid 
peroxidation (Cordeiro, 2014, Gebicki and Bielski, 1981).  
HO2
●  +  LH          L● + H2O2  (6) 
HO2
●  +  TrpH     Trp● + H2O2   (7) 
Lipid radicals and tryptophan radicals are unstable and would react with oxygen to 
form respective peroxyl radicals (8, 9). The lipid peroxyl radicals would then 
ultimately lead to lipid peroxidation chain reaction (Yin et al., 2011). 
 
L● + O2    LOO
● (followed by a chain reaction) (8) 
Trp● + O2     TrpOO
●   (9) 
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Thiol-type antioxidants play a crucial role in protecting cells from oxidative damage 
(Deneke, 2000). The –SH group makes thiols potent nucleophiles and ready to 
interact with electrophilic groups of reactive oxygen species (ROS) (Güngör et al., 
2011). Thiols, like cysteamine, can scavenge superoxide radical in both its anionic 
form (O2
•-) and protonated form (HO2
•) (Cardey et al., 2007, Feroci and Fini, 2007, 
Jones et al., 2003b) and therefore prevent the oxidation reactions. The thiol 
antioxidant, cysteamine, in the present experimental setup completely prevents 
the initial oxidation of LDL by iron through inhibition of LDL lipid and protein 
oxidation. Cysteamine, unlike probucol, greatly protected the oxidation of the 
cholesterol ester-rich hydrophobic LDL core as well preventing the loss of LDL 
tryptophan fluorescence during oxidation with iron. During such antioxidant 
reactions, thiols undergo one-electron oxidation with the formation of thiyl radicals 
(10) and ultimately form a disulphide (11).  
 
        NH2-CH2-CH2-SH + HO2
●     NH2-CH2-CH2-S
● + H2O2
 (10) 
             Cysteamine          thiyl radical 
 
       2NH2-CH2-CH2-S
●            NH2-CH2-CH2-S-S-CH2-CH2-NH2     (11)                                   
   Cysteamine thiyl radical            Cystamine 
 
Work presented in this chapter therefore suggests that the oxidation of LDL via 
hydroperoxyl radicals (HO2
•) is a plausible avenue at which this process may be 
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initiated under lysosomal conditions and also the compounds which scavenge 
these radicals could be potential therapeutic agents in preventing the development 
of atherosclerosis. 
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Chapter 4-  
Antioxidant potential of cysteamine in preventing LDL 
oxidation 
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4.1 Introduction 
Cysteamine is currently used for the treatment of the lysosomal storage disorder 
cystinosis, an inherited disease caused by the absence of functional cystinosin, 
the ubiquitous lysosomal cystine transporter (Kalatzis et al., 2001). Cysteamine 
reacts with intralysosomal cysteine to form the mixed disulfide of cysteamine and 
cysteine, which can in turn leave the lysosome via the lysine transport system 
(Jezegou et al., 2012). Cysteamine is also a potential drug for the treatment of 
various neurodegenerative disorders such as neuronal ceroid lipofuscinoses 
(Zhang et al., 2001) and Huntington’s disease (Dubinsky and Gray, 2006).  
Cysteamine belongs to a group of antioxidants called thiols. Thiols are 
organosulfur compounds that contain a carbon-bonded sulfhydryl group (–SH). 
Thiol compounds are known for general antioxidant properties, such as radical 
quenching, and thus play a crucial role in protecting cells from oxidative damage 
(Deneke, 2000). The –SH group makes thiols potent nucleophiles and ready to 
interact with electrophilic groups of ROS and therefore is an initial and major 
member of the physiological antioxidant defence system (Güngör et al., 2011). 
Thiols in general are mild acids although the presence of a positively charged 
residue, such as lysine or arginine, as well as the formation of a hydrogen bond 
may increase their acidity by 3-4 orders of magnitude (Copley et al., 2004). As 
such, the reactivity of thiols depends on their pKa values (Brandes et al., 2009, 
Nagy, 2013). Biologically derived thiols such as glutathione, cysteine, and 
homocysteine are often called biothiols. The side chain functional group: CH2–SH 
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of cysteinyl residues serves as an active site for most biologically important thiols 
(–SH type-antioxidants) (Konarkowska et al., 2005, Luo et al., 2005).  
Cysteamine is a lysosomotropic drug which greatly inhibits oxidation of LDL by 
iron at lysosomal pH (discussed in the previous chapter) and unpublished animal 
work from this laboratory has shown that, with cysteamine, there was 33% 
reduction in the atherosclerotic lesion area in the aortic arch of LDL receptor 
deficient mice which were fed an atherogenic diet. This work is based on the 
theory that LDL is mostly oxidised by iron in lysosomes of macrophages and 
because cysteamine concentrates in lysosomes by several orders of magnitude 
due to the protonation of its amine group, it is able to inhibit oxidation of LDL. 
Some other lysosomotropic antioxidants have been seen to inhibit oxidation of 
LDL. From the literature it was found that propranolol, amiodarone and 7,8-
dihydroneopterin were promising antioxidants for LDL (Figure 4.1). Propranolol 
and its metabolites concentrate into the lysosomes and have been seen to prevent 
LDL oxidation at pH 7.4 and confer endothelial cytoprotection (Mak et al., 2006, 
Mak and Weglicki, 2004). The antioxidant activity of propranolol and its 
metabolites has been attributed to its antiperoxidative activity and by preventing 
release of iron into the cytosol (Dickens et al., 2002).  
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Figure 4.1 Chemical structures of cysteine, amiodarone, propranolol and 7,8-
dihydroneopterin. 
 
Amiodarone is a lipophilic antiarrhythmic/antianginal drug which is able to 
influence the physicochemical status of biological lipid components by binding to 
lipoproteins. Amiodarone and its primary metabolite, desethylamiodarone, have 
been reported to prevent copper-catalysed oxidation of lipoproteins at pH 7.4 in a 
dose-dependent manner. The activity has been suggested to be due to 
stabilisation of the lipid element of lipoprotein (Lapenna et al., 2001, Ribeiro et al., 
1997). 7,8-Dihydroneopterin is a pteridine secreted by human macrophages when 
stimulated with interferon-gamma during inflammation, as a protective mechanism 
(Gieseg et al., 2009). 7,8-Dihydroneopterin has been shown to prevent copper 
mediated oxidation of native LDL (Greilberger et al., 2004) and to protect human 
macrophages by inhibiting oxidised LDL-dependent generation of lipid peroxyl 
radicals (Baird et al., 2005). A cysteine-specific lysosomal transport system 
enables the delivery of thiol into lysosomes (Pisoni et al., 1990). Cysteine has also 
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been shown to prevent LDL oxidation by copper at pH 7.4 (Patterson et al., 2003b) 
and lipid peroxidation in animals (Saravanan et al., 1995).  
Cysteine, because of its thiol group is an effective scavenger of free radicals as 
well as a major contributor to maintenance of the cellular glutathione status in 
skeletal muscle cells (Kerksick and Willoughby, 2005). Most of the in vitro studies 
on these antioxidants were carried out at pH 7.4 and given the lysosomal LDL 
oxidation theory, it is therefore of interest to study the effect of these antioxidants 
on LDL oxidation by iron at lysosomal pH.  
Copper is the most commonly used transition metal to study the susceptibility of 
LDL towards oxidation and LDL oxidised by copper at pH 7.4 is the most widely 
used oxidised LDL in many in vitro and in vivo experiments (Proudfoot et al., 1997, 
Roland et al., 2001). Higher copper levels in serum are considered as one of the 
risk factor for atherosclerosis (Tasic et al., 2015a). Ceruloplasmin, a copper-
carrying protein in plasma, has been shown to oxidise LDL in vitro at pH 7.4 and in 
smooth muscle and endothelial cells by a superoxide-dependent mechanism 
(Mukhopadhyay et al., 1996). Furthermore, the rate of LDL oxidation by 
ceruloplasmin in macrophages has been seen to increase significantly at acidic pH 
(Lamb and Leake, 1994, Leake, 1997). Recently copper has been detected in 
lysosomes as well (Ren et al., 2015). Hence, we have examined whether 
cysteamine would be able to prevent the oxidation of LDL by copper at interstitial 
pH (pH 7.4) and lysosomal pH (pH 4.5).  
LDL oxidation and aggregation are known to increase the atherogenic potential of 
LDL (Panasenko et al., 2007) and both these forms of modified LDL have been 
reported to be present in the plasma of atherosclerotic patients (Bancells et al., 
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2010b, Pawlak et al., 2013). Oxidation of LDL by iron at lysosomal pH has been 
seen to cause spontaneous aggregation of LDL (Satchell and Leake, 2012). 
Therefore, an effective, antioxidant in addition to inhibiting the oxidation of LDL, 
should be able to prevent the aggregation of LDL.  
Data are presented in this chapter that show that cysteamine is much better at 
preventing LDL oxidation by iron at lysosomal pH than other lysosomotropic 
antioxidants like cysteine, propranolol, amiodarone and 7,8-dihydroneopterin. 
Also, cysteamine is able to prevent the oxidation LDL by copper and the 
aggregation of LDL during oxidation by iron. 
4.2 Methods 
LDL oxidation was studied by measuring the conjugated diene formation as 
described in section 2.3. 
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4.3 Results 
4.3.1 Comparison between antioxidant activity of cysteamine and cysteine 
on LDL oxidation by iron at pH 4.5 
Cysteamine is the simplest stable amino-thiol and a degradation product of 
coenzyme A (Besouw et al., 2013). Both cysteine and cysteamine are known 
antioxidants because of the presence of a thiol group in them. The aim of this 
experiment was to compare the effects of these two thiols in inhibiting LDL 
oxidation by iron at lysosomal pH. In order to compare the antioxidant activity of 
cysteine with cysteamine, native LDL (50 µg protein/ml) in sodium chloride/sodium 
acetate buffer (pH 4.5) was incubated with 5 µM FeSO4 at 37°C in quartz cuvettes, 
in the presence or absence of either cysteamine or cysteine (final concentration 
25µM). The course of oxidation was followed by measuring the formation of 
conjugated dienes at 234 nm.  
Both cysteine and cysteamine inhibited the initial oxidation of LDL (Figure 4.2). 
However, in the presence of cysteine, the time taken during LDL oxidation by iron 
to reach an attenuance of 0.1 was 225 ± 22 min which was not statistically 
significant when compared to the control (78 ± 11 min) to which no antioxidant was 
added. On the other hand, it took 525 ± 57 min for the attenuance to reach 0.1 
when LDL oxidation was conducted in the presence of cysteamine (mean±SEM, 
ANOVA followed by tukey’s test, p<0.01).  
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Figure 4.2 Comparison of antioxidant effect of cysteine and cysteamine on LDL 
oxidation by iron at pH 4.5 
LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated with 5 µM 
FeSO4 at 37°C in quartz cuvettes in the presence or absence of either cysteamine or 
cysteine (final concentration 25 µM). (A) Oxidation was monitored by measuring the 
change in attenuance at 234 nm against appropriate reference cuvettes. This is a 
representative example of at least three independent experiments. (B) The time taken to 
reach an attenuance of 0.1 is shown. (** indicates p<0.01 between two antioxidants, *** 
indicates p<0.001 compared to control, ANOVA followed by tukey’s test). 
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4.3.2 Comparison of antioxidant activity of cysteamine with other known 
lysosomotropic antioxidants 
In order to compare the antioxidant effect between cysteamine and lysosomotropic 
agents like propranolol, amiodarone and 7,8-dihydroneopterin on LDL oxidation by 
iron at lysosomal pH, native LDL (50 µg protein/ml) in sodium chloride/sodium 
acetate buffer (pH 4.5) was incubated with 5 µM FeSO4 at 37°C, in presence or 
absence of either cysteamine or propranolol or amiodarone or 7,8-
dihydroneopterin (final concentration 25 µM). The course of oxidation was followed 
by measuring the formation of conjugated dienes at 234 nm.  
The oxidation of native LDL by iron was inhibited significantly by cysteamine 
(Figure 4.3). During oxidation of LDL by iron, the time taken to reach an 
attenuance of 0.1 was 63 ± 4 min when incubated alone whereas addition of 
cysteamine (25 µM) increased the time to 590 ± 17 min (p<0.001, n=3), which is 
about a 9 fold increase. Addition of propranolol (25 µM) slowed down the oxidation 
LDL at the later stages of the oxidative process, but there was no significant effect 
on the initial oxidation of LDL by iron at pH 4.5 (Figure 4.3). In the presence of 
propranolol, the attenuance of 0.1 was reached in 89 ± 6 min, about a 1.4 fold 
increase, but was not statistically significantly different than the controls.  
The presence 25 µM of 7,8-dihydoneopterin (7,8-DNP) had absolutely no effect on 
the oxidation of LDL by iron at lysosomal pH (Figure 4.4). The time taken to reach 
an attenuance of 0.1 was 61 ± 0.4 min, which was similar to that of the controls, 63 
± 3 min, to which no antioxidant was added. However, as expected cysteamine 
completely inhibited the initial oxidation of LDL and increased the time to reach an 
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attenuance of 0.1 to 582 ± 16 min (mean±SEM, ANOVA followed by tukey’s test, 
p<0.001, n=3). 
Addition of amiodarone (25 µM) did not prevent the oxidation, but gave an initial 
pro-oxidant effect for the first 450 min (Figure 4.5). In the presence of amiodarone, 
the attenuance of 0.1 was reached after 30 ± 8 min, whereas in the controls to 
which no antioxidant was added, the attenuance reached 0.1 after 63 ± 3 min. 
However, cysteamine completely inhibited the initial oxidation and increased the 
time to reach an attenuance of 0.1 to 576 ± 19 min (mean±SEM, ANOVA followed 
by tukey’s test, p<0.001, n=3). 
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Figure 4.3 Comparison of antioxidant effect of propranolol and cysteamine on LDL 
oxidation by iron at pH 4.5 
LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated with 5 µM 
FeSO4 at 37°C in quartz cuvettes in the presence or absence of either cysteamine or 
propranolol (final concentration 25 µM). (A) Oxidation was monitored by measuring the 
change in attenuance at 234 nm against appropriate reference cuvettes. This is a 
representative example of at least three independent experiments. (B) The time taken to 
reach an attenuance of 0.1 is shown. (*** indicates p<0.01, ANOVA followed by tukey’s 
test, n=3). 
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Figure 4.4 Comparison of antioxidant effect of 7,8-dihydroneopterin and cysteamine 
on LDL oxidation by iron at pH 4.5 
LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated with 5 µM 
FeSO4 at 37°C in quartz cuvettes in the presence or absence of either cysteamine or 7,8-
dihydroneopterin (7,8-DNP) at a final concentration 25 µM. (A) Oxidation was monitored 
by measuring the change in attenuance at 234 nm against appropriate reference cuvettes. 
This is a representative example of at least three independent experiments. (B) The time 
taken to reach an attenuance of 0.1 is shown. (*** indicates p<0.01, ANOVA followed by 
tukey’s test, n=3). 
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Figure 4.5 Comparison of antioxidant effect of amiodarone and cysteamine on LDL 
oxidation by iron at pH 4.5 
LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated with 5 µM 
FeSO4 at 37°C in quartz cuvettes in the presence or absence of either cysteamine or 
amiodarone (final concentration 25 µM). (A) Oxidation was monitored by measuring the 
change in attenuance at 234 nm against appropriate reference cuvettes. This is a 
representative example of at least three independent experiments. (B) The time taken to 
reach an attenuance of 0.1 is shown. (*** indicates p<0.01, ANOVA followed by tukey’s 
test n=3). 
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4.3.3 Effect of cysteamine on LDL aggregation during oxidation with iron at 
pH 4.5 
Cysteamine is able to prevent the oxidation of LDL by iron at lysosomal pH. In 
order to study the effect of cysteamine on LDL aggregation by ion at pH 4.5, native 
LDL (50 µg protein/ml) in sodium chloride/sodium acetate buffer (pH 4.5) was 
incubated either alone or with 5 µM FeSO4 at 37°C in quartz cuvettes, in the 
presence or absence of cysteamine (25 µM). The aggregation was monitored by 
measuring light scattering at 680 nm in a spectrophotometer.  
Light scattering at 680 nm showed no change in the samples containing LDL 
alone, and the scattering increased rapidly at around 200 min in the LDL samples 
which were treated with iron. After 500 min the scattering decreased indicating 
sedimentation of large aggregates of LDL below the beam of light (Figure 4.6). 
Cysteamine greatly prevented the aggregation of LDL for about 500 min and the 
sedimentation of the aggregates started after around 800 min of oxidation process. 
The traces became ‘noisier’ at later time points as the aggregates moved into and 
out of the beam of light. The attenuance reached 0.1 after 274 ± 6 when no 
cysteamine was added to LDL, whereas addition of cysteamine increased the time 
to reach the attenuance of 0.1 to 552 ± 10 min (P<0.001, n=3).  
These data collectively show that cysteamine at pH 4.5 is able to delay the 
oxidation of LDL and this in turn delays the aggregation of LDL. Once the 
aggregation of LDL starts it proceeds at the same rate as in the absence of 
cysteamine. 
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Figure 4.6 Effect of cysteamine on aggregation of LDL during oxidation with iron at 
pH 4.5 
LDL (50 µg protein/ml) in sodium acetate buffer (pH 4.5) was incubated with 5 µM FeSO4 
in presence or absence of cysteamine (25 µM) at 37°C in quartz cuvettes. (A) Aggregation 
was monitored by measuring attenuance at 680 nm against appropriate cuvettes. This is a 
representative example of three independent experiments. (B) The time taken to reach an 
attenuance of 0.1 is shown (*** indicates p<0.001, t-test, n=3).   
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4.3.4 Effect of cysteamine on LDL oxidation by copper at pH 4.5 
In order to study the effect of cysteamine on LDL oxidation by copper at lysosomal 
pH, native LDL (50 µg protein/ml) in sodium acetate buffer (pH 4.5) was incubated 
with 5 µM CuSO4 at 37°C in quartz cuvettes, in the absence (control) or presence 
of cysteamine (final concentration (25 µM). The course of oxidation was followed 
by measuring the formation of conjugated dienes at 234 nm. 
The oxidation of LDL by copper showed an initial short lag phase followed by a 
faster oxidation phase, a slower oxidation phase, an aggregation phase and finally 
a sedimentation phase during which the large aggregates sediment in a similar 
manner to iron (Figure 4.7). The time taken to reach an attenuance of 0.1 during 
oxidation with copper was 51 ± 2 min. The effect of 25 µM cysteamine on LDL 
oxidation by copper at pH 4.5 was not as strong as that seen with iron catalysed 
LDL oxidation; however, cysteamine inhibited the initial oxidation of LDL by copper 
for an extra 50 min or so. In presence of cysteamine, it took 91 ± 3 min for the 
attenuance to reach the value of 0.1 which was found to be statistically significant 
(P<0.01) compared to the control to which no cysteamine was added.  
These data suggest that cysteamine would be able to inhibit the oxidation of LDL 
by copper in the lysosomes of cells.  
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Figure 4.7 Effect of cysteamine on LDL oxidation by copper at pH 4.5 
LDL (50 µg protein/ml) in sodium acetate buffer (pH 4.5) was incubated with 5 µM CuSO4 
at 37°C in quartz cuvettes, in the presence or absence of cysteamine (25 µM). (A) 
Conjugated diene formation was monitored by measuring the change in attenuance at 
234. This is a representative example of 3 independent experiments. (B) The time taken 
to reach an attenuance of 0.1 is shown. (** indicates p<0.01 compared to control, t-test, n 
=3). 
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4.3.5 Effect of cysteamine on LDL oxidation by copper at pH 7.4 
Copper at physiological pH has been shown to oxidise LDL effectively and 
involves an initial lag phase followed by a rapid oxidation phase, decomposition 
phase and a slow oxidation phase (Esterbauer et al., 1989, Rodrıǵuez-Malaver et 
al., 1997).  
To study the effect of cysteamine on LDL oxidation by copper at pH 7.4, native 
LDL (50 µg protein/ml) in MOPS buffer (pH 7.4) was incubated with 5 µM CuSO4 
at 37°C in quartz cuvettes, in the absence or presence of cysteamine (final 
concentration 10 µM or 25 µM). The course of oxidation was followed by 
measuring the formation of conjugated dienes at 234 nm. 
The oxidation was much faster with copper at pH 7.4 than pH 4.5 (Figure 4.8). 
Cysteamine, at both the concentrations, inhibited the oxidation of LDL by copper 
by greatly extending the lag phase (Figure 4.8). The antioxidant effect was seen to 
be concentration dependent. In the absence of cysteamine (control), LDL oxidation 
proceeded normally and reached an absorbance of 0.1 after 35 ± 1 minute. The 
term absorbance is used for LDL oxidation at pH 7.4 because LDL does not 
aggregate and scatter ultraviolet radiation at this pH for the incubation periods 
studied here.  
Cysteamine (10 µM) extended the time to reach an absorbance of 0.1 to 130 ± 6 
min which is about a 3.5 fold increase compared to control (p<0.01), while  25 µM  
showed a 6.5 fold increase in this time and reached an absorbance of 0.1 after 
232 ± 18 min (p<0.001). The two concentrations of cysteamine differed 
significantly (p<0.01) in delaying the oxidation of LDL by copper when evaluated in 
terms of reaching an absorbance of 0.1. 
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Figure 4.8 The effect of cysteamine on LDL oxidation by copper at pH 7.4 
LDL (50 µg protein/ml) in MOPS buffer (pH 7.4) was incubated with 5 µM CuSO4 at 37°C 
in quartz cuvettes, in the presence or absence of cysteamine (10 µM or 25 µM). (A) 
Conjugated diene formation was monitored by measuring the change in absorbance at 
234. This is a representative example of 3 independent experiments. (B) The time taken 
to reach an absorbance of 0.1 is shown. (** indicates p<0.01, *** indicates p<0.001 
compared to control, ## indicates p<0.01, ANOVA followed by tukey’s test, n =3). 
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4.4 Discussion 
Thiol compounds are known for general antioxidant properties, such as radical 
quenching and thus play a crucial role in protecting cells from oxidative damage 
(Deneke, 2000).  The –SH group makes thiols potent nucleophiles and ready to 
interact with electrophilic groups of reactive oxygen species (ROS) and therefore 
thiols are the initial and major members of the physiological antioxidant defence 
system (Gungor et al., 2011). In addition, cysteamine is known to exert some of its 
antioxidant effect by increasing cellular glutathione levels in the cells (Revesz and 
Modig, 1965). In general, thiols are mild acids but the presence of a positively 
charged residue, such as lysine or arginine, as well as the formation of a hydrogen 
bond may increase their acidity by 3-4 orders of magnitude (Copley et al., 2004). 
Their reactivity therefore depends on their dissociation constant (pKa) values 
(Brandes et al., 2009, Nagy, 2013).  
In the previous chapter, it was shown that cysteamine, because of its thiol nature, 
is able to prevent oxidation of LDL by iron at lysosomal pH. Here, we have shown 
that another thiol, cysteine, is also able to inhibit the oxidation of LDL by iron at pH 
4.5. However, the antioxidant effect is much lower than cysteamine. This could be 
due to the difference in the pKa values between the two thiols. The pKa values of 
cysteamine are 8.19 for the thiol group and 10.75 for the amine group (Mezyk, 
1995, Serjeant and Dempsey, 1979), while the corresponding value is higher for 
the thiol group of cysteine, 8.33, slightly higher for the amine group, 10.78 
(Jocelyn, 1967, Mezyk, 1995); in addition the carboxylic group in cysteine gives it 
an additional pKa of 1.71 compared to cysteamine. Thus the thiol group of cysteine 
is a weaker acid and would ionise less to produce the thiolate ion (—S-) (12) and 
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hence would be a weaker antioxidant in preventing LDL oxidation than 
cysteamine. 
—SH               —S-     +     H+  (12) 
   Thiol              Thiolate  
Cysteamine is a lysosomotropic drug and recent unpublished work from this 
laboratory has shown that cysteamine is able to reduce atherosclerosis in LDL 
receptor-deficient mice. Other known lysosomotropic drugs like propranolol, 
amiodarone and 7,8-dihydroneopterin have been shown to inhibit LDL oxidation, 
however they do so by different mechanisms. At a given concentration and under 
similar conditions, none of these drugs were better at preventing oxidation of LDL 
by iron at lysosomal pH compared to cysteamine. Although, propranolol was able 
to slow down the oxidation, the inhibition was far less compared to cysteamine and 
it did not produce a prolonged lag phase (Figure 4.3). Amiodarone initially showed 
a significant pro-oxidant like effect and overall the fold inhibition was much lower 
than cysteamine (Figure 4.5). However, 7,8-dihydoneopterin showed no effect on 
LDL oxidation under the current conditions. Therefore, cysteamine is a better 
antioxidant at preventing oxidation of LDL under lysosomal conditions than 
propranolol, amiodarone and 7,8-dihydoneopterin.   
Aggregation is one of the characteristics of extensively oxidised LDL. Oxidation of 
LDL is characterised by several structural and chemical changes to the lipoprotein 
particle that lead to numerous modifications in its functional properties and hence 
is responsible for enhanced cellular recognition and uptake (Vanderyse et al., 
1992). Oxidation of LDL can reduce the LDL surface charge density and therefore 
result in the fusion of LDL particles and the formation of vesicles and membranous 
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structures (Pentikainen et al., 1996). In addition, atherosclerotic plaque formation 
is believed to be initiated by the extracellular aggregation and deposition of 
lipoproteins trapped in the subendothelial matrix. Furthermore, acidic pH has been 
shown to promote LDL and oxidised LDL aggregation (Satchell and Leake, 2012, 
Sneck et al., 2012) and lysosomal pH conditions are considered optimal for 
lipoprotein aggregation (Xu and Lin, 2001). The presence of oxidized and highly 
aggregated lipids within lysosomes has the potential to perturb the function of 
these organelles and to promote atherosclerosis. In agreement with the work 
carried out previously (Satchell and Leake, 2012), oxidation of LDL with ferrous 
iron induced aggregation of LDL after around 200 min and no aggregation was 
seen in the control LDL, to which no oxidising agent was added. The antioxidant 
cysteamine greatly delayed the oxidation and subsequent aggregation of LDL by 
iron at lysosomal pH (pH 4.5). Cysteamine (25 µM) offered more than a 2-fold 
increased delay against LDL oxidation at pH 4.5. This can be explained on the 
basis that cysteamine is able to scavenge superoxide ions (both protonated and 
non-protonated forms) produced during iron-catalysed oxidation (13, 14), thus 
protecting the oxidation induced chemical changes in the lipid and the protein 
portions of LDL. 
 
+NH3-CH2-CH2-S
-  +  HO2
●       +H+ +NH3-CH2-CH2-S
●  + H2O2 (13) 
+NH3-CH2-CH2-S
-  +  O2
●-       +2H+ +NH3-CH2-CH2-S
●  + H2O2 (14) 
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LDL oxidised by copper at pH 7.4 has been extensively studied and is the major 
model used to study the role of oxidised LDL in atherosclerosis, possibly because 
it shares properties with the LDL oxidised by cells. Here we have shown that 
cysteamine is able to inhibit oxidation of LDL by copper at pH of the interstitial fluid 
(pH 7.4). Cysteamine also showed a concentration-dependent increase in the lag 
phase extension during LDL oxidation by copper at pH 7.4. This means that if 
copper is able to cause some oxidation of LDL extracellularly at pH 7.4, as 
suggested by some reports to be important in the pathogenesis of atherosclerosis, 
then treatment with cysteamine would be beneficial as treatment of 
atherosclerosis. 
Recent reports have found that it is unlikely that oxidative modification of LDL can 
occur in extracellular spaces because of the strong antioxidant nature of interstitial 
fluid and plasma (Dabbagh and Frei, 1995, Leake and Rankin, 1990, Patterson 
and Leake, 1998). In vivo it is thought that LDL might be trapped in the arterial wall 
and then oxidised by metal ions under lower pH conditions (Leake, 1997, Lodge et 
al., 2000). LDL oxidation occurred significantly by copper at pH 4.5, however, at a 
slower rate than at pH 7.4, in marked contrast to iron, which may be because 
copper has been shown to bind LDL particles less at low pH (Leake et al., 
unpublished data). Cysteamine is able to inhibit the oxidation by copper at 
lysosomal pH and slows down the overall oxidation process although the 
antioxidant effect was more prominent at pH 7.4. This might be because 
cysteamine acts as an antioxidant by donating electrons (15) rather than hydrogen 
atoms (electron plus proton) (16) to free radicals.  
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     +NH3-CH2-CH2-S
-  +  X●       +H           +NH3-CH2-CH2-S
●  + XH  (faster)      (15) 
     NH2-CH2-CH2-SH  +  X
●       +H            +NH3-CH2-CH2-S
●  + XH  (slower)     (16) 
 
Nevertheless, there was also a significant reduction of LDL oxidation by 
cysteamine at lysosomal pH. Therefore, in addition to preventing the oxidation of 
LDL by iron under lysosomal conditions, cysteamine would be able to prevent the 
possible copper-catalysed oxidation, hence proving to be a potentially effective 
treatment in inhibiting LDL oxidation at pH 4.5 or 7.4. 
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Chapter 5-  
Oxidation of sphingomyelinase aggregated LDL by 
iron under lysosomal pH conditions 
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5.1 Introduction 
Studies which examine foam cell formation by the incubation of macrophages with 
modified monomeric LDL (e.g. oxidised LDL) do not fully reflect the in vivo 
environment, as the majority of the LDL in atherosclerotic plaques is found in an 
aggregated state and bound to subendothelial matrix (Boren et al., 2000, Tabas, 
1999). LDL entrapped by extracellular matrix, particularly by proteoglycans, is 
vulnerable to hydrolysis by lipases and proteases. It has been shown that 
lipoprotein lipase (LPL), secretory sphingomyelinase (S-SMase), secretory 
phospholipase A2 (sPLA2), cholesteryl ester hydrolase (CEH), matrix 
metalloproteinases (MMP), lysosomal proteases and plasmin are capable of 
aggregating LDL to produce atherogenic LDL forms that are rapidly internalized by 
macrophages (Bhakdi et al., 1995, Boyanovsky et al., 2009, Fenske et al., 2008, 
Hakala et al., 2003, Leake and Rankin, 1990, Maor et al., 2000, Torzewski et al., 
2004). Wen and Leake (2007) have also shown that aggregated LDL produced by 
vortexing is rapidly engulfed by macrophages and then oxidised within the 
lysosomes by iron leading to the formation of ceroid (Wen and Leake, 2007). 
These mechanisms of foam cell formation, based on ingestion of aggregated, 
rather than monomeric LDL, are probably more physiologically relevant in vivo.  
Sphingomyelinase is found in atherosclerotic lesions and has been proposed to be 
one of the key enzymes causing aggregation of LDL in interstitial fluid of the 
lesions (Holopainen et al., 2000, Marathe et al., 1999, Portman and Alexander, 
1970). Sphingomyelin constitutes a considerable lipid component of LDL particles 
and together with phosphatidylcholine forms the polar surface of the lipoproteins 
(Merrill et al., 1997, Oorni et al., 1998, Oorni et al., 2005). Sphingomyelinase is a 
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sphingomyelin-specific form of phospholipase C which hydrolyses the 
phosphodiester bond of sphingomyelin to generate ceramide and phosphocholine. 
Ceramide is hydrophobic and causes aggregation of LDL particles (Walters and 
Wrenn, 2008). More recently this laboratory has shown that, human LDL when 
aggregated with sphingomyelinase (SMase) is rapidly taken up by human 
macrophages and oxidised inside the lysosomes by iron (Wen et al., 2015). It was 
further suggested that antioxidants that accumulate in lysosomes have a potential 
for decreasing atherosclerosis by inhibiting the lysosomal oxidation of LDL.  
The macrophages that are treated with modified LDL (e.g. SMase-LDL) would 
therefore, at any time, contain more of SMase-LDL in their lysosomes than native 
LDL. Lipid peroxidation is one of the major pathological mechanisms involved in 
atherosclerosis and lysosomal oxidation of aggregated LDL, including SMase-LDL, 
may explain why oxidised LDL is present within lesions despite the strong 
antioxidant protection within the arterial intima (Dabbagh and Frei, 1995). Oxidised 
LDL formed within the lysosomes might affect cell function or be released into the 
interstitial fluid; both with potentially atherogenic consequences. Thus, it is 
important to study the oxidation pattern of modified LDL in detail under lysosomal 
conditions. Furthermore, it might be necessary for an antioxidant like cysteamine 
to prevent oxidation of SMase-LDL as a part of its effective treatment against 
atherosclerosis. Therefore, the aims of this chapter are to study in detail the 
oxidation pattern of SMase-LDL by iron under lysosomal conditions and also the 
possible protection by cysteamine in preventing oxidation. 
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5.2 Methods 
SMase-LDL was prepared by incubating freshly isolated native LDL with 
sphingomyelinase as described in detail in Chapter 2. Methods used to monitor 
the oxidation of LDL in this section have also been described in detail in sections 
2.2 and 2.3.  
5.3 Results 
5.3.1 Total lipid hydroperoxides in SMase-LDL 
In chapter 3, it was established that the oxidation of native LDL takes place even 
when no pre-existing lipid hydroperoxides are present. In order to see if the same 
holds true for SMase-LDL, total lipid hydroperoxide levels were measured in 
SMase-LDL and compared to native LDL. Freshly isolated native LDL was used to 
prepare SMase-LDL and then analysed for the presence of pre-existing lipid 
hydroperoxides by the tri-iodide method, as described in detail in the Chapter 2. 
In both, native LDL as well as SMase-LDL, no lipid hydroperoxides were detected, 
in fact they were slightly below the blanks in the assay and there was no apparent 
difference in the values (Figure 5.1). The levels in native LDL were -3 ± 2 nmol/mg 
LDL protein and that in SMase-LDL were -2 ± 2 nmol/mg LDL protein (p>0.05, n = 
6). For comparison the levels of lipid hydroperoxides in fully oxidised LDL are 
about 800 nmol/mg protein (Patterson et al., 2003a). 
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Figure 5.1 Pre-existing lipid hydroperoxides in SMase-LDL and native LDL 
Native LDL and SMase-LDL samples were assessed for the presence of pre-existing lipid 
hydroperoxides by tri-iodide assay. The measured absorbances were slightly below the 
blank values Graph represent the mean (± SEM) of at least 6 independent experiments.  
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5.3.2 Measure of oxidation of SMase-LDL by iron at lysosomal pH  
Oxidation of native LDL has been extensively studied, whereas little is known 
about the oxidation characteristics of aggregated LDL, which is presented to the 
lysosomes for oxidation. It is therefore of interest to investigate the oxidation 
pattern of SMase-LDL by iron under lysosomal conditions.  
Freshly prepared SMase-LDL (50 µg LDL protein/ml) and native LDL were 
oxidised in NaCl/sodium acetate buffer (pH 4.5) at 37°C with FeSO4 (5 µM). The 
course of the oxidation was followed by measuring the formation of conjugated 
dienes at 234 nm and loss of LDL-tryptophan fluorescence (Ex/Em = 282/331 nm).  
Incubating, native LDL and SMase-LDL with iron lead to the continuous oxidation 
of LDL lipids (Figure 5.2). SMase-LDL was oxidised significantly more slowly than 
native LDL. The time taken to reach an attenuance of 0.1 was 61 ± 4 min in the 
case of native LDL, compared to 77 ± 3 min for SMase-LDL (Figure 5.2) (p<0.05); 
mean ± SEM of three independent experiments.  
Oxidation of LDL protein was monitored by measuring the loss of fluorescence of 
LDL-tryptophan during LDL oxidation. The loss of LDL-tryptophan fluorescence 
was faster in native LDL than SMase-LDL (Figure 5.3). After 100 min incubation, 
there was 30 ± 1 % loss of LDL-tryptophan fluorescence in the case of native LDL, 
whereas in the case of SMase-LDL the LDL-tryptophan fluorescence decreased 
by 21 ± 1% (Figure 5.3) (p<0.05); mean ± SEM of three independent experiments.  
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Figure 5.2 Comparison of oxidation of SMase-LDL and native LDL by iron at pH 4.5 
(A) SMase-LDL (50 µg protein/mL) and native LDL (50 µg protein/ml) in NaCl/sodium 
acetate buffer (pH 4.5) were incubated with 5 µM FeSO4 at 37°C in capped quartz 
cuvettes. Oxidation was monitored by measuring the change in attenuance at 234 nm 
against appropriate reference cuvettes. This is a representative example of three 
independent experiments. (B) Time taken to reach an attenuance of 0.1 during the 
oxidation with iron is shown here. (* indicates p<0.05, t-test, n = 3 independent 
experiments.  
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Figure 5.3 Loss of LDL-tryptophan fluorescence during oxidation of SMase-LDL and 
native LDL by iron at pH 4.5 
(A) SMase-LDL (50 µg protein/ml) and native LDL (50 µg protein/ml) were oxidised by 5 
µM FeSO4 in NaCl/sodium acetate buffer (pH 4.5) at 37°C in quartz cuvettes and 
tryptophan fluorescence was measured every 10 min at excitation wavelength of 282 nm 
and emission wavelength 331nm in a spectrofluorometer. This is a representative 
example of at least three independent experiments. (B) Shows decrease in LDL-
tryptophan fluorescence after 100 min of oxidation (* indicates p<0.05, t-test, n = 3 
independent experiments).  
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5.3.3 Chemical characterisation of SMase-LDL oxidation by iron at 
lysosomal pH 
Establishing the lipid composition of SMase-LDL oxidised by iron at lysosomal pH 
enables information to be gained about the atherogenicity of the oxidised LDL 
formed in this manner. SMase-LDL (50 µg LDL protein/ml) and native LDL (50 µg 
LDL protein/ml) were oxidised separately in NaCl/sodium acetate buffer (pH 4.5) at 
37°C with FeSO4 (5 µM) in plastic tubes. Samples were taken at different times 
and were processed for HPLC analysis.  
The levels of nonesterified cholesterol declined during the oxidation of SMase-LDL 
from 978 ± 34 nmol/mg LDL protein at the beginning of the oxidation to 646 ± 68 
nmol/mg LDL protein after 24 h, suggesting the cholesterol of LDL was being 
modified during the reaction (Figure 5.4). This decrease in free cholesterol level in 
SMase-LDL was not significantly different from the oxidation of native LDL, where 
the levels decreased from 998 ± 89 nmol/mg LDL protein to 624 ± 52 nmol/mg 
LDL protein after 24 h.  
The major polyunsaturated cholesteryl esters in LDL are cholesteryl linoleate (CL), 
which has two double bonds, cholesteryl arachidonate (CA) which has four double 
bonds (CA) and cholesteryl oleate (CO), which has one double bond (Esterbauer 
et al., 1990). As expected, cholesteryl arachidonate levels decreased faster than 
those of cholesteryl linoleate, which fell faster than those for cholesteryl oleate. 
Levels of CL in both SMase-LDL and native LDL decreased continuously during 
the oxidation process but the decrease was slower in SMase-LDL.  The CL levels 
in SMase-LDL decreased from 1763 ± 79 nmol/mg LDL protein to 1093 ± 203 
nmol/mg LDL protein in the first 12 h (Figure 5.4B) and after that there was a 
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significantly sharp drop in the CL levels to 100 ± 55 nmol/mg LDL protein 
(p<0.001). In the case of native LDL, the levels of CL declined sharply after 6 h 
from 1285 ± 140 nmol/mg LDL protein to 471 ± 99 nmol/mg LDL protein after 12 h 
(p<0.01). However, after 24 h, levels of CL in native LDL were 87 ± 7 nmol/mg 
LDL protein, which were not significantly different from those in SMase-LDL. 
CA levels also decreased in both SMase-LDL and native LDL during the course of 
oxidation process (Figure 5.5). Although, the oxidation process of SMase-LDL 
proceeded at a slower rate than native LDL, the levels in both dropped to the 
same very low level after 24 h. In native LDL, CA levels dropped from 460 ± 32 
nmol/mg LDL protein to 10 ± 5 nmol/mg LDL protein after 24 h of oxidation 
process. The levels in SMase-LDL dropped from 427 ± 36 nmol/mg LDL protein at 
time zero to 203 ± 33 nmol/mg LDL protein after 12 h, but the levels dropped to 7 
± 3 nmol/mg LDL protein after 24 h.  
There was no apparent difference in the decrease of CO levels between SMase-
LDL and native LDL during the course of oxidation (Figure 5.5). In the case of 
SMase-LDL, the CO levels dropped from 196 ± 10 nmol/mg LDL protein at time 
zero to 76 ± 11 nmol/mg LDL protein after 24 h, while in case of native, the levels 
dropped from 208 ± 16 nmol/mg LDL protein to 80 ± 13 nmol/mg LDL protein after 
24 h. 
The cholesterol oxidation product, 7-ketocholesterol, in SMase-LDL increased 
from 0.7 ± 0.6 nmol/mg LDL protein to only 5 ± 3 nmol/mg LDL protein after 12 h 
of oxidation (Figure 5.6). However, there was a significantly sharp increase to 26 ± 
2 nmol/mg LDL protein after 24 h of oxidation (p<0.001). In the case of native LDL, 
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the 7-ketocholesterol levels reached 16 ± 0.3 nmol/mg LDL protein after 6 h and 
19 ± 2 nmol/mg LDL levels after 24 h.  
Cholesteryl linoleate hydroperoxide (CLOOH) levels showed an increased level 
initially in both SMase-LDL and native LDL (Figure 5.6), while the levels peaked to 
513 ± 32 nmol/mg LDL protein in native LDL after 6 h, the SMase-LDL levels 
reached a peak value of 388 ± 23 after 12 h. After 24 h the levels in both the LDL 
forms dropped significantly to 44 ± 6 nmol/mg LDL protein in SMase-LDL and 43 ± 
8 nmol/mg LDL protein in case of native LDL. 
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Figure 5.4 Comparison between lipid profile of SMase-LDL and native LDL during 
oxidation of by FeSO4 at pH 4.5 
SMase-LDL (50 µg LDL protein/ml) and native LDL (50 µg LDL protein/ml) were oxidised 
with freshly dissolved FeSO4 (5 µM) at 37°C in a sodium chloride/sodium acetate buffer, 
pH 4.5. At various time points up to 24 h, oxidation was stopped by addition of EDTA (final 
concentration 2mM) and BHT (2mM). The samples were then assayed for free cholesterol 
(A) and cholesteryl linoleate (B) by reverse phase HPLC. Graph represent mean (± SEM) 
of at least 3 independent experiments (** indicates p<0.01, *** indicates p<0.001 
compared with previous time point; ++ indicates p<0.01 between SMase-LDL and native 
LDL for the same time point, Two-way ANOVA followed by Bonferroni post-test). 
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Figure 5.5 Comparison between lipid profile of SMase-LDL and native LDL during 
oxidation of by FeSO4 at pH 4.5 
SMase-LDL (50 µg LDL protein/ml) and native LDL (50 µg LDL protein/ml) were oxidised 
with freshly dissolved FeSO4 (5 µM) at 37°C in a sodium chloride/sodium acetate buffer. 
At various time points up to 24 h, oxidation was stopped by addition of EDTA (final 
concentration 2mM) and BHT (2mM). The samples were then assayed for cholesteryl 
arachidonate (A) and cholesteryl oleate (B) by reverse phase HPLC. Graph represent 
mean (± SEM) of at least 3 independent experiments (* indicates p<0.05, ** indicates 
p<0.01 compared with previous time point; ++ indicates p<0.01 between SMase-LDL and 
native LDL for the same time point, Two-way ANOVA followed by Bonferroni post-test). 
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Figure 5.6 Oxidation product levels durng oxidation of SMase-LDL and native LDL 
by FeSO4 at pH 4.5  
SMase-LDL (50 µg LDL protein/ml) and native LDL (50 µg LDL protein/ml) were oxidised 
with freshly dissolved FeSO4 (5 µM) at 37°C in a sodium chloride/sodium acetate buffer. 
At various time points up to 24 h, oxidation was stopped by addition of EDTA (final 
concentration 2mM) and BHT (2mM). The samples were then assayed for 7-
ketocholesterol (A) and cholesteryl linoleate hydroperoxide (CLOOH) (B) by reverse 
phase HPLC. Graph represent mean (± SEM) of at least 3 independent experiments (** 
indicates p<0.01, *** indicates p<0.001 compared with previous time point; ++ indicates 
p<0.01, +++ indicates p<0.001 between SMase-LDL and native LDL for the same time 
point, Two-way ANOVA followed by Bonferroni post-test). 
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5.3.4 The effect of cysteamine on oxidation of SMase-LDL by iron at 
lysosomal pH 
Cysteamine was shown to prevent the initial oxidation of native LDL by iron 
possibly via scavenging hydroperoxyl radicals. Cysteamine is a lysosomotropic 
agent (Pisoni et al., 1995) and therefore should inhibit the oxidation of SMase-LDL 
under lysosomal conditions. In order to study the antioxidant activity of cysteamine 
on SMase-LDL oxidation at lysosomal pH, freshly prepared SMase-LDL (50 µg 
protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was oxidised with 5 µM FeSO4 
in the presence or absence of cysteamine (25 µM) at 37°C in quartz cuvettes. The 
course of the oxidation was followed by measuring the formation of conjugated 
dienes at 234 nm and loss of LDL-tryptophan fluorescence (Ex/Em = 282/331 nm). 
As in the case of native LDL, cysteamine (25 µM) completely inhibited the initial 
oxidation of SMase-LDL cholesterol and caused a significant increase in the lag 
phase at pH 4.5 (Figure 5.7). The time taken for SMase-LDL to reach an 
attenuance of 0.1 during oxidation by iron was 76 ± 3 min when no cysteamine 
was added, compared with 352 ± 5 min in the presence of cysteamine (p<0.001, 
n=3), which is a 5 ± 0.2 fold inhibition of LDL oxidation.  
Incubation of SMase-LDL with ferrous sulphate leads to continuous loss of 
tryptophan fluorescence, with a sharp loss initially (Figure 5.8). Cysteamine (25 
µM) when added at time zero significantly prevented the loss of LDL-tryptophan 
fluorescence for 500 ± 50 min. The LDL fluorescence decreased by 34 ± 3% after 
150 min of LDL oxidation with ferrous iron, whereas in the presence of cysteamine 
the fluorescence decreased by only 2 ± 0.9% (p<0.001, n =5).   
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Figure 5.7 The effect of cysteamine on the oxidation of SMase-LDL by iron 
 (A) SMase-LDL (50 µg protein/mL) in NaCl/sodium acetate buffer (pH 4.5) was incubated 
with 5 µM FeSO4 in the presence or absence of cysteamine (25 µM) at 37°C in capped 
quartz cuvettes. Oxidation was monitored by measuring the change in attenuance at 234 
nm against appropriate reference cuvettes. This is a representative example of three 
independent experiments. (B) Time taken to reach an attenuance of 0.1 during the 
oxidation with iron (*** indicates p<0.001, t-test, n = 3 independent experiments.  
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Figure 5.8 The loss of LDL-tryptophan fluorescence during SMase-LDL oxidation by 
iron 
(A) SMase-LDL (50 µg protein/ml) was oxidised by 5 µM FeSO4 in NaCl/sodium acetate 
buffer (pH 4.5) at 37°C in quartz cuvettes with or without 25 µM cysteamine and 
tryptophan fluorescence was measured every 10 min at excitation wavelength of 282 nm 
and emission wavelength 331nm in a spectrofluorometer. This is a representative 
example of at least three independent experiments. (B) Shows decrease in LDL-
tryptophan fluorescence after 150 min of oxidation (*** indicates p<0.001, t-test, n = 3 
independent experiments).  
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5.3.5 Measurement of lysosomal lipid peroxidation in human macrophages 
Lipid peroxidation might be one of the major pathological mechanisms involved in 
atherosclerosis. In the lysosomal LDL oxidation theory, it has been shown that 
aggregated LDL is taken rapidly by the macrophages and oxidised in their 
lysosomes by iron. Having confirmed that the in vitro oxidation of SMase-LDL 
could be prevented by cysteamine, it was of importance to examine whether these 
results could apply to the lysosomes of human cultured macrophages.  
Human THP1 monocytes were differentiated into macrophages with PMA as 
mentioned in detail in chapter 2. These macrophages were incubated in RPMI 
(containing 10% (v/v) fetal calf serum) and treated with no LDL, native LDL (200 
µg protein/ml) or SMase-LDL (200 µg protein/ml) in the presence or absence of 
cysteamine (10 µM or 25 µM) for 24 h to induce lysosomal LDL oxidation. After 24 
h the cells were treated with the lysosome-targetable probe, Foam-LPO (2 µM) for 
15 min and then analysed by two-colour flow cytometry in the green (FL1) and red 
(FL2) channels. Macrophages which were treated with SMase-LDL showed 
decreased fluorescence intensity in the red (FL2) channel compared to control 
macrophages (Figure 5.9), confirming foam cell formation (Zhang et al., 2015). In 
the case of macrophages which were treated with SMase-LDL in the presence of 
cysteamine (10 µM and 25 µM), there was a gain in the fluorescence intensity in 
the FL2 channel.  
The process of lipid peroxidation was quantified by ratiometric analysis of the 
fluorescence intensities of green channel and red channel (FL1/FL2) (Figure 5.10) 
(Zhang et al., 2015). The macrophages which were treated with native LDL 
showed a significant increase in the lipid peroxidation levels compared to control 
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macrophages (p<0.001). The SMase-LDL treated macrophages also showed 
increased lipid peroxidation activity in their lysosomes which was highly significant 
compared to control macrophages (P<0.001) as well as that in native LDL treated 
macrophages (p<0.01). Addition of the lysosomotropic antioxidant, cysteamine (10 
µM and 25 µM) reduced the lipid peroxidation process in the SMase-LDL treated 
THP1 macrophages (p<0.01). Although, the reduction in lipid peroxidation by 
cysteamine was not concentration dependent, both 10 µM and 25 µM cysteamine 
brought down the lipid peroxidation level nearer to native LDL treated 
macrophages. 
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Figure 5.9 Flow cytometry analysis of Foam-LPO in THP1 macrophages 
THP1 macrophages were treated with no LDL, native LDL (200 µg protein/ml LDL protein) 
or SMase-LDL (200 µg protein/ml LDL protein in the presence or absence of 10 µM or 25 
µM cysteamine for 24 h. The cells were then incubated with 2 µM Foam-LPO for 15 min, 
harvested and assayed by flow cytometry. (A) Mean fluorescence intensity (MFI) in red 
channel (FL2) of healthy macrophages and SMase-LDL treated macrophage, (B) MFI in 
FL2 of native LDL treated macrophages and SMase-LDL treated macrophages, (C) & (D) 
FL2 MFI of macrophages treated with SMase-LDL and cysteamine 10 µM and 25 µM 
respectively. The data shown are a representative of four independent experiments. 
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Figure 5.10 Measure of lipid peroxidation by Foam-LPO in lysosomes of 
macrophages  
THP1 macrophages were treated with either no LDL, native LDL (200 µg protein/ml) or 
SMase-LDL (200 µg protein/ml LDL in the presence or absence of 10 µM or 25 µM 
cysteamine) for 24 h. The cells were then incubated with 2 µM Foam-LPO for 15 min, 
harvested and assayed by flow cytometry. Lipid peroxidation was calculated from the ratio 
between the mean fluorescence intensity of the green channel (FL1) and red (FL2) 
channel (*** indicated p<0.001 compared to untreated control cells, ## indicates p<0.01 
compared to SMase-LDL only treated cells, ANOVA followed by tukey’s test, n=3 
independent experiments).  
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5.3.6 Oxidation of SMase-LDL in the lysosomes of macrophages 
It has been established that both mechanically modified (vortexed) LDL as well as 
sphingomyelinase aggregated LDL is oxidised in the lysosomes of macrophages 
and generates ceroid (Wen and Leake, 2007, Wen et al., 2015). Ceroid (lipofuscin) 
is a final product of lipid oxidation that consists of insoluble polymerized lipids and 
is found within foam cells in atherosclerotic lesions (Mitchinson, 1982). Having 
confirmed that the treatment with SMase-LDL for 24 h increases while treatment 
with cysteamine decreases the level of lipid peroxidation in the lysosomes of 
human THP1 macrophages, it was of importance to examine a longer time effect 
of cysteamine on the lysosomal oxidation of SMase-LDL by ceroid formation. Also, 
the antioxidant probucol was unable to prevent the oxidation of LDL by iron at 
lysosomal pH (as discussed in Chapter 3 of this thesis) therefore, to confirm this 
inefficacy in the lysosomes of macrophages, effect of probucol on intra-lysosomal 
ceroid formation was also studied. 
THP1 macrophages grown on cover slips were treated with native LDL or SMase-
LDL (200 µg protein/ml) or without LDL for 24 h and were washed and incubated 
for 7 days in lipoprotein deficient medium with or without the antioxidants, probucol 
(10µM) and cysteamine (10 µM). The cells were then stained for ceroid which was 
clearly visible in the form of Oil Red O stained irregularly shaped granules in cells 
treated with SMase-LDL after soluble lipids had been removed by organic 
solvents. The ceroid levels in the cells were quantified using ImageJ software as 
mean integrated density of at least 100 cells and expressed as percent decrease 
of cells treated with SMase-LDL only.  
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Many of the THP1 macrophages which were treated with SMase-LDL contained 
significant amounts of ceroid whereas no significant ceroid was present in cells 
that had been incubated without LDL or with native LDL (Figure 5.11). 
Furthermore, treatment with probucol did not prevent the development of ceroid. 
After 7 days of treatment with probucol (10 µM), there was no apparent decrease 
in the ceroid levels as they reduced to 86 ± 9% compared to the SMase-LDL 
treated cells (Figure 5.12). Cells which were treated with cysteamine showed 
significant reduction in the ceroid formation in their lysosomes. Compared to the 
SMase-LDL treated cells, cysteamine reduced ceroid development in the 
macrophages to 44 ± 1% which is similar to that in the cells treated with native 
LDL (44.3 ± 13%).  These results show that lysosomal oxidation of LDL is not 
prevented by probucol but can be prevented by antioxidants like cysteamine which 
concentrates in the lysosomes. 
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Figure 5.11 Lysosomal ceroid formation 
THP1 macrophages were grown on cover slips in 6 well sterile tissue culture plates. Wells 
were treated with SMase-LDL (200 µg protein/mL) for 24 h and after washing, were further 
incubated for 7 days in fresh RPMI containing 10% (v/v) lipoprotein deficient serum, either 
alone (C) or with 10 µM probucol (D) or 10 µM cysteamine (E). Untreated cells were taken 
as control (A). Native LDL (200 µg protein/mL) treated cells are also shown (B). After 7 
days, cells were treated with ethanol and xylene, followed by Oil Red O staining, and 
examined by light microscopy to demonstrate ceroid. This is a representative of 3 
independent experiments.  
B A 
C D 
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Figure 5.12 Percentage ceroid in THP1 macrophages 
THP1 macrophages differentiated on coverslips were treated with SMase-LDL for 24 h. 
The cells were washed and further incubated for 7 days in RPMI medium with 10% (v/v) 
lipoprotein deficient serum either alone or with cysteamine (10 µM) or probucol (10 µM). 
Cells treated with neither LDL or nor antioxidants were used as control and native LDL 
treated cells were also used for comparison. At the end of the treatment all the wells were 
processed for ceroid detection by Oil Red O stating procedure. The ceroid levels in the 
cells were quantified using ImageJ as mean integrated density of at least 100 cells for 
each treatment and expressed as percentage ceroid compared to SMase-LDL treated 
macrophages ( * indicates p < 0.05 compared to SMase-LDL only treated group, ANOVA 
followed by tukey’s test, n = 3 independent experiments). 
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5.4 Discussion  
A prominent feature of atherosclerotic plaque is the cholesteryl ester-loaded 
macrophage, or foam cell. Because uptake of native LDL is subject to negative 
feedback regulation (via the LDL receptor), accumulation of excessive amounts of 
LDL-derived cholesterol by macrophages is thought to require modification of LDL 
that permits rapid unregulated internalization. Several types of LDL modification 
(e.g. acetylation, oxidation and aggregation) have been shown to permit 
cholesterol uptake in vitro, producing acetylated LDL (acetyl-LDL), oxidized LDL 
(oxLDL) and aggregated LDL (ag-LDL), respectively (Levitan et al., 2010, 
Lougheed et al., 1999, Zhang et al., 1997). There is no evidence that acetylation of 
LDL occurs to any extent in vivo and the extracellular oxidation of LDL has been a 
point of discussion after the failure of major antioxidants trials and is therefore the 
subject of active debate (Steinberg, 2009). However, there are several lines of 
evidence implying that LDL aggregation takes place in the arterial wall. 
Aggregation of LDL has been proposed to represent an essential and central 
process in atherogenesis (Getz and Reardon, 2015, Pentikainen et al., 1996), and 
LDL extracted from atherosclerotic lesions has been found to be aggregated or 
prone to aggregation (Aviram et al., 1995, Bancells et al., 2010b). Furthermore, 
aggregated LDL has been found to be rapidly endocytosed by macrophages and 
concentrated in their lysosomes where it is then oxidised (Wen and Leake, 2007). 
Aggregated LDL found in atherosclerotic lesions has been found to be rich in 
ceramide (about 10-50 fold higher than un-aggregated LDL) (Schissel et al., 
1996). The involvement of ceramide is of particular interest as this lipid has been 
established as a central messenger in apoptosis (Heinrich et al., 2004, Jin et al., 
2008, Kashkar et al., 2005). Taken together, altered sphingolipid metabolism could 
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represent a risk factor for the development of atherosclerosis and the involvement 
of SMase and ceramide may play a central role in the development of this disease, 
providing also a link to apoptosis. Our laboratory has recently shown that LDL 
aggregated by sphingomyelinase is taken up by human macrophages and 
concentrated in their lysosomes where it is extensively oxidised by iron (Wen et 
al., 2015). The oxidation of native LDL by iron at lysosomal pH has been studied in 
this laboratory previously (Satchell and Leake, 2012), but as mentioned before 
SMase-LDL is the more pathophysiological form of LDL that undergoes oxidation 
in the lysosomes of macrophages. Therefore, it is important to know the oxidation 
pattern of SMase-LDL in depth. 
Both native LDL and SMase-LDL were effectively oxidised by iron at lysosomal pH 
(pH 4.5) and the oxidation process was found to be independent of the presence 
of pre-existing lipid hydroperoxides. The oxidation of SMase-LDL lipids by iron 
followed the same pattern as that of native LDL, with an initial lag, followed by 
rapid oxidation phase, slow oxidation phase and then aggregation and 
sedimentation phases. However, the oxidation of SMase-LDL was slower than 
native LDL. The rate of oxidation of the apoB-100 part of SMase-LDL, studied by 
following the loss of LDL-tryptophan fluorescence, was also found to be slower 
than that of native LDL. SMase treatment of LDL causes aggregation of LDL, as 
the increase in ceramide makes it unstable and there are also changes in the 
secondary structure of apoB-100, such as decrease in α-helix content (Sneck et 
al., 2012). In the current experimental setup, LDL aggregates of around 200 nm 
diameter (native LDL is about 22 nm) are formed and therefore, the slower 
oxidation of SMase-LDL could be due to a reduced accessibility of iron to these 
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LDL aggregates due to lower surface area to volume ratio (Walters and Wrenn, 
2010).  
The lipid composition of SMase-LDL oxidised by iron at lysosomal pH, over a 24 h 
time course, has been characterised and compared to native LDL. Levels of 
nonesterified cholesterol decreased continuously during the oxidation of SMase-
LDL. The decrease was not different from that seen in native LDL, possibly 
because most of the nonesterified cholesterol is found in the outer monolayer of 
LDL.  The levels of one of the oxidation products of cholesterol, 7-ketocholesterol, 
increased during the course of oxidation in both SMase-LDL and native LDL. In 
the case of SMase-LDL, the formation of 7-ketocholesterol was initially slower 
compared to native LDL but after 24 h, SMase LDL has significantly higher levels 
than native LDL. The increase in 7-ketocholesterol was much lower than the 
decrease in free cholesterol, but cholesterol is known to be oxidised to other 
products (not measured here) such as 7-α-hydroperoxylcholesterol, 7-β-
hydroperoxycholesterol, 7-α-hydroxycholesterol, 7-β-hydroxycholesterol, 
cholesterol α-epoxide and cholesterol β-epoxide (Chang et al., 1997, Min et al., 
2015). Oxysterols, such as 7-ketocholesterol, are also present in human 
atherosclerotic plaques and may exert atherogenic effects (reviewed in Brown and 
Jessup, 1999). Oxysterols have been detected at increased levels in the plasma of 
cardiovascular patients (Zhou et al., 2000) and have been found to be relatively 
higher in atherosclerotic plaques than in normal arteries (Garcia-Cruset et al., 
1999, Liu et al., 1997). Oxysterols have been reported to have many 
pathophysiological effects in vitro, such as triggering proinflammatory and 
cytotoxic reactions towards various cells of the vascular wall (Lizard et al., 1999, 
Luthra et al., 2008, Pedruzzi et al., 2004, Rosklint et al., 2002). The fact that after 
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24 h, SMase-LDL oxidised by iron, at lysosomal pH, contains higher amounts of 7-
ketocholesterol than native LDL, suggests that it may exert potentially higher 
atherogenic effects.  
The levels of the three major cholesteryl esters measured, cholesteryl linoleate 
(CL), cholesteryl arachidonate (CA) and cholesteryl oleate (CO), decreased 
significantly over the course of the 24 h oxidation in SMase-LDL. The rate of 
decrease of CL and CA levels in SMase-LDL was slower than in native LDL in the 
first 12 h, but after 24 h both LDL forms had almost negligible amounts of these 
esters left. However, there was no apparent difference in the decrease of CO 
levels between SMase-LDL and native LDL, which could be due to overall slower 
oxidation of CO because of having only one double bond. 
The oxidation of cholesteryl esters involves the oxidation of their polyunsaturated 
fatty acid (PUFA) moieties (described in Chapter 1). PUFAs are oxidised via a free 
radical chain reaction (Esterbauer et al., 1990), which is initiated by the abstraction 
of a hydrogen atom by a free radical to give a lipid alkyl radical. This alkyl radical 
then undergoes intramolecular rearrangement to form the more stable conjugated 
diene alkyl radical which on oxygenation produces a lipid peroxyl radical, which 
abstracts a hydrogen from another unsaturated lipid, thereby instigating a chain 
reaction. Here, CL and CA were more rapidly oxidised than CA, probably due to 
higher number of double bonds present in them. In SMase-LDL, the levels of the 
cholesteryl linoleate oxidation product, cholesteryl linoleate hydroperoxide 
(CLOOH), increased significantly up to 12 h of oxidation, and then appeared to 
decrease again, probably due to its further oxidation in the fatty acyl or cholesterol 
moiety shifting its time of elution in HPLC. While in case of native LDL, the levels 
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peaked at 6 h during oxidation and decreased to similar levels as SMase-LDL after 
24 h. The slow formation of CLOOH in SMase-LDL could therefore be due to the 
slower oxidation of CL seen in it when compared to native LDL.  
The lysosomotropic thiol antioxidant, cysteamine, completely inhibited the initial 
oxidation of SMase-LDL cholesterol by iron at lysosomal pH (pH 4.5). No 
conjugated diene formation was observed in about the first 6 h of oxidation 
process when cysteamine was added, indicating that no lipid peroxidation took 
place during that time. The oxidation of apoB-100 of SMase-LDL as measured by 
tryptophan fluorescence was also prevented effectively by cysteamine during its 
oxidation by iron at lysosomal pH.  
Similar results were noticed in vivo in the lysosomes of macrophages, where 
incubation of macrophages with SMase-LDL caused increased lipid peroxidation in 
their lysosomes, after 24 h, compared to native LDL and treatment with 
cysteamine significantly prevented this lysosomal peroxidation (Figure 5.10). The 
high levels of lipid hydroperoxides present in SMase-LDL oxidised by iron in 
lysosomes may confer atherogenic properties to the LDL by accumulating in the 
lysosomes of macrophages which might affect the subsequent hydrolysis of 
cholesteryl esters (Jerome et al., 2008, Kritharides et al., 1998) and can lead to 
ceroid formation (Carpenter et al., 1990, Shimasaki et al., 1995). 
Ceroid, an end product of LDL oxidation consisting of a complex of insoluble 
oxidised lipids and proteins, is found both intracellularly and extracellularly within 
atherosclerotic lesions (Mitchinson et al., 1985). Our laboratory has already 
established that intralysosomal ceroid is produced in human macrophages when 
they are treated with aggregated LDL (Wen and Leake, 2007, Wen et al., 2015). 
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Here, human THP1 macrophages treated with SMase-LDL contained high 
quantities of intralysosomal ceroid compared to the untreated cells and native 
LDL-treated cells. The amount of ceroid was quantified as total integrated density 
and expressed as percentage of ceroid in SMase-LDL treated cells. THP1 
macrophages which were treated with the lysosomotropic antioxidant, cysteamine 
for 7 days after SMase-LDL treatment had significantly lower ceroid present in 
their lysosomes, whereas the macrophages which received probucol treatment did 
not show any decrease in the ceroid percentage (Figure 5.12).  
Cysteamine is a superoxide scavenger (discussed in Chapter 3) and therefore, 
would be able to prevent the lipid peroxidation of SMase-LDL by scavenging the 
hydroperoxyl radical (HO2
●) formed during the redox cycle of lysosomal iron. 
Treatment with cysteamine every day for 7 days would thus continuously inhibit 
the lysosomal oxidation of LDL cholesterol and protein in the macrophages and 
therefore is able to decrease the formation of intralysosomal ceroid.  
Probucol has a long history of clinical application for the treatment of 
cardiovascular diseases (Yamashita et al., 2008, Yamashita and Matsuzawa, 
2009). It was initially introduced as a cholesterol-lowering drug in early 1970’s, and 
later it was also found to attenuate atherosclerotic lesion development in most 
animal models (Carew et al., 1987, Kita et al., 1987, Sasahara et al., 1994, 
Yoshikawa et al., 2008). It was assumed that probucol inhibited atherosclerosis by 
decreasing the oxidation of LDL, but Stocker’s group suggested that probucol 
might inhibit atherosclerosis by upregulating heme oxygenase-1 (Deng et al., 
2004). However, the findings of The Probucol Quantitative Regression Swedish 
Trial (PQRST) in 1995 showed that the treatment of hypercholesterolaemia 
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patients with probucol did not have any beneficial effects (Walldius et al., 1994). 
Under the current experimental conditions, probucol was unable to prevent the 
lysosomal oxidation of LDL in the macrophages which could be due to its inability 
to protect the oxidation of LDL by iron at lysosomal pH (as discussed in Chapter 
3). The results here provide further evidence of the role of hydroperoxyl radicals in 
initiating the oxidation of LDL by iron under lysosomal conditions. 
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Chapter 6-  
Implications of lysosomal oxidation of LDL  
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6.1 Introduction 
The presence of lipid laden macrophage foam cells is a characteristic feature of 
atherosclerosis (Yu et al., 2013). The atherosclerotic foam cells derive the majority 
of their lipid from uptake of modified lipoprotein, such as aggregated LDL or 
oxLDL, and other extracellular lipid particles (Aviram, 1993, Khoo et al., 1988). 
Under normal conditions, receptor-mediated uptake of lipoproteins trafficks the 
particles to lysosomes where at an acidic pH, the lysosomal enzymes break down 
the protein and lipid components of LDL to products that can readily transverse the 
lysosomal membrane (Ghosh et al., 2010, Goldstein and Brown, 2009). Modified 
LDL such as aggregated LDL has been reported to produce foam cells by 
receptor- independent uptake by macrophages (Steinbrecher and Lougheed, 
1992, Zhang et al., 1997). Oxidised LDL is recognised and taken up by scavenger 
receptors found on macrophages and because of no feedback regulation for such 
uptake, leads to accumulation of cholesterol in these cells. Aggregated LDL on the 
other hand can be taken up by macrophages through processes like phagocytosis, 
pinocytosis or patocytosis (Kruth, 2002, Kruth et al., 1999) and presented to the 
lysosomes where it can be oxidised (Wen and Leake, 2007). Aggregation of LDL 
by the enzyme sphingomyelinase has been reported to cause a 10 fold increase in 
cholesteryl ester accumulation in macrophages compared to native LDL (Xu and 
Tabas, 1991).  
There is good evidence to suggest that lysosomal dysfunction plays an important 
role in foam cell formation and plaque development (Reviewed by Jerome and 
Yancey, 2003). Recently it has been reported that oxLDL and cholesterol are able 
to cause profound lysosomal dysfunction in mouse macrophages through 
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disruptions in the pH, proteolytic capacity and membrane integrity of their 
lysosomes (Emanuel et al., 2014). It is also reported that treatment of human 
macrophages with oxLDL or vortexed LDL can affect the functions of lysosomal 
acid lipase (LAL) and overall loss of lysosomal function by increasing the 
lysosomal pH (Cox et al., 2007).  As mentioned earlier, mouse macrophages 
rapidly phagocytose aggregated LDL into their lysosomes and oxidise it with iron 
(Wen and Leake, 2007). Recently it has been shown that LDL aggregated by 
sphingomyelinase (SMase-LDL), a more pathophysiological form of LDL, is also 
rapidly internalised by macrophages and oxidised in their lysosomes (Wen et al., 
2015). Oxidation of lipoproteins in lysosomes leads to the formation of 7-
ketocholesterol (Wen and Leake, 2007), a major component of oxidised LDL, 
which is reported to promote accumulation of unesterified cholesterol in the 
lysosomes of macrophages (Maor et al., 1995) and to induce permeabilization of 
the lysosomal membrane in human endothelial cells (Li et al., 2011). Accumulation 
of 7-ketocholesterol and other oxysterols in the lysosomes during oxidation of LDL 
generates ceroid/lipofuscin which has been reported to diminish the lysosomal 
proteolytic activity  in cultured human fibroblasts (Terman and Brunk, 1998).  
In the previous chapter of this thesis, it was shown that inhibiting the lysosomal 
oxidation of LDL by the antioxidant cysteamine generates less Intralysosomal 
ceroid in human THP-1 macrophages and also reduced the overall lysosomal lipid 
peroxidation process in them. Taking into consideration the above mentioned data, 
targetting lysosomal dysfunction might be an important step in decreasing 
atherosclerosis. Therefore, it is important to investigate if the lysosomal oxidation 
of SMase-LDL produces lysosomal dysfunction in human macrophages and also if 
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inhibiting this oxidation by the lysosomotropic antioxidant, cysteamine, may restore 
normal lysosomal function in them.  
Ceroid or lipofuscin is an auto-fluorescent lipid-protein complex produced after 
extensive oxidation of lipoproteins in the lysosomes of macrophages and is 
frequently found in the foam cells (Ball et al., 1987, Wen and Leake, 2007, Yin and 
Brunk, 1998). Ceroid was first reported to be present in human atherosclerotic 
lesions in 1946 (Pappenheimer and Victor, 1946) and since then, several reports 
have described ceroid in the full spectrum of atherosclerotic lesions (Burt, 1952, 
Haka et al., 2011, Hartroft, 1953, Mitchinson, 1982, Verbunt et al., 1992). Ceroid is 
believed to have detergent like properties which can disrupt membranes and thus 
release lysosomal contents into the cytosol leading to cell injury or necrosis (Gupta 
et al., 2001) and can therefore, lead to plaque progression. 
 Ceroid is often used as a histological index of cellular senescence and ageing 
(Garay et al., 1979, Jung et al., 2010). This is because the accumulation of 
lipofuscin (or ceroid) has been found to have a linear correlation with age in many 
animals (Hosokawa et al., 1994, Munnell and Getty, 1968, Nakano and Gotoh, 
1992, Sheehy et al., 1995). In humans, it has been demonstrated that the 
accumulation of lipofuscin in myocardium (Strehler et al., 1959), plasma and saliva 
(Feng et al., 2015) are directly related to the age of a person.   
Atherosclerosis is classed as a disease of ageing, as increasing age has been 
found to be an independent risk factor for the development of this disease. 
Atherosclerosis is also seen to be associated with biological ageing, as 
atherosclerotic plaques show evidence of cellular senescence characterized by 
reduced cell proliferation, apoptosis, elevated DNA damage, epigenetic 
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modifications, and telomere dysfunction (reviewed in  Brunk and Terman, 2002). 
Not only is cellular senescence associated with atherosclerosis, there is growing 
evidence that cellular senescence may promote atherosclerosis. For example, 
cellular senescence has been shown to cause vascular smooth muscle 
dysfunction (Gorenne et al., 2006, Wang et al., 2015) and endothelial cell 
dysfunction (Minamino et al., 2002), both of which can exert profound effects on 
atherogenesis and stability of advanced plaques (Minamino and Komuro, 2007). It 
has been proposed that oxidative stress-induced damage to cellular components, 
probably due to the combination of higher reactive oxygen species (ROS) and 
impaired antioxidant defence, is the main contributor to the ageing process (Moon 
et al., 2001). Although it is well established that oxidised lipoproteins and their 
products are able to induce ROS-dependent senescence in cells (Imanishi et al., 
2004, Riahi et al., 2015, Watt et al., 2016), it is not known if lysosomal oxidation of 
LDL can induce senescence in human cells. Therefore, it is of interest to 
investigate if oxidation of SMase-LDL in the lysosomes of macrophages can 
induce senescence in them and if these senescent signs can be reversed by 
cysteamine. The most commonly used biomarker for assessing the process of 
senescence in mammalian cells is to measure the activity of lysosomal enzyme β-
galactosidase, which is highly expressed in pre-senescent and senescent cells 
(Dimri et al., 1995). 
Inflammation participates in atherosclerosis during initiation and throughout all 
stages of plaque development. Expression and secretion of inflammatory 
cytokines, like TNF-α, by the cells in the arterial intima is another characteristic 
feature of atherosclerosis. TNF-α  is seen to participate in the atherosclerotic 
process through various mechanisms, such as stimulation of adhesion molecule 
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expression (Khan et al., 1995), stimulation of scavenger receptor expression and 
cholesterol loading (Li et al., 1995), regulation of plaque stability (Libby et al., 
1995), and stimulation of growth factors important for proliferation (Filonzi et al., 
1993). 
Several studies have shown that oxidised LDL and acetylated-LDL can activate 
macrophages, including inflammatory reactions in the vessel wall. Modified LDL 
can stimulate monocyte migration (Navab et al., 1991), expression of adhesion 
molecules (Khan et al., 1995), and production of TNF-α, IL-8, and MCP-1 (Pollaud-
Cherion et al., 1998, Wang et al., 1996).  Even native LDL has been suggested to 
possess immune-stimulating properties, like stimulation of adhesion molecule 
expression on vascular endothelial cells, chemokine receptor expression, 
monocyte chemotaxis (Han et al., 1998) and even potentiation of 
lipopolysaccharide (LPS)-induced production of TNF-α in human macrophages 
(Netea et al., 2002). The role of aggregated LDL in the expression of 
proinflammatory cytokines is controversial with some studies suggesting that it can 
decrease the secretion of many proinflammatory cytokines such as TNF-α, IL-6 
and IL-8 by human macrophages (Persson et al., 2006, Satchell, 2007), while a  
recently published report suggesting that loading of human macrophages with 
aggregated LDL promotes their release of proinflammatory cytokines (Estruch et 
al., 2013). All these studies used the same form of aggregated LDL produced by 
mechanical vortexing and there is not much known about the effect of 
enzymatically aggregated LDL, a more pathophysiological form of aggregated 
LDL, like SMase-LDL, on the expression of pro-inflammatory cytokines. Data are 
presented here, which show that LDL modified by sphingomyelinase can 
potentiate the LPS-induced expression of TNF-α. 
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6.2 Methods 
The methods used have been explained in detail in section 2.5. 
6.3 Results 
6.3.1 Effect of SMase-LDL and cysteamine on lysosomal function 
The lysosomal function of the macrophages was measured by using the 
lysosomotropic dye called LysoTracker Red.  Human THP-1 monocytes were 
differentiated into macrophages with PMA as described in detail in chapter 2. 
These macrophages were incubated in RPMI (containing 10% v/v fetal calf serum) 
and treated with no LDL, native LDL (100 µg protein/ml) or SMase-LDL (100 µg 
protein/ml) in the presence or absence of cysteamine (10 µM or 25 µM) every 24 h 
for 72 h. The macrophages were treated with LysoTracker Red (500 nM for 30 
min) and then analysed by flow cytometry in the red channel (FL2). The results 
were expressed as percentage loss of signal compared to control cells which 
received no LDL. A decrease in LysoTracker intensity relative to baseline suggests 
disruptions in lysosomal function, integrity, or quantity.  
THP-1 macrophages that were treated with native LDL showed no significant shift 
in LysoTracker Red (LTR) signal compared to control cells, whereas macrophages 
which were treated with SMase-LDL for 72 h showed a significant loss in the LTR 
signal compared to the control (Figure 6.1). Native LDL treated cells showed only 
6 ± 4 % decrease in the LTR signal after 72 h which was not statistically different, 
whereas in macrophages which were treated with only SMase-LDL for 72 h 
showed a significant decrease of 26 ± 2% (p<0.001) in the LTR signal compared 
to the control (Figure 6.2). The loss in LTR signal due to SMase-LDL was largely 
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reversed by 25 µM cysteamine, but not by 10 µM cysteamine. The percentage 
loss of LTR signal when cells received 10 µM cysteamine was 24 ± 1% (p<0.001) 
compared to control, while in macrophages which received 25 µM cysteamine, the 
SMase-LDL induced loss of LTR signal was brought down from 26 ± 2% to 9 ± 3% 
(p<0.01), similar to that in native LDL treated macrophages.  
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Figure 6.1 Effect of SMase-LDL and cysteamine on lysosomal function of 
macrophages 
THP-1 macrophages (1 x 106) were cultured in 12 well tissue culture plates in RPMI 
medium (containing 10%  v/v FCS) alone or containing native LDL or SMase-LDL with or 
without cysteamine (10 µM or 25 µM) for 72 h. All LDL concentrations were 100 µg 
protein/ml. After 72 h, cells were treated with 500 nM Lysotracker Red for 30 min and then 
assayed by flow cytometry. Mean fluorescence intensity peak of Lysotracker Red in the 
FL2 channel was then measured. The data shown are a representative of four 
independent experiments.  
FL2-A      FL2-A    
FL2-A      FL2-A    
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Figure 6.2 Effect of lysosomal oxidation of LDL on lysosomal function of 
macrophages  
THP-1 macrophages (1 x 106) were cultured in 12 well tissue culture plates in RPMI 
medium (containing 10% v/v FCS) alone, or containing native LDL, or SMase-LDL with or 
without cysteamine (10 µM or 25 µM) for 72 h. All LDL concentrations were 100 µg 
protein/ml. After 72 h cells were treated with 500 nM Lysotracker Red for 30 min and then 
assayed by flow cytomtery. The data were expressed as percentage loss of mean 
fluorescence intensity of Lysotracker Red in the FL2-A channel compared to untreated 
control macrophages. (*** indicates p<0.001 compared with untreated cells, ## indicates 
p<0.01, ### indicates p<0.001 compared with SMase-LDL treated cells, ANOVA followed 
by tukey’s test, n = 4 independent experiments). 
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6.3.2 Effect of SMase-LDL oxidation and cysteamine on lysosomal pH of 
macrophages 
For the optimal function of the hydrolytic enzymes of lysosomes, the acidic pH is 
an essential requirement (Mindell, 2012) and any increase in this pH has been 
shown to affect the function of the lysosomal enzyme systems (Ohkuma and 
Poole, 1978). There are reports that modified LDL leads to accumulation of 
cholesterol in the lysosomes of macrophages and can affect lysosomal hydrolysis 
due to changes in lysosomal pH (Cox et al., 2007, Orso et al., 2011). In order to 
determine if the lysosomal oxidation of SMase-LDL affects lysosomal function due 
to changes in the lysosomal pH, a ratiometric lysosomal pH indicator dye called 
LysoSensor Yellow/Blue DND-160 was used to measure the pH of the lysosomes 
in macrophages. 
Briefly, differentiated THP-1 cells at 1 x105 cells per well (96 well black microplate) 
in RPMI medium (containing 10% v/v FCS) were incubated with no LDL, native 
LDL (100 µg protein/ml) or SMase-LDL (100 µg protein/ml) every 24 h for 72 h in 
the presence or absence of cysteamine (10 µM or 25 µM). The cells were then 
washed and treated with 5 µM Lysosensor Yellow/Blue and the pH of the 
lysosomes was calculated as described in section 2.5.7.  
The pH of the lysosomes of untreated THP-1 macrophages was 4.9 ± 0.3 which is 
within the normal range of 4.5 to 5 (Figure 6.3). Native LDL treatment did not 
significantly increase the pH of the lysosomes. Treatment with SMase-LDL for 72 
h increased the lysosomal pH to 6.2 ± 0.2, which was found to be statistically 
significant compared to both control macrophages (p<0.001) and native LDL 
treated macrophages (p<0.01). Cysteamine treatment (10 µM or 25 µM) prevented 
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the SMase-LDL induced increase in lysosomal pH. In the macrophages, which 
received 10 µM cysteamine, the pH was significantly lower than SMase-LDL-
treated macrophages at 5.0 ± 0.1 (p<0.001), whereas 25 µM reduced the SMase-
LDL induced lysosomal pH increase to 4.6 ± 0.2 (p<0.001).  
To determine if the action of cysteamine on lysosomal pH was due to inhibition of 
lysosomal oxidation of LDL or due to direct pH lowering effect of cysteamine, the 
effect of cysteamine was studied separately on untreated THP-1 macrophages 
and native LDL-treated macrophages. It was found that treatment with 10 µM or 25 
µM cysteamine had no significant effect on the lysosomal pH of THP-1 
macrophages in the absence of LDL (Figure 6.4A). The pH of lysosomes in 
untreated cells was found to be 3.9 ± 0.3, while the lysosomal pH was 4.6 ± 0.2 
with 10 µM cysteamine treatment (p>0.05) and 4.5 ± 0.2 with 25 µM cysteamine 
treatment (p>0.05).  
Similarly, cysteamine (10 µM or 25 µM) showed no significant effect on the 
lysosomal pH of THP-1 macrophages when treated with native LDL (Figure 6.4B). 
The pH in the cells which were incubated with only native LDL was found to be 5.8 
± 0.3, while in presence of cysteamine, 10 µM and 25 µM, the pH of the THP-1 
lysosomes was 5 ± 0.2 (p>0.05) and 5.3 ± 0.1 (p>0.05) respectively.  
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Figure 6.3 Effect of lysosomal oxidation of SMase-LDL on the pH of lysosomes in 
THP-1 macrophages. 
THP-1 macrophages were cultured in black 96-well microplate at 1 x 105 per well in RPMI 
medium (containing 10% v/v FCS) with no LDL, native LDL (100 µg protein/ml) or SMase-
LDL (100 µg protein/ml) with or without cysteamine (Cyst) (10 µM or 25 µM) for 72 h. The 
cells were then treated with 5 µM Lysosensor Yellow/Blue for 30 min at 37°C. The 
samples were then read in a Fluo Star Optima fluorometer (BMG Labtech), with excitation 
at 355nm. The ratio of emission at 440nm and 535nm was then calculated for each 
sample and the pH values determined from the standard plot. (** indicates p<0.01 and *** 
indicates p<0.001 compared to SMase-LDL treated macrophages, ANOVA followed by 
tukey’s test, n=6 independent experiments). 
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Figure 6.4 Effect of cysteamine on lysosomal pH of macrophages 
THP-1 macrophages were cultured in black 96-well microplate at 1 x 105 per well in RPMI-
1640 medium (containing 10% v/v FCS) with no LDL, or native LDL (100 µg protein/ml) 
with or without cysteamine (10 µM or 25 µM) for 72 h. The cells were then treated with 5 
µM Lysosensor Yellow/Blue for 30 min at 37°C with 5% CO2. The samples were then read 
in Fluo Star Optima fluorometer (BMG Labtech), with excitation at 355nm. The ratio of 
emission at 440nm and 535nm was then calculated for each sample and the pH values 
determined from the standard plot. (A) shows effect of cysteamine on control cells, (B) 
shows effect of cysteamine on native LDL treated cells (ANOVA followed by tukey’s post-
test, n=4 independent experiments).  
A 
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6.3.3 Effect of lysosomal oxidation of SMase-LDL on cell senescence  
Intralysosomal accumulation of ceroid (or lipofuscin) has been associated with 
cellular ageing (Georgakopoulou et al., 2013, Katz et al., 1984) and there is 
evidence that cellular senescence is present in atherosclerosis (Alique et al., 
2015). To investigate if lysosomal oxidation of LDL induces the expression of 
senescence markers, human THP-1 macrophages were treated with SMase-LDL 
(100 µg protein/ml) for 72 h in the presence or absence of cysteamine (10 µM) and 
then stained for the expression of senescence-associated β-galactosidase (as 
described in detail in chapter 2), a lysosomal enzyme seen in senescent human 
cell types (Dimri et al., 1995). Cells were also treated with native LDL (100 µg 
protein/ml) and untreated THP-1 macrophages were taken as control. The results 
were expressed as percentage of senescent cells (i.e. blue-green stained) in each 
group. 
Incubation of THP-1 macrophages with native LDL increased the senescence-
associated β-galactosidase (SaβG) levels in their lysosomes (Figure 6.5). SMase-
LDL treated macrophages showed higher expression of SaβG compared to native 
LDL-treated cells and cysteamine treatment reduced the SMase-LDL induced 
SaβG expression. About 23 ± 4% of untreated control cells were found to be 
senescent (Figure 6.6), while native LDL treatment increased the senescent cell 
percentage to 46 ± 2% (p<0.001). In the case of cells which were treated with 
SMase-LDL, 69 ± 3% of cells were seen to express the senescent marker SaβG, 
which was highly significant compared to both control (p<0.001) and native LDL 
treated macrophages (p<0.001). However, treatment of macrophages with 
cysteamine reduced the SMase-LDL induced number of senescent cells to 38 ± 25 
% (p<0.001).  
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Figure 6.5 Effect of lysosomal oxidation of LDL on senescence of THP-1 
macrophages 
THP-1 macrophages were cultured in 12 well tissue culture plates at 3000 cells per well in 
RPMI medium (containing 10% v/v lipoprotein-deficient serum) containing either no LDL 
(A), native LDL (100 µg protein/ml) (B), SMase-LDL (100 µg protein/ml) alone (C) or 
SMase-LDL (100 µg protein/ml) with 10 µM cysteamine (D) for 72 h. The cells were then 
stained to identify any senescent cells by visualisation under bright-field microscopy for 
blue-green colouration indicating increased levels of lysosomal β-galactosidase activity. 
The images shown are representative of three independent experiments. 
  
A B 
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Figure 6.6 Effect of cysteamine on SMase-LDL induced senescence in THP-1 
macrophages 
THP-1 macrophages cultured in 12 well tissue culture plates at 3000 cells per well in 
RPMI medium (containing 10% v/v lipoprotein deficient serum) were incubated for 72 h 
with no LDL, with native LDL (100 µg protein/ml) or with SMase-LDL (100 µg protein/ml), 
with or without 10 µM cysteamine (Cyst). The macrophages were then assessed for the 
presence of senescent cells by the senescence associated β-galactosidase assay. The 
results where expressed as percentage of senescent cells in 100 cells. (*** indicates 
p<0.001 compared to untreated cells, ### indicated p<0.001 compared to SMase-LDL 
treated cells, One-way ANOVA followed by tukey’s post-test, n = 4 independent 
experiments).  
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6.3.4 The effect of lysosomal oxidation of SMase-LDL on macrophage TNF-
α expression 
Preliminary experiments were conducted to assess the effect of lysosomal LDL 
oxidation on macrophages TNF-α expression, using a ELISA kit, as described in 
Chapter 2. SMase-LDL was used in these experiments, so that the LDL could 
enter the macrophage lysosomes in a non-oxidised form, in order to exclusively 
assess the effects of oxidation occurring intracellularly. THP-1 macrophages were 
cultured in RPMI-1640, supplemented with 10% (v/v) FCS to prevent extracellular 
LDL oxidation. The macrophages were incubated for 12 or 24 h with native LDL or 
LDL that had been aggregated with sphingomyelinase to greatly increase its 
uptake by the macrophages. To investigate the effect of the antioxidant 
cysteamine on TNF-α secretion, THP-1 macrophages were treated with 
cysteamine (10 µM or 25 µM) prior to incubation with SMase-LDL, so as to prevent 
the initial oxidation of LDL in the lysosomes. After LDL treatments, the 
macrophages were washed and then stimulated with LPS (10 ng/ml) in culture 
medium for 4 h at 37°C. At the end of the incubation time, the medium was 
collected and assayed for TNF-α secretion.  
 The THP-1 macrophages showed a significant increase in the LPS stimulated 
TNF-α secretion after both 12 and 24 h incubation with native LDL or SMase-LDL 
(Figure 6.7). While the secretion of TNF-α, although insignificant, showed an 
upward trend from 12 h to 24 h LDL treatment, interestingly in the control cells, 
which received no LDL, the TNF-α levels dropped from 270 ± 9 pg/ml after 12 h 
incubation to 137 ± 2 pg/ml after 24 h incubation (p<0.001). Treatment of THP-1 
macrophages with native LDL for 12 h increased the TNF-α secretion to 334 ± 19 
pg/ml (p<0.01), while SMase-LDL increased it to 458 ± 24 pg/ml (p<0.001) after 12 
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h compared to the control cells. In macrophages which were treated with native 
LDL for 24 h, the TNF-α concentrations were found to be 386 ± 40 pg/ml (p<0.05 
compared to control), while incubation with SMase-LDL increased the 
concentration to 534 ± 70 pg/ml (p<0.001 compared to control). There was a 
significant difference in the TNF-α concentrations between native LDL-treated and 
SMase-LDL treated cells after 12 h, however no significant difference was found in 
the 24 h treated cells.  
Prior treatment of cysteamine for 24 h was seen to reduce the SMase-LDL 
associated secretion of TNF-α compared to the macrophages incubated with only 
SMase-LDL (Figure 6.7).  In the macrophages which were incubated with SMase-
LDL for 12 h, cysteamine produced similar, but significant reduction in the TNF-α 
concentrations from 458 ± 24 pg/ml to 355 ± 23 pg/ml (p<0.05) and 352 ± 12 pg/ml 
(p<0.05), respectively, by 10 µM and 25 µM cysteamine. Although, cysteamine 
reduced the TNF-α secretion in the macrophages treated with SMase-LDL for 24 h 
from 534 ± 70 pg/ml to 505 ± 18 pg/ml and 418 ± 23 pg/ml with 10 µM and 25 µM 
concentrations, respectively, but it was not found to be statistically significant.  
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Figure 6.7 Effect of SMase-LDL on TNF-α expression in THP-1 macrophages 
THP-1 monocytes were differentiated into macrophages with 25 ng PMA /ml in 12 well 
tissue culture plates at a density of 3.5 x 105 cells/ml in RPMI-1640 medium (with 10% v/v 
FBS) for 72 h. The cells were washed and rested for another 24 h, after which they were 
then incubated in fresh RPMI-1640 medium (with 10% v/v FBS), alone or with native LDL 
or SMase-LDL (both at 50 µg protein/ml) for either 12 h or 24 h (A). Two sets of wells 
were pre-incubated with cysteamine (10 µM or 25 µM) for 24 h prior to SMase-LDL 
treatment (B). After LDL treatment, the cells were washed with PBS and then stimulated 
with LPS (10 ng/ml) for 4 h at 37 °C and the medium was collected and assayed for TNF-
α. In (A) +++ indicates p<0.001, ** and *** indicates p<0.01 and p<0.001 respectively 
compared to 12 h untreated cells, # and ### indicates p<0.05 and p<0.001 compared to 24 
h untreated cells, && indicates p<0.01. In (B) * indicates p<0.05 compared to SMase-LDL 
treated cells. The data shown are from 4 independent experiments and the statistics 
shown are One-way ANOVA followed by tukey’s post-test.  
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6.4 Discussion 
Acidic pH is essential for the optimal function of degradative enzymes present in 
the lysosomes of cells. Almost all of the lysosomal enzymes are acid hydrolases, 
which are active at acidic pH (between 4.5 and 5) (Coffey and De Duve, 1968) and 
any change in this pH can cause lysosomal dysfunction (Ohkuma and Poole, 
1978). Lysosomes generate and maintain their pH gradients by using the activity 
of a proton-pumping V-type ATPase, which uses metabolic energy in the form of 
ATP to pump protons into the lysosome lumen (Ohkuma et al., 1982). The 
lysosome receives extracellular cargo (via endocytosis) and cytoplasmic material 
(via autophagy) for degradation (Eskelinen and Saftig, 2009). Failure of the 
lysosome to process its contents efficiently leads to an accumulation of undigested 
material inside the lumen and can cause lysosomal dysfunction (Platt et al., 2012).  
The accumulation of lysosomal free cholesterol has been shown to directly cause 
an increase in lysosomal membrane cholesterol content (Cox et al., 2007). The 
data presented here have shown that treatment of human THP-1 macrophages 
with SMase-LDL for 3 days decreases lysosomal function in them in terms of 
Lysotracker Red accumulation (Figures 6.1 and 6.2). The lysosomotropic 
antioxidant, cysteamine is able to improve lysosomal function, with a 25 µM 
concentration being able to almost completely reverse the SMase-LDL induced 
lysosomal dysfunction. It was also noticed that treatment with native LDL did not 
have any considerable effect on the lysosomal function of the THP-1 
macrophages. The data here also suggest that the decrease in lysosomal function, 
due to atherogenic lipid loading in the THP-1 macrophages appears to be due to 
the loss of lysosomal acidification (or rise in lysosomal pH). SMase-LDL treatment 
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for 72 h was seen to increase the lysosomal pH of the THP-1 macrophages 
considerably from 4.9 to 6.2 (which represents a decrease in hydrogen ion 
concentration of 20 times), compared to the baseline pH of untreated cells and 
native LDL treated cells (Figure 6.3). The increase in pH would decrease the 
degradation of LDL and lead to more lipid accumulation in lysosomes, leading to 
more lipid-laden foam cells. It was also noticed that cysteamine was able to 
prevent the SMase-LDL induced increase in the lysosomal pH. Furthermore, it was 
noted that cysteamine had no great effect on the lysosomal pH of macrophages in 
absence of LDL or in the presence of native LDL. In chapter 4 it was shown that 
macrophages treated with SMase-LDL for 24 h showed increased levels of lipid 
peroxidation in their lysosomes which was greatly inhibited by cysteamine. In the 
present experimental conditions, the continuous treatment of THP-1 macrophages 
with SMase-LDL for 72 h would have induced extensive lipid peroxidation in their 
lysosomes by iron generating lipid peroxidation products like 7-ketocholesterol, 4-
hydroxynonenal and malondialdehyde which have previously been shown to inhibit 
the activity of lysosomal v-ATPase causing lysosomal dysfunction (Cox et al., 
2007, Krohne et al., 2010a, Sudo et al., 2015).  
Cysteamine, on the other hand had little effect on the lysosomal pH of control or 
native LDL treated macrophages suggesting that the effect of cysteamine in 
preventing the SMase-LDL altered lysosomal pH is due to the inhibition of 
lysosomal peroxidation of aggregated LDL and is independent of any effect on the 
lysosomal v-ATPase.  
There is strong evidence suggesting that decreased lysosomal proteolytic activity 
and increased lysosomal pH occurs as a consequence of aging in long-lived post 
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mitotic cells (Martinez-Vicente et al., 2005, Rajawat et al., 2009, Terman and 
Brunk, 2006). In fact, increasing lysosomal function is being considered as a 
plausible avenue for anti-ageing interventions so as to increase the longevity of 
cells (Carmona-Gutierrez et al., 2016). 
 It has been proposed that oxidative stress-induced damage to cellular 
components, probably due to the combination of higher reactive oxygen species 
(ROS) and impaired antioxidant defence, is the main contributor to the ageing 
process (Moon et al., 2001). The accumulation of oxidation products of cholesterol 
(oxysterols) has been seen to induce senescence in human cells, through the 
generation of reactive oxygen species (Carmona-Gutierrez et al., 2016, Zarrouk et 
al., 2014). Data presented here have shown that both native LDL and SMase-LDL 
treatment for 3 days induces senescent like properties in human THP-1 
macrophages (Figures 6.5 and 6.6). The incidence of senescence was found to be 
much higher with SMase-LDL compared to native LDL and treatment with 
cysteamine significantly decreased the SMase-LDL induced senescence. 
Superoxide radicals are considered by some to be the major cause of ageing in 
cells (Hamilton et al., 2001, Jacobson et al., 2007, Sawada and Carlson, 1987) 
and as explained earlier lysosomes are ideal places for the generation of 
superoxide anions (O2
●-) from oxidation of catalytically active ferrous ions, which 
under lysosomal pH conditions can form more toxic hydroperoxyl radicals (HO2
●) 
(De Grey, 2002, Grady and Chasteen, 1991). HO2
●, a stronger oxidant, is capable 
of initiating lipid peroxidation (Bielski et al., 1983) under lysosomal conditions and 
therefore can generate intralysosomal ceroid, an ageing pigment (Kieseier et al., 
1996, Yin et al., 2011). Cysteamine, being a superoxide scavenger (Sunman et al., 
1993), is able to inhibit the lipid peroxidation of LDL in the lysosomes and thus 
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prevent the formation of senescent-associated intralysosomal ceroid in human 
macrophages.  
Inflammation plays a key role in the initiation, progression and rupture of 
atherosclerotic lesions (reiewed in Libby, 2012). Both minimally oxidised LDL and 
oxLDL have been shown to cause the secretion of proinflammatory cytokines by 
macrophages (Bekkering et al., 2014, Miller et al., 2005) by enhancing the 
expression of toll-like receptor-4 (TLR-4). However, some studies have shown that 
oxidised LDL inhibits the production of inflammatory cytokines by macrophages in 
response to inflammatory stimuli such as lipopolysaccharide (LPS) (Page et al., 
1999, Thai et al., 1995). The effect of vortexed and acetylated LDL on the 
expression of the proinflammatory cytokine, TNF-α, is controversial with some 
reports showing a decrease in its levels (Ares et al., 1995, Satchell, 2007) and 
others showing an increase (Estruch et al., 2013). LPS is considered a classical 
ligand of TLR4 receptors (Lu et al., 2008). Here, we sought to determine whether 
lysosomal oxidation of SMase-LDL by human THP-1 macrophages, could alter the 
LPS induced secretion of TNF-α levels.   
The data presented here suggests that both native LDL and SMase-LDL treatment 
for 12 h increases the LPS induced expression of TNF-α in THP-1 macrophages 
(Figure 6.7). The secretion of TNF-α was seen to be considerably higher with 
SMase-LDL after 12 h compared to both control macrophages and native LDL 
treated macrophages. The potentiation of LPS-induced TNF-α secretion by native 
LDL is in agreement with the previous studies by Netea et al. (2002). Although the 
LPS induced TNF-α secretion was seen to increase after 24 h LDL treatment 
compared to 12 h, the difference was not statistically different. The TNF-α levels 
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secreted by the control macrophages that were incubated for 24 h were lower than 
the ones incubated for 12 h, for unknown reasons. Pre-incubation with cysteamine 
for 24 h decreased the secretion of TNF-α by macrophages incubated with 
SMase-LDL for 12 h (but not for 24 h).   
The explanation for increased expression of TNF-α by both native LDL and 
SMase-LDL could be due to increased expression of CD14 receptors on the THP-
1 macrophages (Esfahani et al., 1993). CD14 is a component of the innate 
immune system, expressed on human monocytes and macrophages and is a 
receptor for LPS (Fenton and Golenbock, 1998). In addition, SMase-LDL 
treatment might increase the expression of toll-like receptor-4 (TLR4) on the 
macrophage surface, either due to the ceramide present in SMase-LDL (Tawadros 
et al., 2015) or due to the oxidative stress caused by the lysosomal oxidation of 
LDL (Powers et al., 2006). The increased expression of TNF-α by lysosomal LDL 
oxidation in human macrophages can participate in the atherosclerosis process 
possibly by stimulating adhesion molecule expression (Bevilacqua, 1993), 
stimulating growth factors important for proliferation (Filonzi et al., 1993) and 
regulation of plaque stability (Libby et al., 1995). TNFα once released enhances 
through NF-κB activation the expression of acyl-CoA-cholesterol transferase 1 to 
promote cholesterol uptake and cholesteryl ester-laden cell formation from 
differentiating monocytes (Lei et al., 2009). TNFα has been seen to reduce the life 
span of endothelial cells (EC) in culture in a concentration- and time-dependent 
manner through increased rate of apoptosis (Csiszar et al., 2007, Gaur and 
Aggarwal, 2003). Increased TNFα formation and concentration in the vascular wall 
of the aorta and of carotid and coronary arteries contribute along with EC 
apoptosis to impaired endothelial function (Csiszar et al., 2004). TNFα also 
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stimulates NOX and superoxide dismutase (SOD) in VSMC, consequently the 
formation of ROS and H2O2 is enhanced. ROS and/or H2O2 facilitates the 
activation of other stress related ERK and p38MAPK pathways and therefore the 
growth and movement of VSMC (Xu et al., 2009). The exact mechanism of 
increased TNF-α secretion by SMase-LDL needs detailed investigation, as does 
the effect of lysosomal oxidation of SMase-LDL on the expression of other 
proinflammatory cytokines.  
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Chapter 7- General discussion 
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7.1 General discussion 
This thesis has many potential applications in the field of atherosclerosis. The 
main outcomes of the research presented in this thesis can be summarised as: 
 The initial oxidation of LDL by iron at lysosomal pH (pH 4.5) occurs in the 
hydrophobic cholesteryl ester core first and doesn’t depend on the pre-
existing lipid hydroperoxides in LDL. 
 Under lysosomal conditions protonated superoxide ions known as 
hydroperoxyl radicals (HO2
●) are the main oxidising species capable of 
causing LDL oxidation and superoxide scavengers like cysteamine are able 
to inhibit this oxidation, while antioxidant probucol is unable to prevent it. 
 Incubation of human macrophages with SMase-LDL leads to intralysosomal 
ceroid generation in human macrophages which is greatly inhibited by 
lysosomotropic antioxidant cysteamine. 
  Lysosomal oxidation of LDL can lead to lysosomal dysfunction in human 
THP-1 macrophages by altering the lysosomal pH and inhibiting the 
oxidation by cysteamine restores the functions of lysosomes. 
 Lysosomal oxidation of LDL induces senescence in human THP-1 
macrophages which is greatly inhibited by cysteamine. 
 Lysosomal oxidation of SMase-LDL potentiates LPS-induced TNF-α 
secretion in human THP-1 macrophages whereas pre-incubation with 
cysteamine greatly decreases it. 
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The existence of modified forms of LDL to convert macrophages into foam cells 
has been in the limelight since 1970’s (Goldstein and Brown, 1973, 1974). The 
presence of oxidised LDL in atherosclerotic plaques has been demonstrated and a 
plethora of atherogenic properties of oxidised LDL have been discovered 
(reviewed in Stocker and Keaney, 2004). Oxidised LDL was widely believed to be 
the main culprit in the development of atherosclerosis, doubt about its importance 
has grown due to the lack of effect of the large antioxidant trials using vitamin E. In 
fact, this laboratory has recently shown that vitamin E enrichment of LDL actually 
increased the initial oxidation of LDL by iron at lysosomal pH (Satchell and Leake, 
2012). The lack of effect of the clinical trials does not therefore necessarily 
invalidate the oxidised LDL hypothesis of atherosclerosis, but the actual site and 
the mechanisms by which it is produced in vivo are still a matter of debate 
(reviewed in Steinberg and Witztum, 2010). The use of copper ions at pH 7.4 is a 
widely employed method for producing oxidised LDL in vitro, however, it is 
questionable as to whether copper oxidises LDL in vivo. Recently it was shown 
that LDL aggregated by vortexing could be oxidised by redox active iron within the 
lysosomes of macrophages in a cell culture system (Wen and Leake, 2007). LDL 
oxidation by iron at lysosomal pH has been characterised in this laboratory 
previously (Satchell and Leake, 2012), however the exact mechanism through 
which iron is able to oxidise LDL is yet to be established.  
Work presented in this thesis has shown that at lysosomal pH, the hydroperoxyl 
radical (HO2
●) is the main oxidising species which can induce extensive oxidation 
of LDL. Due to the acidic and reducing environment within lysosomes, most of the 
iron present in them occurs in the ferrous state (Schafer et al., 2000), which on 
oxidation is converted to the ferric form (Figure 3.4) with the generation of 
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superoxide anion (O2
-) (Morgan and Leake, 1993). Superoxide anion is a weak 
oxidant, but at lysosomal pH most of it will be protonated to form stronger oxidant, 
hydroperoxyl radical (HO2
●) which has a pKa of 4.8, close to the lysosomal pH of 
about 4.5 (Bielski, 1985, Grady and Chasteen, 1991). Our HPLC data (Figure 
3.11) revealed that initial oxidation of LDL by iron at lysosomal pH occurs in the 
cholesteryl ester-rich hydrophobic core of LDL particles, which is not prevented by 
the chain breaking antioxidant, probucol (Figures 3.8 and 3.11), due to probucol’s 
limited access to the LDL core, but is completely prevented by the more 
hydrophobic chain breaking antioxidant, DPPD. Although DPPD is able to prevent 
the oxidation in LDL’s core (Figure 3.9) it is unable to prevent the oxidation of the 
apoB-100 part of LDL (Figure 3.10). Cysteamine, which is a thiol based 
lysosomotropic antioxidant, offers complete inhibition of LDL oxidation by iron in 
vitro at lysosomal pH, including the inhibition of lipid peroxidation in the 
hydrophobic core and phospholipid monolayer as well as inhibiting the oxidation of 
apoB-100 (Figures 3.12, 3.13 and 3.14). The fact that cysteamine completely 
inhibits the oxidation of all the parts of LDL suggests that oxidation of LDL by iron 
under lysosomal conditions is mediated by protonated superoxide ions (HO2
●), 
which because of their neutral charge can freely enter the hydrophobic core. 
Cysteamine was also found to be better at preventing LDL oxidation by iron at 
lysosomal pH when compared to another thiol molecule, cysteine (Figure 4.2), as 
well as other known lysosomotropic drugs such as propranolol (Figure 4.3), 
amiodarone (Figure 4.4) and 7,8-dihydroneopterin (Figure 4.5).  
Native and oxidised-LDL are prone to aggregation and atherosclerotic plaque 
formation is believed to be initiated by the extracellular aggregation and deposition 
of lipoproteins in the subendothelial matrix. The results presented here 
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demonstrate that cysteamine is able to prevent the oxidation-induced aggregation 
of LDL (Figure 4.6). In addition, the antioxidant activity of cysteamine at pH of 7.4 
was also demonstrated, should the oxidation of LDL occur under interstitial pH 
conditions (Figure 4.7).  
Foam cell formation via the incubation of macrophages with oxidised LDL does not 
accurately reflect the in vivo environment, as most LDL in atherosclerotic plaques 
is found in the aggregated state and bound to subendothelial matrix. It has been 
shown that enzymes secreted in the arterial intima like lipoprotein lipase (LPL), 
sphingomyelinase (SMase), phospholipase A2 (PLA2), cholesteryl ester hydrolase 
(CEH), matrix metalloproteinases (MMP) and plasmin can cause LDL aggregation 
to produce atherogenic LDL forms that are rapidly internalized by macrophages. 
Previous work from this laboratory has shown that sphingomyelinase-aggregated-
LDL (SMase-LDL) is rapidly endocytosed by human macrophages in their 
lysosomes and oxidised by redox active iron present in them (Wen et al., 2015). In 
this thesis, the oxidation of SMase-LDL by iron at lysosomal conditions has been 
characterised and results have been compared to the oxidation of native LDL 
(Figure 5.4, 5.5). Although, SMase-LDL is oxidised more slowly than native LDL, 
after 24 h both the forms of LDL reach similar levels of oxidation generating 
products like 7-ketocholesterol and cholesteryl ester hydroperoxides (Figure 5.6). 
The presence of cysteamine inhibits this oxidation significantly (Figure 5.7).   
The data presented here also demonstrate that cysteamine, unlike probucol, is 
able to prevent the oxidation of SMase-LDL in the lysosomes of human 
macrophages. Probucol, initially introduced as a cholesterol-lowering drug, was 
found to attenuate atherosclerotic lesion development in animals (Carew et al., 
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1987); however the findings of The Probucol Quantitative Regression Swedish 
Trial (PQRST) in 1995 showed that the treatment of hypercholesterolaemia 
patients with probucol did not have any beneficial effects (Walldius et al., 1994). In 
the current experimental conditions, probucol was unable to prevent the lysosomal 
oxidation of LDL in the macrophages, which could be due to its inability to protect 
the oxidation of LDL by iron at lysosomal pH. The lysosomotropic property of 
cysteamine, allows it to concentrate more in the lysosomes of cells where it is able 
to greatly inhibit the oxidation of LDL as indicated by the decrease in the overall 
intralysosomal lipid peroxidation process and reduction in the SMase-LDL induced 
intralysosomal ceroid formation (Figure 5.11). These results therefore further 
provide evidence of the role of hydroperoxyl radicals (HO2
●) in initiating the 
oxidation of LDL by iron under lysosomal conditions.  
Acidic pH is essential for the optimal function of degradative enzymes present in 
the lysosomes of cells (Ohkuma et al., 1982). Almost all of the lysosomal enzymes 
are acid hydrolases, which are active at acidic pH (between 4.5 and 5) and any 
change in this pH can cause lysosomal dysfunction (Platt et al., 2012). Lysosomes 
generate and maintain their pH gradients by using the activity of a proton-pumping 
V-type ATPase, which uses metabolic energy in the form of ATP to pump protons 
into the lysosome lumen (Ohkuma et al., 1982). The lysosome receives 
extracellular cargo (via endocytosis) and cytoplasmic material (via autophagy) for 
degradation. Failure of the lysosome to process its contents efficiently leads to an 
accumulation of undigested material inside the lumen and can cause lysosomal 
dysfunction. The data presented here have shown that treatment of human THP-1 
macrophages with SMase-LDL decreases their lysosomal function when incubated 
continuously for 3 days with SMase-LDL. The lysosomotropic antioxidant, 
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cysteamine is able to improve the lysosomal function and with a 25 µM 
concentration, [which is attained in cystinosis patients treated with cysteamine 
(Dohil et al., 2006)] being able to completely reverse the SMase-LDL induced 
lysosomal dysfunction (Figure 6.1, 6.2). It was also noticed that treatment of native 
LDL did not have any considerable effect on the lysosomal function of 
macrophages. The data here also suggest that the decrease in lysosomal function, 
due to atherogenic lipid loading in the THP-1 macrophages appears to be due to 
loss of lysosomal acidification (or rise in lysosomal pH). SMase-LDL treatment for 
72 h increased the lysosomal pH of the THP-1 macrophages considerably, 
compared to the baseline pH of untreated cells and native LDL-treated cells 
(Figure 6.3). It was also shown that cysteamine was able to prevent the SMase-
LDL induced increase in the lysosomal pH. Furthermore, it was noted that 
cysteamine had little effect on the lysosomal pH of macrophages in the absence of 
LDL or in the presence of native LDL (Figure 6.4).  
As mentioned above, macrophages when treated with SMase-LDL show 
increased levels of lipid peroxidation in their lysosomes, which is greatly inhibited 
by cysteamine. Lipid peroxidation products like 7-ketocholesterol, 4-
hydroxynonenal and malondialdehyde have been shown to induce lysosomal 
dysfunction by inhibiting the activity of lysosomal v-ATPase (Krohne et al., 2010b, 
Sudo et al., 2015). In the present experimental conditions, the continuous 
treatment of THP-1 macrophages with SMase-LDL for 72 h would have induced 
extensive peroxidation in their lysosomes and thus increasing their pH. 
Cysteamine, on the other hand, had no effect on the lysosomal pH of control or 
native LDL treated macrophages suggesting that the effect of cysteamine in 
maintaining the SMase-LDL altered lysosomal pH is due to the inhibition of 
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lysosomal lipid peroxidation of aggregated LDL and is independent of any effect 
on the lysosomal v-ATPase.  
Inflammation is considered an important element in vulnerable plaque formation 
and plaque rupture. It is also a key component in the initiation and progression of 
the disease (Libby, 2002). An attempt was made in the work presented in this 
thesis, to determine whether intralysosomal LDL oxidation altered the expression 
of the inflammatory cytokine, tumour necrosis factor-alpha (TNF-α). While both 
native LDL and SMase-LDL increased the LPS-induced secretion of TNF-α by 
human THP-1 macrophages, the effect was more pronounced with SMase-LDL 
(Figure 6.7). Prior treatment of macrophages with cysteamine produced significant 
reduction in the SMase-LDL induced TNF-α secretion possibly due to prevention 
of intralysosomal LDL oxidation. Further investigation is required in this field, 
looking at the effect of lysosomal oxidation of SMase-LDL on other inflammatory 
cytokines. The increased secretion of TNF-α by both native LDL and SMase-LDL 
could be due to increased expression of the LPS receptor, CD14 (Esfahani et al., 
1993) or of Toll-like receptor-4 (TLR4) on the surface of THP-1 macrophages, 
probably due to the ceramide present in SMase-LDL (Tawadros et al., 2015) or 
due to the oxidative stress (Powers et al., 2006) from the spilling of oxidised 
lysosomal contents in the cytosol. Cysteamine might possibly block all these 
effects, thus reducing the secretion of TNF-α. The exact mechanism of increased 
TNF-α secretion by oxidised LDL needs detailed investigation, as well as the effect 
of lysosomal oxidation of SMase-LDL on the expression of other proinflammatory 
cytokines. 
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Superoxide radicals are considered by some to be a major cause of ageing in cells 
(Hamilton et al., 2001, Jacobson et al., 2007). HO2
●, a stronger oxidant, is capable 
of initiating lipid peroxidation (Bedwell et al., 1989, Bielski, 1985, Yin et al., 2011) 
under lysosomal conditions and generating intralysosomal ceroid, an ageing 
pigment (Kieseier et al., 1996). There is mounting evidence that lysosomal 
dysfunction is associated with many age-related diseases and accumulation of 
oxidation products of cholesterol (oxysterols) has been seen to induce senescence 
in human cells, through the generation of reactive oxygen species (Carmona-
Gutierrez et al., 2016, Zarrouk et al., 2014). Data presented here have shown that 
both native LDL and SMase-LDL treatment for 3 days induces senescence like 
properties in human THP-1 macrophages in terms of β-galactosidase activity 
(Figure 6.5, 6.6). The incidence of senescence was found to be much higher with 
SMase-LDL compared to native LDL and treatment with cysteamine significantly 
inhibited the SMase-LDL induced senescence. Cysteamine, being a superoxide 
scavenger (Sunman et al., 1993), is able to inhibit the lipid peroxidation of LDL in 
the lysosomes and thus might prevent the increase in the senescence marker β-
galactosidase.  
Therefore, therapeutic strategies to target lysosomes with antioxidants like 
cysteamine to prevent the intralysosomal oxidation of LDL, seems a plausible 
avenue to decrease the development of atherosclerosis. 
7.2 Limitations of the study 
Although the work presented in this thesis has many potential applications in the 
field of atherosclerosis in terms of targetting the lysosomal oxidation of LDL in 
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macrophages with lysosomotropic drugs, there are some limitations which need 
further investigation. Although, it was established through various experiments that 
hydroperoxyl radical (HO2
●) is the main oxidising species during LDL oxidation 
with iron but the generation of HO2
● ions could not be studied. Furthermore, in the 
current study only THP-1 monocytes derived macrophages were used to study the 
lysosomal oxidation of LDL and sue to the time constraints the results could not be 
further confirmed on peripheral human blood monocyte derived macrophages. 
7.3 Future work 
Due to the above mentioned limitations there is a scope for further investigation of 
the current work like: 
 Monitoring the generation of HO2
● radicals during iron mediated LDL 
oxidation under lysosomal conditions by electron spin resonance (ESR). 
 Study the effect of lysosomal oxidation of LDL on the function of lysosomal 
acid lipase. 
 If the oxidation of LDL by iron at pH 4.5 and in lysosomes produces 
bioactive oxidised phospholipids and if it is inhibited by cysteamine. 
 If oxidized lipids formed at lysosomal pH increase the secretion of other 
inflammatory cytokines and metalloproteinases and if it is inhibited by 
cysteamine. 
 If cysteamine can reduce the progression of existing atherosclerosis in 
mice. 
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